ticlopidine has been researched along with thiophenes in 764 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 193 (25.26) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 140 (18.32) | 29.6817 |
2010's | 428 (56.02) | 24.3611 |
2020's | 3 (0.39) | 2.80 |
Authors | Studies |
---|---|
Abiko, Y; Ashida, S | 1 |
Altomonte, F; Armani, U; Griffanti-Bartoli, F; Piana, A; Pitton, L | 1 |
Dechavanne, M; Ghazi, I; Lagarde, M | 1 |
Horikoshi, S; Mitsuka, S; Miyagi, O; Nukui, H; Ohe, C; Sasaki, H; Shibasaki, T; Tamada, J; Toyoda, O | 1 |
Bonnetblanc, JM; Julia, A; Rigaud, M | 1 |
Kienast, J; Verstraete, M | 1 |
Cannizzaro, S; Davì, G; Giubilato, A; Strano, A | 1 |
Bronchi, GF; Carini, A; Karavassili, M; Tesi, M | 1 |
Campisi, D; Davì, G; Francavilla, G; Paterna, S; Pinto, A; Strano, A | 1 |
Chapillon, M; Enon, B; Jacob, JP; Lavenet, F; Riberi, P; Spiesser, R | 1 |
Hurault De Ligny, B; Kessler, M; Louis, J; Renoult, E; Vagner, JC | 1 |
Asaka, M; Iida, H; Izumino, K; Mizumura, Y; Sasayama, S | 1 |
Abou-Khalil, S; Abou-Khalil, WH; Yunis, AA | 2 |
Inoue, H; Kawada, S; Koide, S; Ogawa, J; Shohtsu, A; Tsurumi, T | 1 |
Boissel, JP; Destors, JM; Gauthier, E; Lelong, S | 1 |
Hayashida, N | 1 |
Ojeda, G; Portolés, A; Portolés, MP; Rojo, JM | 1 |
Capecchi, PL; Ceccatelli, L; Di Perri, T; Laghi Pasini, F; Orrico, A; Pasqui, AL | 1 |
Hongo, T; Kwan, T; Setaka, M | 1 |
Grimaldi, MG | 1 |
Harker, LA | 2 |
Cerbone, AM; Di Minno, G; Iovine, C; Mancini, M; Mattioli, PL; Turco, S | 1 |
Benoit, G; Brasseur, L; Charpentier, B; Fries, D; Lang, P; Plaisant, B | 1 |
Berglund, U; Wallentin, L | 3 |
Alberca, I; Cattaneo, M; Coccato, MP; Faioni, E; Mannucci, PM; Mari, D; Vianello, L; Vicente, V | 1 |
Brown, BG; Chesebro, JH; Ekeström, S; Harker, LA; Henderson, AH; Jewitt, DE; Oliver, MF; Sleight, P; Verstraete, M | 1 |
Bowles, MJ; Khurmi, NS; Kohli, RS; Raftery, EB | 1 |
Katori, M; Kawana, S; Nishiyama, S; Ohta, M | 1 |
Hatsuoka, M; Kashii, A; Sasaki, K; Seiki, M | 1 |
Akiyama, K; Endo, K; Kobayashi, S; Kohata, K; Mori, M; Morita, A | 1 |
Lecompte, T; Lecrubier, C; Potevin, F; Samama, M | 1 |
Grosso, B; Nyffeneger, G; Pistone, AM; Podestà, F; Raviolo, E; Testa, D; Toselli, P | 1 |
Arpaia, MR; del Guercio, R; Leonardo, G | 1 |
Cepelák, V; Köcher, P; Opatrný, K; Racek, J | 1 |
Edgerton, TA; Faust, KB; Geisinger, KR; Hansen, KJ; Howe, HR; Kon, ND; Meredith, JH | 1 |
Almirall, L; Bastida, E; Escolar, G; Ordinas, A | 1 |
Imai, Y; Matsumura, H; Nishikawa, K; Terashita, Z | 1 |
Di Perri, T | 1 |
Drouet, L | 1 |
Anderton, JL; Burnet, ME; Fiskerstrand, CE; Thompson, IW; Williams, P | 1 |
Goebel, N; Krayenbühl, HP; Pfluger, N; Rothlin, ME; Senning, A; Speiser, K; Steinbrunn, W; Turina, M | 1 |
Gröntoft, KC; Gutierrez, A; Mulec, H; Olander, R | 1 |
Gormsen, J; Kjøller, E; Knudsen, JB; Skagen, K | 1 |
Berglund, U; von Schenck, H; Wallentin, L | 1 |
Aversa, F; Del Favero, A; Giordano, G; Guerciolini, R | 1 |
Díez, M; Fernández, A; Gil, M; Lasierra, J; Velázquez, E; Viladés, E | 1 |
Castaigne, JP; Labie, D; Sablayrolles, M; Wajcman, H | 2 |
Hashimoto, N; Kholoussy, AM; Kumashiro, R; Matsumoto, T; Piotrowski, JJ | 1 |
Bernat, A; Maffrand, JP; Roncucci, R; Vallée, E | 1 |
Cattaneo, M; Groves, HM; Kinlough-Rathbone, RL; Mustard, JF; Packham, MA; Somers, DA; Winocour, PD | 1 |
de Artaza, M; de Teresa, E; Lorenz, P; Marin, MC; Martín-Júdez, V; Ugarte, M | 1 |
Takayama, T | 2 |
Loveday, BE; Nuttall, A; Smith, HJ | 1 |
Cohn, M; Eldor, A; Matzner, Y | 1 |
Lotti, G; Marmont, AM; Martinengo, M; Morgano, A; Nati, S | 1 |
Charbonnier, R; Pistone, MA; Resegotti, L; Testa, D; Toselli, P; Vivalda, S | 1 |
Avello, F; Carmona, J; Criado, A; Juffé, A; Otero, C | 1 |
Glukhov, AI; Goriunov, VS; Kirichenko, AA; Smirnova, LA | 1 |
Almeida-Dias, A; Pina-Cabral, JM; Ribeiro-da-Silva, A | 1 |
Alessandri, C; Balsano, F; Ghiselli, A; Iuliano, L; Perrone, A; Violi, F | 1 |
Battocchio, F; Crociani, ME; Fabris, F; Girolami, A; Randi, ML | 1 |
Glusa, E | 1 |
Verstraete, M | 2 |
Caen, JP; Dunn, FW; Lee, H; Soria, C; Soria, J; Thomaidis, A | 1 |
Fox, KM; Jonathan, A; Selwyn, AP | 1 |
Breddin, HK; Pauliks, V; Weichert, W | 1 |
Offerhaus, L | 1 |
Cacciatore, L; De Marco, F; Giardina, MG; Matarazzo, M | 1 |
Tullio, D | 1 |
Gragnoli, G; Signorini, AM; Tanganelli, I | 1 |
Garrido García, H; Martín Infante, A; Rivas Marín, J; Vilaplana Serrano, F | 1 |
Najean, Y; Poirier, O | 1 |
Claas, FH; de Fraiture, WH; Meyboom, RH | 2 |
Alessandri, C; Balsano, F; Frattaroli, S; Ghiselli, A; Violi, F | 1 |
Abbate, R; Breschi, C; Costanzo, G; Favilla, S; Gensini, GF; Neri Serneri, GG | 1 |
Ritchie, JL; Stratton, JR | 1 |
Numano, F | 1 |
Kester, RC | 1 |
Carniti, E; Fiorini, L; Iezzi, BG; Sbalzarini, G | 1 |
Díaz, R; Portolés, A; Rojo, JM | 1 |
Avellone, G; Davì, G; Mandalà, V; Novo, S; Pinto, A; Raneli, G; Riolo, FP | 1 |
Daveloose, D; Leterrier, F; Molle, D; Sablayrolles, M | 1 |
Gaillard, JL; Kher, A; Lecompte, T; Samama, M | 1 |
Eugene, C; Gury, B; Lefebvre, JF; Quevauvilliers, J | 1 |
Arimura, GK; Lo, L; Yunis, AA | 1 |
Kawai, C | 1 |
Andriani, A; Beni, A; Chiappetta, MG; Fabiani, M; Mosiello, G | 1 |
Cove, DH; Neumann, V; Shapiro, LM; Trethowan, N | 1 |
Picard-Fraire, C | 2 |
Bruno, JJ | 1 |
Almasio, P; Ascari, E; Piovella, F; Ricetti, MM; Samaden, A; Semino, G | 1 |
Hess, H; Ingrisch, H; Mietaschk, A; Stiegler, H; Trampisch, HJ | 1 |
Gordon, JL | 1 |
Blanchard, J; Panak, E; Roe, RL | 1 |
Katsumura, T | 1 |
David, JL; Limet, R; Rigo, P | 1 |
Cabannes, R; Castaigne, JP; Lonsdorfer, J; Ondo, A; Plassard, A; Zohoun, I | 1 |
Baarsma, GS; Henkes, HE; Houtsmuller, AJ; Klompe, M; Tijssen, J; Vermeulen, JA; Zahn, KJ | 1 |
Mirouze, J | 1 |
Kikuchi, H; Kitamura, K; Mizukami, M; Ono, H | 1 |
Hass, WK; Kamm, B | 1 |
Tohgi, H | 1 |
Ellis, D; Gent, M | 1 |
Day, HJ | 1 |
Al-Hasani, SF; Kioy, P; Savidge, GF; Semple, MJ | 1 |
Bonta, IL; de Wit, CM; Vincent, JE; Zijlstra, FJ | 1 |
Almasio, P; Giddings, JC; Piovella, F; Ricetti, MM; Thomas, JE | 1 |
Goebel, N; Pfluger, N; Rothlin, M; Speiser, K; Turina, M | 1 |
Gutiérrez González, JR; Méndez Martín, A; Ortiz González, A | 1 |
Bruno, JJ; Chang, LF; McSpadden, MM; Yang, D | 1 |
Díez, MM; Fernández, A; Gil, M; Lasierra, J; Velázquez, E; Viladés, E | 1 |
Butler, KD; White, AM | 1 |
Naruse, T; Ogawa, S | 1 |
Carfagna, S; Carrieri, P; Fioretti, A; Indaco, A; Orefice, G | 1 |
Abou-Khalil, S; Abou-Khalil, WH; Lim, LO; Yunis, AA | 1 |
Herce Muñoz, M | 1 |
Cánovas, M; Navarro, C; Padró, T; Villaverde, C | 1 |
Caulet, T; de Lacharrière, O; Kalis, B; Léonard, F; Renard, T; Triller, R | 1 |
Barbe, G; Gruyer, P; Guyot, L; Lapeyrère, X; Saint-Paul, B | 1 |
Pinon, JF | 1 |
Ebata, H; Harada, M; Hidaka, T; Ishii, Y; Mashiko, N; Nouno, R; Satoh, K; Tanikawa, K; Ueda, H | 1 |
Hanson, SR; Harker, LA | 1 |
d'Avenia, V; di Minno, G; Iovine, C; Mattioli, PL; Turco, S | 1 |
Goyan, JE | 1 |
Berthe, J; Combes, M; Garbay, TM; Gouy, D; Lacheretz, F; Mazué, G; Remandet, B; Vic, P | 1 |
Bogui, P; Cabannes, R; Castaigne, JP; Dosso, Y; Lenormand, E; Lonsdorfer, J; Otayeck, A | 1 |
Bernat, A; Delebassée, D; Maffrand, JP; Tissinier, A; Vallée, E | 1 |
Girard, P; Lecrubier, C; Noire, P; Samama, M | 1 |
Battais, E; Bonne, C | 1 |
López-Trigo Picho, J; Sancho Rieger, J | 1 |
Chevigné, M; David, JL; Limet, R; Rigo, P | 1 |
Kholoussy, AM; Kumashiro, R; Matsumoto, T; Pavlides, CA | 1 |
de Zeeuw, RA; Drenth, BF; Ghijsen, RT; Overzet, F; Rurak, A; van der Voet, H | 1 |
Chowhan, ZT; Yang, IC | 1 |
Blanchard, J; Maffrand, JP; Panak, E; Picard-Fraire, C; Roncucci, R; Vallée, E | 1 |
Bono, F; Cambi, V; Castiglioni, A; De Gasperi, T; Menta, R; Savazzi, GM; Zanelli, P | 1 |
Paris, J | 1 |
Blanchard, J; Blatrix, C; Panak, E; Thébault, JJ | 2 |
Bertelé, V; de Gaetano, G | 2 |
Aurell, M; Blohmé, G; Jagenburg, R; Larsson, O; Nyberg, G; Westberg, NG | 1 |
Aukland, A; Hawker, RJ | 1 |
Bando, H; Tsubura, E; Yamashita, T | 1 |
Lasierra, J; Martínez Peñuela, JM; Sánchez Casajús, A; Velázquez, E | 1 |
Benveniste, J; Chignard, M; Delabassee, D; Delautier, D; Lalau Keraly, C | 1 |
Andriani, A; Chiappetta, MG; Fabiani, M | 1 |
Caen, JP; Lee, H; Paton, RC; Ruan, C | 1 |
Bonta, IL; vd Veerdonk, MA; Vincent, JE; Zijlstra, FJ | 1 |
Chevolet, C; Dresse, A; Grosdent, JC; Reiters, GM | 1 |
Conard, J; Horellou, MH; Lecrubier, C; Samama, M | 1 |
Ariganello, M; Borzi, M; Cannata, D; Filice, A; Galante, A; Lenci, R; Sommariva, L | 1 |
Dohi, S; Mayumi, T | 1 |
Furukawa, Y; Kondo, M; Murakami, M; Takemura, S; Yoshikawa, T | 1 |
Benghozi, R; Bienvenu, MP; Castaigne, A | 1 |
Kamiya, K; Katsumura, T; Mishima, Y; Sakaguchi, S; Sakuma, A; Tanabe, T | 1 |
Aukland, A; George, AJ; Hurlow, RA; Stuart, J | 1 |
Lefort, J; Randon, J; Vargaftig, BB | 1 |
Bauters, F; Canuel, C; de Gramont, A; Degos, L; Krulik, M; Marty, M; Najean, Y | 1 |
Glasson, S; Tillement, JP; Zini, R | 1 |
Donner, M; Nicolas, A; Solagna, S; Stoltz, JF; Verry, M | 1 |
Egbring, R; Klingemann, HG | 1 |
Blanchard, J; Blatrix, C; Panak, E; Thébault, J | 1 |
Davies, JA; Doig, RL; Kester, RC; McNicol, GP; Menys, VC; Paton, RC; Tindall, H | 1 |
Alberani, M; Manotti, C; Megna, A; Poli, T; Potì, R | 1 |
Bush, H; Flamenbaum, W; Gross, ML; Hamburger, RJ; Weinger, R | 1 |
Dewanjee, MK; Fuster, V; Kaye, MP; Murphy, KP; Pumphrey, CW; Vlietstra, RE | 1 |
Aubert, D; Ferrand, C; Loubrie, JC; Tuong, A; Tuong, CC | 1 |
Bousser, MG; Conard, J; Horellou, MH; Lecrubier, C; Samama, M; Scarabin, PY | 1 |
Kawaguchi, Y; Kobayashi, K; Koshikawa, S; Maeda, K; Naito, C; Shimizu, N | 1 |
Brommer, EJ | 1 |
Fujie, K; Fujie, Y | 1 |
Chap, H; Douste-Blazy, L; Simon, MF | 1 |
Bouyssou, A; Cuong, TG; Paret, J; Tuong, A | 1 |
Chow, YP; Chowhan, ZT | 1 |
Ishihara, M; Kinjo, M; Kohga, S; Ogawa, H; Tanaka, K; Tanaka, N | 1 |
Kawaguchi, S; Kobayashi, K; Maeda, K; Narita, M; Ohbayashi, S; Ohta, K; Saito, A; Shinzato, T; Usuda, M | 1 |
Abiko, Y; Ashida, S; Sakuma, K | 1 |
Akashi, A; Hirohashi, M; Kasahara, A; Tamura, K; Watanabe, K | 1 |
Bousser, J; Bousser, MG; Conard, J; Lecrubier, C | 1 |
Lindsay, R; Nunn, B | 1 |
Jogestrand, T; Johnsson, H; Kirstein, P; Olsson, AG | 1 |
Curtet, JM; Guilmet, D; Renner, C | 1 |
Asai, F; Inoue, T; Koike, H; Ogawa, T; Sugidachi, A | 1 |
Dalvie, DK; O'Connell, TN | 1 |
Asai, F; Jakubowski, JA; Niitsu, Y; Sugidachi, A | 1 |
Antman, EM; Behounek, BD; Braunwald, E; Carney, RJ; Lazzam, C; McCabe, CH; McKay, RG; Murphy, SA; Weerakkody, G; Winters, KJ; Wiviott, SD | 1 |
Brandt, JT; Darstein, C; Jakubowski, JA; Jernberg, T; Naganuma, H; Payne, CD; Siegbahn, A; Wallentin, L; Winters, KJ | 1 |
Lowry, DR; Malinin, AI; Meilman, H; Midei, MG; Serebruany, VL | 1 |
Serebruany, VL | 8 |
Antman, EM; Braunwald, E; Gibson, CM; McCabe, CH; Montalescot, G; Riesmeyer, J; Warmke, JW; Weerakkody, G; Winters, KJ; Wiviott, SD | 1 |
Gurbel, PA; Tantry, US | 1 |
Asai, F; Brandt, JT; Freestone, S; Hirota, T; Jakubowski, JA; Matsushima, N; Naganuma, H; Winters, KJ | 1 |
Bliden, KP; Gurbel, PA; Tantry, US | 1 |
Brandt, JT; Farid, NA; Jakubowski, JA; Naganuma, H; Payne, CD; Small, DS; Weerakkody, G; Winters, KJ; Wiviott, SD | 1 |
Cattaneo, M | 5 |
Araki, H; Batory, LA; McInnis, CE; Njardarson, JT; Rogers, E | 1 |
Huber, K; Schrör, K; Siller-Matula, J; Wojta, J | 1 |
Brandt, JT; Darstein, C; Ernest, CS; Farid, NA; Jakubowski, JA; Payne, CD; Salazar, DE; Small, DS; Winters, KJ | 1 |
Brandt, JT; Farid, NA; Jakubowski, JA; Lachno, DR; Li, YG; Naganuma, H; Payne, CD; Weerakkody, GJ; Winters, KJ | 1 |
Asai, F; Hagihara, K; Hashimoto, M; Jakubowski, JA; Kurihara, A; Niitsu, Y; Ogawa, T; Sugidachi, A | 1 |
Brandt, JT; Farid, NA; Jakubowski, JA; Naganuma, H; Payne, CD; Warner, MR; Weerakkody, GJ; Winters, KJ; Zhu, J | 1 |
Brandt, JT; Jakubowski, JA; Naganuma, H; Payne, CD; Weerakkody, GJ; Winters, KJ | 1 |
de Lemos, JA; Wiviott, SD | 1 |
Brandt, JT; Close, SL; Ernest, CS; Farid, NA; Iturria, SJ; Lachno, DR; Payne, CD; Salazar, D; Winters, KJ | 1 |
Antman, EM; Ardissino, D; Braunwald, E; De Servi, S; Gibson, CM; Gottlieb, S; McCabe, CH; Montalescot, G; Murphy, SA; Neumann, FJ; Riesmeyer, J; Ruzyllo, W; Weerakkody, G; Wiviott, SD | 1 |
Bhatt, DL | 1 |
Asai, F; Hashimoto, M; Isobe, T; Jakubowski, JA; Niitsu, Y; Ogawa, T; Otsuguro, K; Sugidachi, A | 1 |
Brandt, JT; Ernest, CS; Farid, NA; Jakubowski, JA; Li, YG; Payne, CD; Salazar, DE; Small, DS; Winters, KJ | 1 |
Braun, OO; Erlinge, D; Jakubowski, JA; James, S; Siegbahn, A; Sugidachi, A; Varenhorst, C; Wallentin, L; Winters, KJ | 1 |
Angiolillo, DJ; Antman, EM; Braunwald, E; Cairns, R; Frelinger, AL; Hod, H; Jakubowski, JA; McCabe, CH; Michelson, AD; Miller, DL; Montalescot, G; Murphy, SA; Neumann, FJ; O'Donoghue, M; Trenk, D; Wiviott, SD | 1 |
Huber, K; Schrör, K | 1 |
Angiolillo, DJ | 1 |
Brandt, JT; Farid, NA; Jakubowski, JA; Li, YG; Payne, CD; Salazar, DE; Small, DS; Winters, KJ | 3 |
Buckland, RJ; Jakubowski, JA; Judge, HM; Storey, RF; Sugidachi, A | 1 |
Brandt, JT; Farid, NA; Li, YG; Payne, CD; Salazar, DE; Small, DS; Weerakkody, GJ; Winters, KJ | 1 |
Schaerlig, E | 1 |
Serebruany, V | 2 |
Di Sciascio, G; Pasceri, V; Patti, G | 1 |
Paulus, W; Riggert, J; von Lewinski, F | 1 |
Antman, EM; Braunwald, E; Downey, WE; Herrman, JP; Horvath, I; Keltai, M; McCabe, CH; Murphy, SA; Scirica, BM; Van de Werf, F; Wiviott, SD | 1 |
Eikelboom, JW; Hankey, GJ; Langton, PE | 1 |
De Servi, S; Lettino, M | 1 |
Ajani, AE; Lefkovits, J | 1 |
Antman, EM; Braunwald, E; Murphy, SA; Wiviott, SD | 1 |
Dovlatova, NL; Heptinstall, S; Jakubowski, JA; Sugidachi, A | 1 |
Antman, EM; Braunwald, E; Chandna, H; Hasin, Y; Macias, W; McCabe, CH; Murphy, SA; Voitk, J; Widimsky, P; Wiviott, SD | 1 |
Alvarez, W | 1 |
Haber, SL; Riley, AB; Tafreshi, MJ | 1 |
Dovlatova, N; Heptinstall, S; Johnson, A | 1 |
Alberts, MJ; Hanley, DF; Serebruany, VL | 1 |
Barker, CM; Price, MJ | 1 |
Sosnowski, C | 1 |
Antman, EM; Braunwald, E; Huber, K; Lopez-Sendon, J; McCabe, CH; Morocutti, G; Murphy, SA; Weerakkody, G; Wiviott, SD | 1 |
Ramaraj, R | 1 |
Cohen, M; Giugliano, R; Granger, CB; Gurbel, PA; Hoekstra, J; Hollander, JE; Manoukian, SV; Pollack, CV; Saucedo, JF | 1 |
Angiolillo, DJ; Antman, EM; Braunwald, E; Corbalan, R; Dalby, AJ; Goodman, SG; McCabe, CH; Meisel, S; Murphy, SA; Purdy, DA; Verheugt, FW; Wiviott, SD | 1 |
Ernest, CS; Farid, NA; Li, YG; Payne, CD; Salazar, DE; Small, DS; Winters, KJ | 1 |
Preobrazhenskiĭ, DV | 1 |
Klauss, V; Krötz, F; Sohn, HY | 1 |
Brandt, JT; Braun, OO; Erlinge, D; Jakubowski, JA; James, S; Johnell, M; Siegbahn, A; Varenhorst, C; Wallentin, L; Winters, KJ | 1 |
Wiviott, SD | 1 |
Eikelboom, JW; Hirsh, J; Raju, NC | 1 |
Ernest, CS; Rohatagi, S; Salazar, DE; Small, DS; Wallentin, L; Winters, KJ; Wrishko, RE | 1 |
Goodsaid, FM | 1 |
Brandt, JT; Ernest, CS; Farid, NA; Jakubowski, JA; Konkoy, CS; Li, YG; Payne, CD; Salazar, DE; Small, DS; Winters, KJ | 1 |
Farid, NA; Hagihara, K; Ikeda, T; Ito, T; Kurihara, A; Miura, S; Nishiya, Y; Tajima, M | 1 |
Brandt, JT; Braun, OO; Erlinge, D; Jakubowski, JA; James, S; Siegbahn, A; Sugidachi, A; Varenhorst, C; Wallentin, L; Winters, KJ | 1 |
Cairns, JA; Eikelboom, J | 1 |
Dachs, R; Darby-Stewart, A; Graber, MA | 1 |
De Servi, S; Mariani, G; Mariani, M | 1 |
Farid, NA; Hagihara, K; Ikeda, T; Kazui, M; Kurihara, A; Nishiya, Y | 1 |
Calatzis, A | 1 |
Kopyleva, O; Serebruany, V; Shalito, I | 1 |
Crain, EJ; Hua, J; Rehfuss, R; Schumacher, WA; Watson, CA; Wong, PC | 1 |
Akram, F; Akram, S; Postuła, M | 1 |
Faxon, DP; Freedman, JE | 1 |
Brandt, JT; Braun, OO; Erlinge, D; Jakubowski, JA; James, S; Olofsson, S; Siegbahn, A; Varenhorst, C; Wallentin, L; Winters, KJ | 1 |
Stone, GW | 3 |
Antman, EM; Braunwald, E; Gibson, CM; McCabe, CH; Montalescot, G; Murphy, SA; Wiviott, SD | 1 |
Giugliano, RP; Thomas, D | 1 |
Farid, NA; Fusegawa, K; Hagihara, K; Ikeda, T; Ikenaga, H; Kazui, M; Kurihara, A; Nanba, T; Okazaki, O; Takahashi, M | 1 |
Sabatine, MS | 1 |
Antonino, MJ; Gurbel, PA; Mahla, E; Tantry, US | 1 |
Angiolillo, DJ; Capranzano, P; Ferreiro, JL | 1 |
Butt, M; Lip, GY; Shantsila, E; Siddique, A | 1 |
Gleason, PP; Kjesbo, NK; Schafer, JA | 1 |
Brandt, JT; Braun, OO; Close, SL; Erlinge, D; James, S; Man, M; Siegbahn, A; Varenhorst, C; Walker, J; Wallentin, L; Winters, KJ | 1 |
Angiolillo, DJ; Antman, EM; Braunwald, E; Downey, WE; Frelinger, AL; Jakubowski, JA; Li, Y; McCabe, CH; Michelson, AD; Murphy, SA; Qin, J; Wiviott, SD; Xenopoulos, NP | 1 |
Marzot, F; Pengo, V | 1 |
Cryer, B | 1 |
Das, K; Das, P; Koshy, SK; Robinson, A | 1 |
Antman, EM; Bonaca, MP; Bramucci, E; Braunwald, E; McCabe, CH; Morrow, DA; Murphy, SA; Nicolau, JC; Ruff, CT; Scirica, BM; White, HD; Wiviott, SD | 1 |
Price, MJ | 3 |
Motovska, Z; Widimsky, P | 1 |
Floyd, J; Wolfe, S | 1 |
Gladding, P; Webster, MW | 1 |
Shil, AB; Strohm, MP | 1 |
Barthélémy, O; Beygui, F; Collet, JP; Funck-Brentano, C; Hulot, JS; Montalescot, G; Pena, A; Silvain, J | 1 |
Makarov, LM; Serebruany, VL | 1 |
Rees, C; Spinler, SA | 1 |
Curtiss, FR; Fairman, KA | 1 |
Eberli, FR; Roffi, M | 1 |
Petersen, KU | 1 |
Alban, S; Dingermann, T | 1 |
Alban, S | 1 |
Breitkreutz, J | 1 |
Kereiakes, DJ | 1 |
Wallentin, L | 1 |
Brandt, JT; Ernest, CS; Farid, NA; Jakubowski, JA; Li, YG; Ni, L; Payne, CD; Rohatagi, S; Small, DS; Winters, KJ | 1 |
Duggan, ST; Keating, GM | 1 |
Antman, EM; Braunwald, E; Finkelstein, A; Fridrich, V; McCabe, CH; Murphy, SA; O'Donoghue, M; Penny, WF; Sabatine, MS; Steg, PG; Wiviott, SD | 1 |
Kumar, A; Roberts, DH | 1 |
Berntsson, P; Björkman, JA; van Giezen, JJ; Zachrisson, H | 1 |
Hayden, EC | 1 |
Dauerman, HL | 1 |
Antman, EM; Braunwald, E; Buros, JL; Gibson, CM; Pride, YB; Tariq, MU; Wiviott, SD; Zorkun, C | 1 |
Farid, NA; Hagihara, K; Honda, K; Ikeda, T; Kazui, M; Kurihara, A; Okazaki, O; Yoshiike, M | 1 |
Schömig, A | 1 |
Kastrati, A; Sibbing, D | 1 |
Antman, EM; Bates, ER; Braunwald, E; Close, SL; Hautvast, RW; Mega, JL; Michelson, AD; Murphy, SA; O'Donoghue, ML; Rozenman, Y; Sabatine, MS; Shen, L; Ver Lee, PN; Wiviott, SD | 1 |
Schrör, K | 1 |
Farid, NA; Hagihara, K; Ikeda, T; Kurihara, A; Nishiya, Y; Okazaki, O; Okudaira, N | 1 |
Collet, JP; Hulot, JS; Montalescot, G | 1 |
Menon, V; Raymond, C | 1 |
Oberpichler-Schwenk, H | 1 |
Abu-Fadel, M; Norgard, NB | 1 |
Eshaghian, S; Kaul, S; Shah, PK | 1 |
Banach, M; Hannam, S; Kowalczyk, M; Mikhailidis, DP; Rysz, J | 1 |
Dobesh, PP | 1 |
Baker, WL; Reinhart, KM; White, CM | 1 |
Farid, NA; Kurihara, A; Wrighton, SA | 1 |
Lazar, LD; Lincoff, AM | 1 |
del Río, A; Heras, M | 1 |
Guerra, DR; Tcheng, JE | 1 |
Antman, E; Arnold, SV; Braunwald, E; Cohen, DJ; Mahoney, EM; Proskorovsky, I; Wang, K; Wiviott, S | 1 |
Jilma, B; Krumphuber, J; Siller-Matula, JM | 1 |
Bal dit Sollier, C; Barthélémy, O; Beygui, F; Cohen, R; Collet, JP; Drouet, L; Henry, P; Lim, P; Luo, J; Marshall, D; Meuleman, C; Montalescot, G; Petitjean, H; Sideris, G | 1 |
Solomon, S; Vacek, JL | 1 |
Cattaneo, M; Podda, GM | 1 |
Lip, GY; Shantsila, E; Tapp, L | 1 |
Farid, NA; Jakubowski, JA; Kelly, R; Kothare, P; Li, YG; Natanegara, F; Ni, L; Payne, CD; Richard Lachno, D; Salazar, DE; Small, DS; Teng Loh, M; Tomlin, M; Winters, KJ; Yuen, E | 1 |
Banning, AP; Bedogni, F; Bhindi, R; Biondi Zoccai, GG; Brambilla, N; Lanotte, S; Latini, RA; Laudisa, ML; Pizzocri, S; Testa, L; Valgimigli, M; Van Gaal, WJ | 1 |
Islam, AM; Patel, PM | 1 |
Fareed, J; Jeske, WP; Mousa, SA | 1 |
Gladding, P; Webster, M; White, H | 1 |
Guo, KW; Tan, JW | 1 |
Aylward, PE; Behan, MW; Chew, DP | 1 |
Jakubowski, JA; Li, YG; Luo, J; Payne, CD; Small, DS; Tomlin, ME; Winters, KJ | 1 |
Bareiss, P; Kessler, L; Morel, O; Ohlmann, P | 1 |
Abbate, R; Crea, F; De Servi, S; Filippi, E; Gensini, GF; Golinos, P; Savonitto, S | 1 |
Chew, DP; Prakash, R; Wong, YW | 1 |
Neumann, FJ | 1 |
Amin, AP; Marso, SP | 1 |
Duconge, J; Ruaño, G; Seip, RL | 1 |
Dixon, SR; Grines, CL; O'Neill, WW | 1 |
Bauters, C; Bonello, L; Delhaye, C; Lablanche, JM; Lemesle, G; Maluenda, G; Sudre, A | 1 |
Horowitz, JD; McKinnon, RA; Sorich, MJ; Vitry, A; Ward, MB | 1 |
Erdem, G; Flather, MD; Geisler, T | 1 |
Bagust, A; Boland, A; Dickson, R; Dundar, Y; Fisher, M; Fleeman, N; Greenhalgh, J; Kolamunnage-Dona, R; McLeod, C; Proudlove, C; Saborido, CM | 1 |
Cairns, JA; Eikelboom, JW; Hirsh, J; Paikin, JS | 1 |
Armstrong, PW; Brown, E; Chin, CT; Fox, KA; Lokhnygina, Y; Marshall, DA; Ohman, EM; Petitjean, H; Prabhakaran, D; Roe, MT; White, HD | 1 |
Boonbaichaiyapruck, S; Ge, J; Goh, YS; Hong, BK; Hou, CJ; Pinton, P; Zhu, J | 1 |
Gratsianskiĭ, NA | 1 |
Pakhomov, IaM | 2 |
Antman, EM; Braunwald, E; Wiviott, SD | 1 |
Caglayan, E; Er, F; Erdmann, E; Gassanov, N; Nia, AM | 1 |
Aïssaoui, N; Danchin, N | 1 |
Gurbel, PA; Mahla, E; Metzler, H; Tantry, US | 1 |
Antman, EM; Braunwald, E; Close, SL; Mega, JL; Sabatine, MS; Shen, L; Simon, T; Walker, JR; Wiviott, SD | 1 |
Abbate, R; Giusti, B | 1 |
Hallström, S; Jakubowski, A; Koidl, B; Lang, P; Mächler, H; Pelzmann, B; Zorn-Pauly, K | 1 |
Laizure, SC; Parker, RB | 1 |
Angiolillo, DJ; Costigan, TM; Deraad, R; Effron, MB; Frelinger, AL; Gurbel, PA; Jakubowski, JA; Ojeh, CK; Saucedo, JF | 1 |
Braber, TL; Van Der Have-Roeffel, SM; van Werkum, JW; Verheggen, PW | 1 |
Fletcher, B; Thalinger, KK | 1 |
Ancrenaz, V; Besson, M; Daali, Y; Dayer, P; Desmeules, J; Fontana, P; Samer, C | 1 |
Ferrandis, R; Gómez-Luque, A; Llau, JV; Sierra, P | 1 |
Abraham, NS; Antman, EM; Bhatt, DL; Bjorkman, DJ; Clark, CB; Furberg, CD; Hlatky, MA; Johnson, DA; Kahi, CJ; Laine, L; Mahaffey, KW; Quigley, EM; Scheiman, J; Sperling, LS; Tomaselli, GF | 2 |
Bhavaraju, K; Gartner, TK; Georgakis, A; Jin, J; Kunapuli, SP; Nurden, A; Nurden, P; Tomiyama, Y | 1 |
Capranzano, P; Dangas, G; Mehran, R; Stone, GW; Tamburino, C | 1 |
De Rosa, G; Napodano, M; Padrini, R; Pengo, V; Plebani, M; Silvano, M; Zambon, CF | 1 |
Antman, EM; Baracioli, L; Braunwald, E; Giugliano, RP; Heuer, H; Lotan, C; Merkely, B; Murphy, SA; Ruff, CT; Schersten, F; Seabro-Gomes, R; Wiviott, SD | 1 |
Silber, S | 1 |
Cannon, C; Croce, K; Kirshenbaum, J; Manica, A; Marchini, J; Morrow, D; Resnic, F | 1 |
Armani, AM | 1 |
Angiolillo, DJ; Tello-Montoliu, A; Tomasello, SD | 1 |
Minarelli, M; Valgimigli, M | 1 |
Frey, N; Ivandic, B | 1 |
Ağırbaşlı, M; Cinçin, A; Güvenç, H | 1 |
Endres, HG; Engelhardt, A; Kaiser, AF; Krüger, JC; Kusber, A; Lask, S; Mügge, A; Neubauer, H; Pepinghege, F | 1 |
Angiolillo, DJ; Badimon, JJ; Baker, BA; Effron, MB; Frelinger, AL; Jakubowski, JA; Michelson, AD; Ojeh, CK; Saucedo, JF; Zhu, B | 1 |
Cohen Arazi, H; Di Girolamo, G; Giorgi, MA; Gonzalez, CD | 1 |
Baker, BA; Effron, MB; Jakubowski, JA; Kulkarni, MP; Li, YG; Luo, J; Miller, DL; Small, DS; Winters, KJ; Zhu, B | 1 |
Engelen, S; Sinnaeve, P; Van Damme, H; Verhamme, P | 1 |
Hamm, CW; Rassaf, T | 1 |
Achar, S | 1 |
Campo, G; Ferrari, R; Fileti, L; Marchesini, J; Valgimigli, M | 1 |
Smetana, GW; Srour, JF | 1 |
Lange, CG | 1 |
Arntz, HR; Boudriot, E; Garlichs, C; Helms, TM; Hoffmann, S; Ince, H; Klingenheben, T; Silber, S; Steiger, H; Weil, J; Zugck, C | 1 |
Scharf, RE | 1 |
Baty, SR; Griffith, CB; Phillippe, HM | 1 |
Storey, RF | 1 |
Briongos Figuero, S; de Juan-Bagudá, J; Martí-Sánchez, D; Salido-Tahoces, L | 1 |
Alexopoulos, D; Athanassiadou, A; Davlouros, P; Dimitropoulos, G; Hahalis, G; Kassimis, G; Stavrou, EF; Xanthopoulou, I | 1 |
Bellemain, A; Collet, JP; Ecollan, P; Montalescot, G; Silvain, J | 1 |
Behr, T; Behr, W; Kuch, B; von Scheidt, W | 1 |
Castriota, F; De Luca, G; De Servi, S; Kozinski, M; Kubica, J; Navarese, EP; Schaffer, A; Suriano, P; Verdoia, M | 1 |
Cattaneo, GJ; Cattaneo, M; Podda, GM | 1 |
Easton, JD | 1 |
Antman, EM; Braunwald, E; Contant, CF; Dalby, AJ; Giugliano, RP; Guo, J; Hochholzer, W; Montalescot, G; Wiviott, SD | 1 |
Moliterno, DJ; Rajan, L | 1 |
Eikelboom, JW; Fitchett, DH; Goodman, SG; Mehta, SR; Quinlan, DJ; Théroux, P; Welsh, RC | 1 |
Martin, MT; Nutescu, EA; Spinler, SA | 1 |
Kanadiya, MK; Koshal, VB; Singhal, S | 1 |
Ferro, A; Passacquale, G | 1 |
Close, SL; Farid, NA; Ho, M; Jakubowski, JA; Kelly, RP; Natanegara, F; Shen, L; Small, DS; Walker, JR; Winters, KJ | 1 |
Antman, EM; Braunwald, E; Costigan, TM; Frelinger, AL; Jakubowski, JA; McCabe, CH; Michelson, AD; Miller, DL; Neumann, FJ; Trenk, D; Wiviott, SD | 1 |
Carballo, D; Carballo, S; Keller, PF; Roffi, M | 1 |
Flaherty, MP; Johnston, PV; Rade, JJ | 1 |
Byrne, RA; Hausleiter, J; Laugwitz, KL; Orban, M; Sibbing, D | 1 |
Alexopoulos, D | 1 |
Alber, HF; Frick, M; Huber, K; Pachinger, O | 1 |
Bonello, L; de Labriolle, A; Doazan, JP; Lemesle, G | 1 |
Anderson, RA; Bundhoo, SS; Dada, J; Halcox, JP; Harris, R; James, PE; Lang, D; Sagan, E | 1 |
Abell, LM; Liu, EC | 1 |
Bonafede, M; Deitelzweig, SB; Gdovin Bergeson, J; Graham, J; Jing, Y; Liffmann, D; Makenbaeva, D | 1 |
Bernlochner, I; Contant, CF; Guo, J; Hochholzer, W; Kastrati, A; Mega, JL; Morath, T; Neumann, FJ; O'Donoghue, ML; Sabatine, MS; Schömig, A; Sibbing, D; Stratz, C; Trenk, D; Valina, CM; Wiviott, SD | 1 |
Beddingfield, R; Held-Godgluck, BM; Peppard, SR | 1 |
D'Urbano, M; De Servi, S; Navarese, EP; Savonitto, S | 1 |
Rayoo, R; Sharma, N; van Gaal, WJ | 1 |
Alexopoulos, D; Davlouros, P; Hahalis, G; Mavronasiou, E; Panagiotou, A; Plakomyti, TE; Xanthopoulou, I | 1 |
Alexopoulos, D; Davlouros, P; Fourtounas, C; Goumenos, D; Kassimis, G; Komninakis, D; Panagiotou, A; Xanthopoulou, I | 1 |
Danenberg, HD; Raccah, BH; Shalit, M | 1 |
Angiolillo, DJ; Calvi, V; Capodanno, D; Capranzano, P; D'Urso, L; Miccichè, E; Tamburino, C | 1 |
Cayla, G; Collet, JP; Montalescot, G; O'Connor, SA; Silvain, J | 2 |
Bae, JP; Cohen, DJ; Graham, JB; Magnuson, EA; Mauskopf, JA; Meadows, ES; Ramaswamy, K; Zagar, AJ | 1 |
Barthélémy, O; Bellemain-Appaix, A; Beygui, F; Cayla, G; Collet, JP; Finzi, J; Hulot, JS; Kerneis, M; Montalescot, G; O'Connor, SA; Silvain, J | 1 |
Alexopoulos, D; Plakomyti, TE; Xanthopoulou, I | 1 |
Basra, SS; Lakkis, NM; Tsai, P | 1 |
Barakoti, M; Neupane, P; Pant, S; Ramesh, KC | 1 |
Chopra, P; Klaustermeyer, WB; Verma, P | 1 |
Ikeda, Y; Isshiki, T; Kimura, T; Ogawa, H; Yokoi, H | 1 |
Collet, JP; De Luca, L; Wouter Jukema, J | 1 |
Damman, P; de Winter, RJ; James, SK; Kuijt, WJ; Woudstra, P | 1 |
Becker, RC; Cutlip, DE; Dauerman, HL; French, PA; Granada, JF; Price, MJ; Smyth, SS; Steinhubl, SR | 1 |
Braunwald, E | 1 |
Abraham, T; Balmir, E; Oh, EY; Rapp, JH; Saad, N; Vastey, FL | 1 |
Janknegt, R; Ruiters, L; Ten Cate, H | 1 |
Davies, JE; Francis, DP; Nijjer, SS | 1 |
Castriota, F; Grzesk, E; Grzesk, G; Kozinski, M; Krzyzanowski, M; Kubica, A; Kubica, J; Navarese, EP; Siller-Matula, JM | 1 |
Gurbel, PA; Jeong, YH; Ohman, EM; Tantry, US | 1 |
Kern, MJ | 1 |
Hsu, PI | 1 |
Mutnick, JL | 1 |
Mackay, SM; Tcheng, JE | 1 |
Contractor, H; Ruparelia, N | 1 |
Baker, BA; Bernlochner, I; Brown, PB; Gupta, N; Jakubowski, JA; Kastrati, A; Morath, T; Schömig, A; Sibbing, D; Winters, KJ; Zhou, C | 1 |
Carbonell-Porras, A; Fernández-Ruiz, M; García-Reyne, A; López-Medrano, F | 1 |
Coulter, CJ; Montandon, SV | 1 |
Grześk, G; Koziński, M; Kubica, J | 1 |
Grajek, S | 1 |
Gong, Y; Jiao, B; Lv, F; Qi, X; Shan, J; Sun, H; Yuan, F; Zhang, B; Zheng, W; Zhu, Y | 1 |
Askari, AT; Stephens, JC | 1 |
Bristot, L; Campo, G; Ferrari, R; Gambetti, S; Monti, M; Parrinello, G; Tebaldi, M; Valgimigli, M | 1 |
Bradley, SM; Guzauskas, GF; Hughes, DA; Veenstra, DL | 1 |
Cavallari, LH; Schumock, GT | 1 |
Beitelshees, AL; Daniel Mullins, C; Onukwugha, E; Reese, ES | 1 |
Dick, A; Druce, I; Froeschl, M; Glover, C; Gollob, MH; Goncalves, S; Labinaz, M; Le May, MR; Marquis, JF; O'Brien, E; Roberts, JD; So, DY; Stewart, A; Wells, GA | 1 |
Harding, SA; Johnston, LR; La Flamme, AC; Larsen, PD; Michel, JM; Simmonds, MB | 1 |
Goss, FR; Pauker, SG | 1 |
Angiolillo, DJ; Gawaz, M; Jakubowski, JA; Kastrati, A; Müller, U; Neumann, FJ; Richardt, G; Stone, GW; Trenk, D | 1 |
Ferro, A; Floyd, CN; Passacquale, G | 1 |
Angiolillo, DJ; Azmoon, S | 1 |
Lyseng-Williamson, KA | 1 |
Mustonen, P; Puurunen, M | 1 |
Halperin, JL; Varughese, CJ | 1 |
Bessereau, J; Bonello, L; Camoin-Jau, L; Paganelli, F; Uhry, S | 1 |
Chen, CH; Lin, CJ; Uang, YS; Yang, JC | 1 |
Chen, L; Coyle, D; Moertl, D; Steiner, S; Wells, GA | 1 |
Goodnough, LT; Lenarz, LA; Levy, JH; Poston, RS; Short, MA; Smith, PK; Weerakkody, GJ | 2 |
Christ, G; Dechant, C; Delle-Karth, G; Francesconi, M; Gouya, G; Jilma, B; Maurer, G; Podczeck-Schweighofer, A; Ruzicka, K; Siller-Matula, JM | 1 |
Hausleiter, J; Joner, M; Kastrati, A; Massberg, S; Okrojek, R; Orban, M; Riegger, J; Sibbing, D; Tada, T | 1 |
Bounthavong, M; Madkour, N | 1 |
Gupta, A; Hirst, J; McKay, RG; Rai, M; Ruaño, G; Seip, RL; Thompson, PD | 1 |
Freynhofer, MK; Höchtl, T; Huber, K; Mahla, E; Prüller, F | 1 |
Heptinstall, S; Joshi, R; Wijeyeratne, YD | 1 |
Angiolillo, DJ; Baker, BA; Heiselman, DE; Jakubowski, JA; Li, W; Logan, DK; Price, MJ; Walder, JS; Winters, KJ | 1 |
Ahmad, S; Storey, RF | 1 |
Bessereau, J; Bonello, L; Camoin-Jau, L; Laine, M; Paganelli, F; Sébastien, A | 1 |
Bhatt, DL; Kar, S | 1 |
Barn, K; Steinhubl, SR | 1 |
Grove, EL; Hvas, AM; Kristensen, SD | 1 |
Carrié, D; Garcia, C; Lhermusier, T; Mejean, S; Sié, P; Voisin, S | 1 |
Budaj, A; Gurbel, PA; Tantry, US | 1 |
Gurbel, PA; Jeong, YH; Tantry, US | 1 |
Alexopoulos, D; Damelou, A; Davlouros, P; Galati, A; Hahalis, G; Kassimis, G; Makris, G; Mavronasiou, E; Theodoropoulos, KC; Tsigkas, G; Xanthopoulou, I | 1 |
Alexander, KP; Foody, JM; Funk, M; Granger, CB; Li, L; Lopes, RD; Peterson, ED; Wang, TY | 1 |
Limper, U; Lynch, J | 1 |
Chan, KH; Chan, MY; Lee, CH; Li, Y; Low, A; Phua, QH; Richards, MA; Roe, MT; Sia, W; Sim, TB; Tai, BC; Tan, HC; Teo, SG; Yeo, TC | 1 |
Huber, K | 1 |
Harrison, P | 1 |
Bernlochner, I; Braun, S; Kastrati, A; Koch, W; Mayer, K; Morath, T; Schömig, A; Schulz, S; Sibbing, D | 1 |
Bernlochner, I; Sibbing, D | 1 |
Ardissino, D; Armstrong, PW; Aylward, PE; Bhatt, DL; Boden, WE; Brown, EB; Cinteză, M; Clemmensen, P; Corbalan, R; Cornel, JH; Dalby, AJ; Fox, KA; Gasparovic, V; Goodman, SG; Gottlieb, S; Goudev, AR; Gurbel, PA; Hamm, C; Hochman, JS; Huber, K; Leiva-Pons, JL; Lokhnygina, Y; Martinez, F; McGuire, DK; McLendon, RC; Merkely, B; Nicolau, JC; Ohman, EM; Oto, A; Parkhomenko, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; Topacio, GO; Tseng, CD; White, HD; Winters, KJ | 1 |
Alexopoulos, D; Athanassiadou, A; Damelou, A; Davlouros, P; Hahalis, G; Kassimis, G; Stavrou, EF; Theodoropoulos, KC; Tsigkas, G; Xanthopoulou, I | 1 |
Chan, MY; Li, Y | 1 |
Brown, PM; Gladding, P; Panattoni, L; Te Ao, B; Webster, M | 1 |
Kastrati, A | 1 |
Badr Eslam, R; Calatzis, A; Gremmel, T; Koppensteiner, R; Lang, IM; Panzer, S | 1 |
Benedetti, G; Biondi-Zoccai, G; Calcagno, S; Canali, E; Di Roma, A; Fedele, F; Guadagni, F; Lucisano, L; Mancone, M; Palmirotta, R; Pennacchi, M; Sardella, G; Stio, RE | 1 |
Badimon, JJ; Becker, EM; Bütehorn, U; Kast, R; Klipp, A; Laux, V; Lücker, C; Perzborn, E | 1 |
Angiolillo, DJ; Bergmeijer, T; Brown, PB; Erlinge, D; Foley, D; Jakubowski, JA; James, S; Luo, J; Moser, B; Small, DS; Ten Berg, J; Wagner, H; Winters, KJ; Zhou, C | 1 |
Alessi, MC; Beguin, S; Bonnet, JL; Cuisset, T; Dubois, N; Dutour, A; Gaborit, B; Loosveld, M; Loundou, AD; Morange, PE; Moro, PJ; Quilici, J | 1 |
Arthur, AS; Hoit, DA; Jones, GM; Twilla, JD | 2 |
Choi, KN; Chung, SR; Do, U; Jang, JS; Jin, HY; Kim, DK; Kim, DS; Kim, HJ; Seo, JS; Yang, TH | 1 |
Armstrong, JM; Bandarenko, N; Barnato, SE; Bennett, CL; Carey, PM; Chen, F; Chen, H; Clark, WF; Cursio, JF; Danielson, C; Dunn, BL; Fujimura, Y; Jacob, S; Kiss, JE; Kwaan, HC; Matsumoto, M; McKoy, JM; Ortel, TL; Pandey, DK; Qureshi, ZP; Raife, TJ; Raisch, DW; Rock, G; Sarode, R; Weiss, I; Winters, JL; Zheng, XL | 1 |
Armstrong, PW; Brown, E; Chan, MY; Cornel, JH; Erlinge, D; Fox, KA; Goodman, SG; Gurbel, PA; Huber, K; Jakubowski, JA; Neely, B; Neely, M; Ohman, EM; Prabhakaran, D; Roe, MT; Tantry, US; White, HD; Zhou, C | 1 |
Abtan, J; Aubry, P; Barthélémy, O; Belle, L; Beygui, F; Boueri, Z; Carrié, D; Cayla, G; Collet, JP; Cuisset, T; Elhadad, S; Henry, P; Kerneis, M; Monségu, J; Montalescot, G; Motreff, P; O'Connor, SA; Pouillot, C; Rangé, G; Rousseau, H; Sabouret, P; Saint-Etienne, C; Silvain, J; Van Belle, E; Vicaut, E | 1 |
Berger, JS; Hochman, JS; Ladapo, JA; Lala, A; Scott Braithwaite, R; Sharma, G | 1 |
Baeriswyl, G; Cook, S; Goy, JJ; Lehmann, S; Lehner, C; Oberhänsli, M; Puricel, S; Stauffer, JC; Togni, M | 1 |
Bolognese, L; De Servi, S | 1 |
Chen, X; Fan, Z; Li, N; Liu, Q; Lu, Y; Qiu, Z; Song, L; Tian, F; Wang, X | 1 |
Aradi, D; Komócsi, A; Serebruany, VL; Vorobcsuk, A | 1 |
Cohen, DJ; Jones, PG; Li, Y; Salisbury, AC; Spertus, JA; Wang, K | 1 |
Chatterjee, S; Frankel, R; Ghose, A; Guha, G; Mukherjee, D; Sharma, A | 1 |
Amann, M; Hochholzer, W; Leggewie, S; Neumann, FJ; Nührenberg, TG; Ristau, I; Stratz, C; Trenk, D; Valina, CM | 1 |
Angiolillo, DJ; Costigan, TM; DeRaad, R; Duvvuru, S; Effron, MB; Frelinger, AL; Gurbel, PA; Jakubowski, JA; Ojeh, CK; Saucedo, JF | 1 |
Alexopoulos, D; Damelou, A; Davlouros, P; Hahalis, G; Mavronasiou, E; Plakomyti, TE; Theodoropoulos, KC; Xanthopoulou, I | 1 |
Kiss, RG | 1 |
Chen, F; Kent, KM; Kitabata, H; Loh, JP; Pendyala, LK; Pichard, AD; Satler, LF; Suddath, WO; Torguson, R; Waksman, R | 1 |
Benjamin, MM; Donsky, MS; Filardo, G; Schussler, JM | 1 |
Fareed, J; Jeske, W; Thethi, I | 1 |
Ohman, EM; Roe, MT | 1 |
Dantzler, DM; Lynch, DR; Zhao, D | 1 |
Daly, RL; Dhutia, AJ; Ecob, R; Howgego, KE; Judge, HM; Mehra, S; Morton, AC; Storey, RF; Sumaya, W | 1 |
Goto, S; Tomiya, A | 1 |
Eslam, RB; Gremmel, T; Koppensteiner, R; Lang, IM; Panzer, S | 1 |
Maddox, TM | 1 |
Bernlochner, I; Braun, S; Kastrati, A; Mayer, K; Morath, T; Orban, M; Schömig, A; Schulz, S; Sibbing, D | 1 |
Bakhai, A; Barrett, A; Davies, A; Graham-Clarke, P; Schmitt, C; Sculpher, M | 1 |
Alessi, MC; Beguin, S; Bonnet, JL; Camoin, L; Cohen, W; Cuisset, T; Gaborit, B; Grosdidier, C; Lambert, M; Loosveld, M; Morange, PE; Moro, PJ; Pankert, M; Quilici, J; Saut, N | 1 |
Jung, DK; Kim, MH; Zhang, HZ | 1 |
Can, MM; Dinicolantonio, JJ; Goto, S; Serebruany, VL | 1 |
Clemmensen, P; Dridi, NP; Holmvang, L | 1 |
Aronow, WS | 2 |
Alexopoulos, D; Xanthopoulou, I | 1 |
Agewall, S; Andreotti, F; Atar, D; Cattaneo, M; Collet, JP; Grove, EL; Huber, K; Husted, S; Kjeldsen, K; Lip, GY; Morais, J; Pathak, A; Rosano, G; Storey, RF; Verheugt, FW; Wassmann, S | 1 |
Abtan, J; Barthélémy, O; Beygui, F; Brugier, D; Cayla, G; Collet, JP; Kerneis, M; Martin, R; Montalescot, G; O'Connor, SA; Silvain, J; Vignalou, JB | 1 |
Angiolillo, DJ; Rollini, F | 1 |
Kim, MH; Lee, DH; Lee, MS; Park, JS; Park, K; Park, TH; Seo, JM; Zhang, HZ | 1 |
Felix-Getzik, E; Sylvia, LM | 1 |
Alexopoulos, D; Davlouros, P; Mavronasiou, E; Siapika, A; Stavrou, K; Tsoni, E; Xanthopoulou, I | 1 |
Kastrati, A; Martischnig, A; Mayer, K; Mehilli, J; Sarafoff, N; Sibbing, D; Wealer, J | 1 |
Bonello, L; Frere, C; Laine, M; Paganelli, F; Toesca, R | 1 |
Bertho, G; Dansette, PM; Hessani, A; Levent, D; Mansuy, D | 1 |
Gurbel, PA; Jeong, YH; Kubica, J; Navarese, EP; Tantry, US | 1 |
Stiefelhagen, P | 1 |
Wang, H; Wang, WE; Wang, X; Zeng, C | 1 |
Erlinge, D; Larsson, J; Ohman, J; Salmi, H; Torngren, K | 1 |
Angiolillo, DJ; Bailey, WL; Baker, BA; Bliden, KP; Gurbel, PA; Jakubowski, JA; Jeong, YH; Kereiakes, DJ; Lasseter, KC; Logan, DK; Maa, JF; Nolin, TD; Ojeh, CK; Tantry, US; White, A | 1 |
Gremmel, T; Kopp, CW; Koppensteiner, R; Panzer, S; Seidinger, D; Steiner, S | 1 |
Franken, CC; Kaiser, AF; Krüger, JC; Mügge, A; Neubauer, H; Overbeck, K | 1 |
Coleman, CI; Limone, BL | 1 |
Eikelboom, J; Fitchett, D; Mazer, CD; Verma, S | 1 |
Oprea, AD; Popescu, WM | 1 |
Enar, R | 1 |
Göddertz, R | 1 |
de Lemos, JA; Diercks, DB; Hollander, JE; Holmes, DN; Kontos, MC; Mumma, BE; Saucedo, JF; Wiviott, S | 1 |
Baron, TH; Kamath, PS; McBane, RD | 1 |
DiNicolantonio, JJ; Serebruany, VL | 1 |
Huber, K; Lip, GY | 1 |
Angiolillo, DJ; Brown, PB; Erlinge, D; Foley, DP; Gurbel, PA; Jakubowski, JA; James, S; Lindahl, TL; Luo, J; Moser, BA; Small, DS; Svensson, P; Ten Berg, JM; Wagner, H; Winters, KJ; Zhou, C | 1 |
Bonello, L; Frère, C; Laine, M; Paganelli, F | 1 |
Apostolakis, S; Lip, GY; Shantsila, E | 1 |
Conde, D; Elissamburu, P; Lalor, N; Rodriguez, L; Trivi, M | 2 |
Christ, G; Francesconi, M; Grohs, K; Hafner, T; Podczeck-Schweighofer, A; Siller-Matula, JM; Wilhelm, E | 1 |
Pollack, CV | 1 |
Ardissino, D; Armstrong, PW; Aylward, PE; Bassand, JP; Boden, WE; Dalby, AJ; Fox, KA; Goodman, SG; Gottlieb, S; Hochman, JS; Martinez, F; McGuire, DK; Ohman, EM; Prabhakaran, D; Roe, MT; Stevens, SR; White, HD; Winters, KJ | 1 |
Can, MM; Dinicolantonio, JJ; Kuliczkowski, W; Pershukov, IV; Serebruany, VL | 1 |
Bray, PF; DeLa Cadena, RA; Garcia, AE; Kunapuli, SP; Liverani, E; Rico, MC | 1 |
Aradi, D; Baumstarck, K; Bessereau, J; Bonello, L; Camilleri, E; Camoin-Jau, L; Dignat-George, F; Fernandez, J; Laine, M; Maillard, L; Paganelli, F; Peyrol, M; Piot, C; Roubille, F | 1 |
Alessi, MC; Beguin, S; Bonnet, G; Bonnet, JL; Cuisset, T; Deharo, P; Grosdidier, C; Morange, P; Pankert, M; Pons, C; Quilici, J | 1 |
Franklin, JM; Glynn, RJ; Patrick, AR; Schneeweiss, S; Weinstein, MC | 1 |
Abtan, J; Barthélémy, O; Beygui, F; Brugier, D; Collet, JP; Kerneis, M; Montalescot, G; O'Connor, SA; Silvain, J; Vignalou, JB | 1 |
Dinicolantonio, JJ; Norgard, NB | 1 |
Acosta, J; Benezet, J; Cubero Gómez, JM; Díaz DE LA Llera, LS; Fernández-Cisnal, A; Parejo, J; Rangel, D; Zafra, F | 1 |
Feldman, DN; Swaminathan, RV | 1 |
Armstrong, PW; Bhatt, DL; Boden, WE; Clemmensen, P; Fox, KA; Hafley, G; Hamm, C; Leiva-Pons, J; Lokhnygina, Y; Menozzi, A; Nicolau, JC; Ohman, EM; Oto, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; White, HD; Widimsky, P; Winters, KJ; Wiviott, SD | 1 |
Alessi, MC; Beguin, S; Bonnet, JL; Camoin, L; Cuisset, T; Grosdidier, C; Lambert, M; Loosveld, M; Loundou, AD; Morange, PE; Pankert, M; Quilici, J | 1 |
Gross, L; Massberg, S; Orban, M; Sibbing, D | 1 |
Beigel, R; Elian, D; Fefer, P; Fink, N; Guetta, V; Hod, H; Matetzky, S; Novikov, I; Rosenberg, N; Segev, A | 1 |
Aylward, PE; Sinhal, AR | 1 |
Alexopoulos, D; Angelidis, C; Deftereos, S; Goudevenos, JA; Hahalis, G; Hamilos, M; Kanakakis, I; Ntalas, IV; Parissis, H; Petousis, S; Sitafidis, G; Stefanadis, C; Vavuranakis, M; Xanthopoulou, I | 1 |
Ackman, ML; Bauer, RD; Bell, AD; Cartier, R; Chan, WS; Douketis, J; Mehta, SR; Roussin, A; Schnell, G; Tanguay, JF; Verma, S; Wong, G | 1 |
Moertl, D; Steiner, S | 1 |
Angiolillo, DJ; Braun, OÖ; Costigan, TM; Duvvuru, S; Effron, MB; Ferreiro, JL; Jakubowski, JA; Kleiman, NS; Saucedo, JF; Sundseth, S; Varenhorst, C; Walker, JR; Winters, KJ | 1 |
Grove, EL; Würtz, M | 1 |
Chua, D; Nishi, C | 1 |
Chen, X; Gao, W; Jing, J; Li, N; Lu, Y; Parekha, HS; Qiu, Z; Ren, S; Song, L; Tian, F; Wang, X | 1 |
He, B; Kun, L; Liu, X; Wu, B | 1 |
Abbate, R; Antoniucci, D; Carrabba, N; Gensini, GF; Marcucci, R; Migliorini, A; Parodi, G; Valenti, R | 1 |
Antman, EM; Braunwald, E; Cannon, CP; Giugliano, RP; Mogabgab, O; Sabatine, MS; Sloan, S; Wiviott, SD | 1 |
Angiolillo, DJ; Cardillo, TE; Diodati, JG; Effron, MB; Fisher, HN; French, JK; Fung, AY; Henneges, C; Saucedo, JF | 1 |
Curkovic, I; Egbring, M; Kullak-Ublick, GA | 1 |
Dugdale, M; Fabian, TC; Gordon, JL; Lee, MD | 1 |
Acharji, S; Kaluski, E; Lakshmanadoss, U; Rudzinski, W; Stapleton, DD | 1 |
Adsett, G; Jayasinghe, R; Markham, R | 1 |
Becker, RC; Breithardt, G; Califf, RM; Fox, KA; Goodman, SG; Hacke, W; Halperin, JL; Hankey, GJ; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Stevens, SR; White, HD | 1 |
Antman, EM; Braunwald, E; Cannon, CP; Kohli, P; Murphy, SA; Udell, JA; Wiviott, SD | 1 |
Angiolillo, DJ; Bass, TA; Darlington, A; Desai, B; Ferreiro, JL; Guzman, LA; Patel, R; Rollini, F; Tello-Montoliu, A; Ueno, M | 1 |
Meinertz, T | 1 |
Damman, P; Eriksson, P; Erlinge, D; James, SK; Koul, S; Lagerqvist, B; Varenhorst, C | 1 |
Bode, C; Diehl, P; Moser, M; Olivier, CB; Schnabel, K; Weik, P; Zhou, Q | 1 |
Alessi, MC; Bonnet, G; Bonnet, JL; Cuisset, T; Deharo, P; Dutour, A; Gaborit, B; Lambert, M; Loundou, AD; Morange, PE; Pankert, M; Quilici, J; Valéro, R; Verdier, V | 1 |
Brennan, T; Canestaro, WJ; Chaplin, D; Choudhry, NK; Desai, NR; Kyrychenko, P; Martell, LA; Matlin, OS | 1 |
Verheugt, FW | 1 |
Antman, EM; Bates, ER; Mega, JL; Murphy, SA; O'Donoghue, ML; Ojeifo, O; Sabatine, MS; Udell, JA; Wiviott, SD | 1 |
Clemmensen, P; Dridi, NP; Engstrøm, T; Helqvist, S; Holmvang, L; Johansson, PI; Jørgensen, E; Kelbæk, H; Pedersen, F; Qayyum, A; Radu, MD; Saunamäki, K; Stissing, T | 1 |
Dhillon, K; Dovlatova, N; Fox, SC; Glenn, JR; Heptinstall, S; White, AE | 1 |
Alexopoulos, D; Angelidis, C; Davlouros, P; Deftereos, S; Goudevenos, J; Hamilos, M; Kanakakis, I; Parissis, H; Petousis, S; Sitafidis, G; Stakos, D; Stefanadis, C; Vavouranakis, M; Xanthopoulou, I | 1 |
Arrich, J; Gouya, G; Gurbel, PA; Huber, K; Pirker-Kees, A; Siller-Matula, JM; Verheugt, FW; Wolzt, M | 1 |
Angiolillo, DJ; Baker, BA; Heiselman, DE; Jakubowski, JA; Li, W; Price, MJ | 1 |
Balasubramaniam, K; Koshy, A; Noman, A; Zaman, AG | 1 |
Arntz, HR; Boudriot, E; Garlichs, C; Helms, TM; Hoffmann, S; Ince, H; Klingenheben, T; Schäfer, A; Silber, S; Weil, J; Zugck, C | 1 |
Ay, C; Badr Eslam, R; Eichelberger, B; Gremmel, T; Lang, IM; Panzer, S; Posch, F | 1 |
Gasparovic, H; Petricevic, M | 1 |
Alessi, MC; Bonnet, JL; Cuisset, T; Quilici, J | 1 |
Alexander, T; Babu, PR; Dani, S; Dasbiswas, A; Hiremath, S; Nayak, R; Patel, T; Pathak, K; Prakash, VS; Rao, MS; Singh, DP; Srivastava, A; Tyagi, S; Vijayvergiya, R; Yadav, MK | 1 |
Hirschl, MM | 1 |
Aradi, D; Faluközy, J; Horváth, IG; Komócsi, A; Kónyi, A; Magyari, B; Pintér, T; Tornyos, A; Veress, G; Vorobcsuk, A | 1 |
Gupta, K; Singh, D; Vacek, JL | 1 |
Bohn, RL; Choudhry, NK; Daniel, GW; Gagne, JJ; Liu, J; Patrick, AR; Rassen, JA; Schneeweiss, S; Sridhar, G | 1 |
Gnall, EM; Ice, DS; Kowey, PR; Shapiro, TA | 1 |
Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ | 1 |
Bailey, WL; Baker, BA; Bliden, KP; Gurbel, PA; Tantry, US | 1 |
Coons, JC; Harris, J; Schwier, N; Seybert, AL | 1 |
Christoph, M; Ibrahim, K; Jellinghaus, S; Kolschmann, S; Mues, C; Pfluecke, C; Quick, S; Schmeinck, S; Schmieder, K; Schoener, L; Steiding, K; Strasser, RH; Wunderlich, C | 1 |
Duraj, L; Fedor, M; Fedorová, J; Galajda, P; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Šimonová, R; Staško, J | 1 |
Sabouret, P; Taiel-Sartral, M | 1 |
Brener, SJ; El-Omar, M; Gibson, CM; Maehara, A; Mehran, R; Oldroyd, KG; Stone, GW; Witzenbichler, B; Xu, K | 1 |
Braun, D; Gershlick, AH; Hauschke, D; Ibrahim, T; Kastrati, A; Laugwitz, KL; Mayer, K; Mehilli, J; Mehran, R; Morath, T; Neudecker, J; Richardt, G; Schulz, S; Schunkert, H; Tölg, R | 1 |
Hartung, P; Hill, K; Schaefer, M; Schulze, A | 1 |
Delzor, F; Nanau, RM; Neuman, MG | 1 |
Antoniucci, D; De Luca, G; Marino, P; Parodi, G; Schaffer, A; Suryapranata, H; Verdoia, M | 1 |
Abbate, R; Antoniucci, D; Bellandi, B; Carrabba, N; Comito, V; De Luca, G; Gensini, GF; Marcucci, R; Migliorini, A; Parodi, G; Ramazzotti, RN; Valenti, R | 1 |
Caldeira, D; Ferreira, JJ; Pinto, FJ | 1 |
Bouatou, Y; Gabrielli, A; Saudan, P | 1 |
Angiolillo, DJ; Cardillo, TE; Diodati, JG; Duvvuru, S; Effron, MB; Fisher, HN; Henneges, C; Jakubowski, JA; Lipkin, FR; Saucedo, JF; Sundseth, SS; Walker, JR | 1 |
Bernlochner, I; Braun, S; Hausleiter, J; Kastrati, A; Laugwitz, KL; Massberg, S; Mayer, K; Morath, T; Schulz, S; Schunkert, H; Sibbing, D | 1 |
Boothroyd, DB; Dudley, RA; Garber, AM; Hlatky, MA; Kazi, DS; Mell, MW; Moshkevich, S; Owens, DK; Rhee, C; Shah, RU | 1 |
Taylor, J | 1 |
Delemos, J; Peng, SA; Peterson, ED; Roe, MT; Sherwood, MW; Wang, TY; Wiviott, SD | 1 |
Al-Attar, N; Amour, J; Ascione, R; Collet, JP; Falk, V; Huber, K; Leite-Moreira, AF; Sousa-Uva, M; Storey, R; Taggart, D | 1 |
Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Yokoi, H | 1 |
Adamski, P; Fabiszak, T; Grześk, G; Koziński, M; Kubica, J; Navarese, EP; Ostrowska, M; Paciorek, P | 1 |
Gislason, G; Sørensen, R | 1 |
Elosua, R; Marrugat, J; Vila, J | 2 |
Catalá-López, F | 1 |
Fortmann, SD; Serebruany, VL | 1 |
Abdel-Wahab, M; Anette Fiedler, K; Gershlick, AH; Hoppmann, P; Ibrahim, T; Kastrati, A; Kufner, S; Laugwitz, KL; Mehilli, J; Mehran, R; Morath, T; Neudecker, J; Richardt, G; Schneider, S; Schulz, S; Schunkert, H; Tölg, R | 1 |
Massberg, S; Sibbing, D | 1 |
Harrington, RA; Himmelmann, A; Steg, PG; Storey, RF; Wallentin, L | 1 |
De Servi, S; Goedicke, J; Schirmer, A; Widimsky, P | 1 |
Bataille, V; Carrié, D; Garcia, C; Lhermusier, T; Lipinski, MJ; Mejean, S; Murat, G; Sié, P; Voisin, S | 1 |
Bolliger, D; Drews, S; Eckstein, F; Grapow, M; Kaiser, C; Matt, P; Reuthebuch, O | 1 |
Jelliffe, R | 1 |
Antoniucci, D; Migliorini, A; Valenti, R | 1 |
Takahashi, J | 1 |
Maloof, JA; Williams, MF | 1 |
Antman, EM; Braunwald, E; Montalescot, G; Murphy, SA; Udell, JA; Wiviott, SD | 1 |
Roe, MT; Sherwood, MW | 1 |
Chan, NC; Eikelboom, JW; Ginsberg, JS; Hirsh, J; Lauw, MN; Vanassche, T; Weitz, JI | 1 |
Armstrong, PW; Clemmensen, P; Cornel, JH; Fox, KA; Gurbel, PA; Neely, B; Ohman, EM; Prabhakaran, D; Roe, MT; Sritara, P; White, HD; Zamoryakhin, D | 1 |
Angiolillo, DJ; Bergmeijer, TO; Brown, PB; Duvvuru, S; Erlinge, D; Gurbel, PA; Jakubowski, JA; James, S; Lindahl, TL; Moser, BA; Small, D; Sundseth, S; Svensson, P; Tantry, US; ten Berg, JM; Walker, JR; Winters, KJ | 1 |
Abtan, J; Anzaha, G; Barthélémy, O; Beygui, F; Brugier, D; Cayla, G; Charland, SL; Collet, JP; Galier, S; Gallois, V; Hulot, JS; Kerneis, M; Montalescot, G; O'Connor, SA; Silvain, J; Stanek, EJ | 1 |
Costigan, T; Iqbal, K; Lopez-Sendon, J; Ramos, Y; Widimsky, P; Wilcox, R | 1 |
Calcagno, S; Sardella, G | 1 |
Aradi, D; Komócsi, A | 1 |
Bae, JP; Effron, MB; Ernst, FR; Faries, DE; Lieu, HD; Lipkin, C; Moretz, C; Zhao, Z | 1 |
Alexander, KP; Bagai, A; Bhatt, DL; Cheema, AN; Curtis, JP; Granger, CB; Gurm, HS; McNamara, RL; Peterson, ED; Roe, MT; Saucedo, JF; Shah, B; Wang, TY; Wang, Y | 1 |
Abendschein, D; Broekman, MJ; Chen, R; Drosopoulos, JH; Jeong, SS; Marcus, AJ; Moeckel, D; Nguyen, A; Robson, SC; Sun, X | 1 |
Christ, G; Dechant, C; Delle-Karth, G; Francesconi, M; Grohs, K; Gruber, C; Jilma, B; Podczeck-Schweighofer, A; Siller-Matula, JM | 1 |
Bernlochner, I; Braun, S; Hadamitzky, M; Hausleiter, J; Hoppmann, P; Kastrati, A; Laugwitz, KL; Massberg, S; Mayer, K; Mehilli, J; Morath, T; Orban, M; Schulz, S; Schunkert, H; Sibbing, D; Tiroch, K | 1 |
Fauchère, I; Schreiber, P; Wyss, C | 1 |
Ahn, JH; Gurbel, P; Jeong, YH; Kim, KH; Tantry, US | 1 |
Nakamura, M; Saito, S | 1 |
Crivera, C; Dea, K; Fields, LE; Germain, G; Laliberté, F; Lefebvre, P; Lynch, SM; Ma, YW; Olson, WH; Schein, JR | 1 |
Vengoechea, F | 1 |
Ikeda, Y; Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Yokoi, H | 1 |
Biocina, B; Boban, M; Ivancan, V; Konosic, S; Mihaljevic, MZ; Petricevic, M; Samardzic, J | 1 |
Christ, G; Dechant, C; Francesconi, M; Grohs, K; Podczeck-Schweighofer, A; Siller-Matula, JM | 1 |
Chieffo, A; Colombo, A | 1 |
Braunwald, E; Cohen, DJ; Cutlip, DE; Dauerman, HL; Driscoll-Shempp, P; Garratt, KN; Hermiller, J; Holmes, DR; Kandzari, DE; Kereiakes, DJ; Krucoff, MW; Lee, DP; Massaro, JM; Mauri, L; Normand, SL; Pow, TK; Rinaldi, MJ; Simon, DI; Steg, PG; Ver Lee, P; Wiviott, SD; Yeh, RW | 1 |
Huynh, K | 1 |
Bae, JP; Candrilli, SD; Drenning, D; Fortenberry, J; Jakubowski, JA; Meyers, JL | 1 |
Andell, P; Björnsson, S; Erlinge, D; Götberg, M; Harnek, J; Koul, S; Martinsson, A; Norström, E; Scherstén, F; Smith, JG | 1 |
Anderson, JL; Goto, S; Huo, Y; Jeong, YH; Levine, GN; Mega, JL; Smith, SC; Taubert, K | 1 |
Arntz, HR; Diller, F; Mark, B; Mochmann, HC; Montalescot, G; Thiele, H; Zahn, R; Zeymer, U | 1 |
Lhermusier, T; Waksman, R | 1 |
Assinger, A; Kral, JB; Scharbert, G; Schrottmaier, WC; Weber, T; Wetzel, L | 1 |
Jiang, M; You, JH | 1 |
Bultas, J | 1 |
Baker, N; Bliden, KP; Chen, F; Escarcega, RO; Gurbel, PA; Lhermusier, T; Lipinski, MJ; Magalhaes, MA; Minha, S; Ota, H; Pendyala, L; Tantry, US; Tian, W; Torguson, R; Waksman, R | 1 |
Bolliger, D; Drews, S; Eckstein, F; Kaiser, C; Matt, P | 1 |
Helft, G | 1 |
Calıskan, A; Demirtas, S; Guclu, O; Kaplan, I; Karahan, O; Tezcan, O; Yavuz, C; Yazıcı, S | 1 |
Amsallem, M; Bal dit Sollier, C; Dillinger, JG; Drouet, L; Henry, P; Manzo-Silberman, S; Sideris, G; Voicu, S | 1 |
Keaney, JF | 1 |
Guyatt, G; Spencer, FA | 1 |
Steg, PG; Wiviott, SD | 1 |
Auer, R; Carballo, D; Gencer, B; Heg, D; Jaguszewski, M; Jakob, P; Jüni, P; Klingenberg, R; Landmesser, U; Lüscher, TF; Mach, F; Maier, W; Matter, CM; Meier, B; Nanchen, D; Räber, L; Rodondi, N; Roffi, M; Stähli, BE; Stefanini, GG; Templin, C; Vogt, P; Windecker, S | 1 |
Chen, L; Liu, D; Liu, Y; Tao, Z; Xia, G; Zhi, S | 1 |
Bode, C; Cohen, M; Fox, K; Gibson, CM; Halperin, J; Husted, S; Lip, GY; Mehran, R; Peterson, E; van Eickels, M; Verheugt, F; Wildgoose, P | 1 |
Kereiakes, DJ; Mauri, L; Yeh, RW | 1 |
Sipahi, I | 1 |
Dohan, JL | 1 |
Marrs, JC | 1 |
Jeger, R; Kaiser, C; Pfisterer, M | 1 |
Tomoda, H | 1 |
Angoulvant, D; Angoulvant, TB; Fauchier, L | 1 |
Liakishev, AA | 1 |
Chen, HB; Huang, BY; Liang, HB; Liu, XW; Xiu, J; Zhang, XL; Zhang, XY | 1 |
Lozano, I; Rondan, J; Segovia, E; Vegas, JM | 1 |
Montalescot, G; Zeymer, U | 1 |
Alexopoulos, D; Bhatt, DL; Hamm, CW; Steg, PG; Stone, GW | 1 |
Ahsan, CH; Ali, ML; Amin, MN; Chowdhury, MZ; Haq, MM; Karim, MR; Khan, SR; Mansur, M; Millat, MH; Rashid, MA | 1 |
Bangalore, S; Bavishi, C; Messerli, FH; Panwar, S | 1 |
Ofosu, FA | 1 |
Desch, S; Eitel, I; Empen, K; Ferenc, M; Fuernau, G; Hambrecht, R; Hausleiter, J; Hennersdorf, M; Limbourg, T; Neumann, FJ; Olbrich, HG; Orban, M; Pöss, J; Richardt, G; Schneider, S; Schuler, G; Thiele, H; Werdan, K; Zeymer, U | 1 |
Angiolillo, DJ; Franchi, F | 1 |
Fawcett, JP; Gu, J; Liu, M; Meng, X; Su, C; Wang, H; Xu, X; Yang, Y; Yang, Z; Zhao, X | 1 |
Parker, WA; Storey, RF | 1 |
Ji, JZ; Jia, YM; Tai, T; Xie, HG | 1 |
Ding, Y; Gong, Y; Lai, X; Li, X; Li, Y; Liu, C; Liu, X; Liu, Y; Sun, H; Wei, H; Xia, Y; Zhan, Y; Zhang, H; Zhang, Y; Zhong, D; Zhu, X; Zhu, Y | 1 |
Galford, KF; Jose, AM | 1 |
Gong, Y; He, Y; Lai, X; Li, YG; Liu, X; Liu, Y; Sun, H; Yan, X; Zhang, EY; Zhang, L | 1 |
202 review(s) available for ticlopidine and thiophenes
Article | Year |
---|---|
[Mechanism of platelet aggregation inhibition].
Topics: Adenylyl Cyclases; Animals; Blood Platelets; Cyclic AMP; Depression, Chemical; Phosphodiesterase Inhibitors; Platelet Aggregation; Prostaglandins; Pyridines; Rats; Thiophenes; Ticlopidine | 1979 |
Pharmacology of the interaction between platelets and vessel wall.
Topics: Animals; Aspirin; Blood Platelets; Blood Vessels; Dextrans; Diltiazem; Dipyridamole; Epoprostenol; Humans; Imidazoles; Ketanserin; Piperidines; Pyrazoles; Pyrazolones; Sulfinpyrazone; Sulfonamides; Thiophenes; Ticlopidine | 1986 |
[Platelet function inhibitors in peripheral arteriopathies].
Topics: Adrenal Cortex Hormones; Adrenergic alpha-Antagonists; Anti-Inflammatory Agents; Arachidonic Acid; Arachidonic Acids; Arteriosclerosis Obliterans; Aspirin; Blood Platelets; Calcium Channel Blockers; Clinical Trials as Topic; Cyclic AMP; Dipyridamole; Extremities; Heparin; Humans; Imidazoles; Prostaglandins; Prostanoic Acids; Pyrazoles; Pyrazolones; Quinacrine; Thiophenes; Thromboembolism; Thrombosis; Ticlopidine; Vascular Diseases | 1986 |
[Thrombosis in various diseases: myocardial infarct].
Topics: Angioplasty, Balloon; Aspirin; Dipyridamole; Humans; Myocardial Infarction; Platelet Aggregation; Thiophenes; Thrombosis; Ticlopidine | 1986 |
Antiplatelet drugs in the management of patients with thrombotic disorders.
Topics: Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Blood Coagulation Disorders; Blood Platelets; Catheterization; Cerebrovascular Disorders; Coronary Disease; Dipyridamole; Glomerulonephritis; Humans; Sulfinpyrazone; Suloctidil; Thiophenes; Thrombophlebitis; Thrombosis; Ticlopidine; Vascular Diseases; Vascular Surgical Procedures | 1986 |
Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis.
Topics: Anticoagulants; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Cardiovascular Diseases; Clinical Trials as Topic; Dipyridamole; Double-Blind Method; Female; Glomerulonephritis; Graft Occlusion, Vascular; Heart Valve Prosthesis; Humans; Ischemic Attack, Transient; Male; Myocardial Infarction; Postoperative Complications; Random Allocation; Sulfinpyrazone; Thiophenes; Ticlopidine | 1986 |
Rationale for the use of drugs inhibiting platelet function in claudicating patients with atherosclerotic leg arteries.
Topics: Anticoagulants; Arteriosclerosis; beta-Thromboglobulin; Blood Platelets; Clinical Trials as Topic; Humans; Intermittent Claudication; Leg; Platelet Aggregation; Platelet Factor 4; Suloctidil; Thiophenes; Thrombosis; Thromboxane A2; Ticlopidine | 1984 |
[Role of antiaggregant platelet drugs in thromboembolism].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Anti-Bacterial Agents; Aspirin; Cerebrovascular Disorders; Dextrans; Dipyridamole; Humans; Mitral Valve; Platelet Aggregation; Platelet Function Tests; Pyridines; Pyridinolcarbamate; Random Allocation; Sulfinpyrazone; Suloctidil; Thiophenes; Thromboembolism; Ticlopidine | 1981 |
Cyclic nucleotides, prostaglandins, and ischemic heart disease.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Arteriosclerosis; Coronary Disease; Diet, Atherogenic; Myocardial Contraction; Myocardial Infarction; Nucleotides, Cyclic; Prostaglandins; Rabbits; Thiophenes; Thromboxane A2; Ticlopidine | 1984 |
[Platelet anti-aggregant drugs and ischemic cardiopathy: evaluation of the effect on platelet aggregation and on antithrombin III].
Topics: Adult; Anticoagulants; Antithrombin III; Arrhythmias, Cardiac; Clofibrate; Dipyridamole; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation; Pyridines; Sulfinpyrazone; Suloctidil; Thiophenes; Ticlopidine | 1981 |
[Pharmacology of anti-platelet agents].
Topics: Animals; Anticoagulants; Aspirin; Blood Platelets; Cyclic AMP; Cyclooxygenase Inhibitors; Dipyridamole; Epoprostenol; Female; Fibrinolytic Agents; Humans; In Vitro Techniques; Intestinal Absorption; Kinetics; Male; Papio; Platelet Aggregation; Prostaglandin Antagonists; Rabbits; Sulfinpyrazone; Thiophenes; Thrombosis; Thromboxane A2; Ticlopidine | 1983 |
Ticlopidine hydrochloride: relationship between dose, kinetics, plasma concentration and effect on platelet function.
Topics: Adenosine Diphosphate; Animals; Blood Coagulation; Blood Platelets; Collagen; Dose-Response Relationship, Drug; Fibrinolytic Agents; Humans; Kinetics; Platelet Aggregation; Rats; Thiophenes; Ticlopidine; Time Factors | 1983 |
The mechanisms of action of ticlopidine.
Topics: Adenosine Diphosphate; Animals; Fibrinolytic Agents; Humans; In Vitro Techniques; Malondialdehyde; Platelet Aggregation; Prostaglandins; Thiophenes; Ticlopidine; Time Factors | 1983 |
Overview: pharmacology of ticlopidine.
Topics: Animals; Anticoagulants; Bleeding Time; Blood Vessels; Humans; Kinetics; Platelet Aggregation; Thiophenes; Thrombosis; Ticlopidine | 1984 |
Overview: clinical experiences with ticlopidine.
Topics: Anemia, Sickle Cell; Anticoagulants; Arterial Occlusive Diseases; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Artery Bypass; Extracorporeal Circulation; Humans; Renal Dialysis; Retinal Diseases; Subarachnoid Hemorrhage; Thiophenes; Ticlopidine | 1984 |
Pharmacokinetic and metabolic characteristics of ticlopidine in relation to its inhibitory properties on platelet function.
Topics: Anticoagulants; Biotransformation; Dose-Response Relationship, Drug; Humans; Kinetics; Platelet Aggregation; Thiophenes; Ticlopidine | 1984 |
[Platelet aggregation and antiaggregant drugs].
Topics: Dipyridamole; Humans; Papaverine; Platelet Aggregation; Prostaglandins; Theophylline; Thiophenes; Thromboxane A2; Ticlopidine; Verapamil | 1982 |
Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity.
Topics: Adenosine Diphosphate; Adult; Animals; Aspirin; Biotransformation; Clinical Trials, Phase I as Topic; Clopidogrel; Collagen; Drug Evaluation, Preclinical; Drug Synergism; Fibrinolytic Agents; Hemostasis; Humans; Male; Membrane Proteins; Molecular Structure; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Pyridines; Rats; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Thrombin; Thrombosis; Ticlopidine | 2005 |
Aspirin and clopidogrel resistance: consideration and management.
Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Restenosis; Drug Resistance; Humans; Membrane Proteins; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine | 2006 |
Prasugrel.
Topics: Adenosine Diphosphate; Animals; Aspirin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Clopidogrel; Collagen; Coronary Disease; Drug Evaluation, Preclinical; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Drugs, Investigational; Humans; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Pyridines; Rats; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2006 |
Platelet P2 receptors: old and new targets for antithrombotic drugs.
Topics: Adenosine; Adenosine Monophosphate; Angina, Unstable; Animals; Blood Platelets; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Interactions; Fibrinolytic Agents; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Receptors, Purinergic P2X; Syndrome; Thiophenes; Ticagrelor; Ticlopidine | 2007 |
Thienopyridines in cardiovascular disease: focus on clopidogrel resistance.
Topics: Blood Platelets; Cardiovascular Diseases; Clopidogrel; Drug Design; Drug Resistance; Drugs, Investigational; Humans; Membrane Proteins; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2007 |
Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis.
Topics: Adenosine Diphosphate; Adolescent; Adult; Aged; Bayes Theorem; Clinical Trials, Phase I as Topic; Clopidogrel; Databases, Factual; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Treatment Outcome | 2007 |
ADP receptor antagonism: what's in the pipeline?
Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Disease; Humans; Membrane Proteins; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2007 |
Will prasugrel supersede clopidogrel for acute coronary syndromes?
Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticlopidine | 2008 |
Prasugrel: a novel antiplatelet agent.
Topics: Acute Coronary Syndrome; Animals; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Thrombolytic Therapy; Ticlopidine | 2008 |
Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion.
Topics: Acute Coronary Syndrome; Algorithms; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiovascular Agents; Clinical Trials as Topic; Clopidogrel; Emergency Treatment; Evidence-Based Medicine; Fibrinolytic Agents; Hirudins; Humans; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Hemorrhage; Practice Guidelines as Topic; Prasugrel Hydrochloride; Recombinant Proteins; Risk Assessment; Stents; Thiophenes; Thrombosis; Ticlopidine | 2008 |
Antiplatelet drugs in cardiological practice: established strategies and new developments.
Topics: Atherosclerosis; Clopidogrel; Drug-Eluting Stents; Humans; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Thromboxane; Signal Transduction; Thiophenes; Thrombosis; Ticlopidine | 2008 |
Intensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine | 2008 |
Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future.
Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; History, 20th Century; History, 21st Century; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Stents; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2008 |
Is prasugrel more effective than clopidogrel in patients with acute coronary syndrome scheduled for PCI?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Dose-Response Relationship, Drug; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticlopidine; Treatment Outcome | 2008 |
Prasugrel development - claims and achievements.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Aspirin; Blood Platelets; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Drug Administration Schedule; Drug Discovery; Drug Resistance; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Research Design; Risk Assessment; Stents; Thiophenes; Ticlopidine; Treatment Outcome | 2009 |
Current problems, new opportunities and future directions of anti-platelet therapy - increasing role of novel antiplatelet agents in cardiovascular diseases.
Topics: Adenosine; Adenosine Monophosphate; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Humans; Imines; Lactones; Patents as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptor, PAR-1; Receptors, Purinergic P2Y12; Receptors, Thrombin; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Coronary Angiography; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Severity of Illness Index; Survival Analysis; Thiophenes; Thromboembolism; Ticlopidine; Treatment Outcome | 2009 |
Response variability and the role of platelet function testing.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2009 |
Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2009 |
New antiplatelet drugs: beyond aspirin and clopidogrel.
Topics: Adenosine; Adenosine Monophosphate; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Drug Design; Humans; Imines; Lactones; Naphthalenes; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propionates; Purinergic P2 Receptor Antagonists; Pyridines; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Critical review of prasugrel for formulary decision makers.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Drug Interactions; Formularies, Hospital as Topic; Humans; Managed Care Programs; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Thiophenes; Ticlopidine | 2009 |
Prasugrel for the treatment of patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Treatment Outcome | 2009 |
Management of patients with high gastrointestinal risk on antiplatelet therapy.
Topics: Aspirin; Clopidogrel; Gastrointestinal Hemorrhage; Humans; Peptic Ulcer; Peptic Ulcer Hemorrhage; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Risk Factors; Thiophenes; Ticlopidine | 2009 |
Prasugrel: newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Resistance; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticlopidine | 2009 |
Bedside evaluation of thienopyridine antiplatelet therapy.
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Clinical Trials as Topic; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Resistance; Drug Therapy, Combination; Humans; Mass Screening; Myocardial Infarction; Nephelometry and Turbidimetry; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Point-of-Care Systems; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Thrombelastography; Ticlopidine; United States | 2009 |
Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Diabetes Complications; Drug Resistance; Drug Therapy, Combination; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Stents; Thiophenes; Ticlopidine; Treatment Outcome | 2009 |
Review of prasugrel for the secondary prevention of atherothrombosis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atherosclerosis; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Thrombosis; Ticlopidine | 2009 |
Aggressive chronic platelet inhibition with prasugrel and increased cancer risks: revising oral antiplatelet regimens?
Topics: Animals; Aspirin; Clopidogrel; Colonic Neoplasms; Gastrointestinal Hemorrhage; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine | 2009 |
Diabetes and acute coronary syndromes.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Blood Glucose; Clopidogrel; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Enoxaparin; Hirudins; Humans; Hypoglycemic Agents; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Recombinant Proteins; Thiophenes; Thrombosis; Ticlopidine | 2009 |
[Prodrug activation as a crucial difference. Prasugrel - a new ADP receptor antagonist].
Topics: Animals; Biotransformation; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Thiophenes; Thrombosis; Ticlopidine | 2009 |
[Technological and biopharmaceutical aspects. Antiplatelet agents for oral administration].
Topics: Administration, Oral; Animals; Aspirin; Clopidogrel; Dipyridamole; Humans; Patents as Topic; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2009 |
Improving adjunctive pharmacotherapy for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: beyond the HORIZONS-AMI trial.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Chemotherapy, Adjuvant; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Heparin; Hirudins; Humans; Myocardial Infarction; Peptide Fragments; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Recombinant Proteins; Risk Assessment; Thiophenes; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2009 |
P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 Enzyme System; Humans; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Thiophenes; Ticlopidine | 2009 |
Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects.
Topics: Adult; Clopidogrel; Coronary Artery Disease; Data Collection; Female; Humans; Kinetics; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Young Adult | 2009 |
Prasugrel: a review of its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Blood Loss, Surgical; Clopidogrel; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine; Tissue Distribution; Young Adult | 2009 |
Challenges in oral antiplatelet therapy: ST-segment elevation myocardial infarction.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration Schedule; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2009 |
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.
Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Proton Pump Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticlopidine; Treatment Outcome | 2009 |
Prasugrel (Effient) vs. clopidogrel (Plavix).
Topics: Animals; Clopidogrel; Drug Approval; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine; United States | 2009 |
Dual antiplatelet therapy in coronary artery disease: a case-based approach.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Thiophenes; Ticlopidine | 2009 |
Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome | 2009 |
Advances in antiplatelet treatment for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Forecasting; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Biotransformation; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Prasugrel: a critical comparison with clopidogrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Animals; Clinical Trials as Topic; Clopidogrel; Drug Inverse Agonism; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; United States | 2009 |
Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticlopidine | 2010 |
Update on antiplatelet therapy in acute coronary syndromes: what do new drugs bring into clinical practice?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Prasugrel: Clinical development and therapeutic application.
Topics: Acute Coronary Syndrome; Angioplasty; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Thrombosis; Ticlopidine | 2009 |
Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases.
Topics: Adenosine; Adenosine Monophosphate; Benzofurans; Blood Platelets; Carbamates; Clinical Trials as Topic; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Receptor, PAR-1; Receptors, Proteinase-Activated; Thiophenes; Ticagrelor; Ticlopidine; von Willebrand Factor | 2010 |
State of the art of new P2Y12 antagonists.
Topics: Adenosine; Adenosine Monophosphate; Clopidogrel; Humans; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel.
Topics: Clopidogrel; Drug Evaluation, Preclinical; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Risk Factors; Thiophenes; Ticlopidine | 2010 |
Preventing serious sequelae after an acute coronary syndrome: the consequences of thrombosis versus bleeding with antiplatelet therapy.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Risk Factors; Thiophenes; Thrombosis; Ticlopidine | 2010 |
Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials, Phase III as Topic; Clopidogrel; Drug Evaluation, Preclinical; Drug Therapy, Combination; Hemorrhage; Humans; Ischemia; Kidney Failure, Chronic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2010 |
Management of antiplatelet therapy during acute percutaneous coronary intervention: new strategies and therapeutics.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Therapy, Combination; Electrocardiography; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
The role of antiplatelet therapy in the secondary prevention of coronary artery disease.
Topics: Adenosine; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Interactions; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Secondary Prevention; Thiophenes; Thromboxane A2; Ticagrelor; Ticlopidine | 2010 |
Diabetes and the platelet: toward new therapeutic paradigms for diabetic atherothrombosis.
Topics: Acute Coronary Syndrome; Apoptosis; Aspirin; Blood Platelets; Clopidogrel; Diabetes Complications; Diabetes Mellitus; Glycoproteins; Humans; Models, Biological; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Thiophenes; Thromboplastin; Thrombosis; Ticlopidine | 2010 |
[Extent of platelet aggregation inhibition and clinical events: new evidence with prasugrel].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Treatment Outcome | 2010 |
Antiplatelet therapy in percutaneous coronary intervention: recent advances in oral antiplatelet agents.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Pyridines; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
Acute coronary syndrome in the patient with diabetes: is the management different?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel; Diabetes Mellitus; Drug-Eluting Stents; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticlopidine | 2010 |
Implementing genotype-guided antithrombotic therapy.
Topics: Anticoagulants; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 4; Dose-Response Relationship, Drug; Genetic Privacy; Genotype; Health Policy; Humans; Mixed Function Oxygenases; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2 Receptor Antagonists; Thiophenes; Ticlopidine; Vitamin K Epoxide Reductases; Warfarin | 2010 |
The year in interventional cardiology.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Coronary Angiography; Coronary Disease; Coronary Occlusion; Coronary Restenosis; Drug-Eluting Stents; Foramen Ovale, Patent; Hospital Mortality; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Radiology, Interventional; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Dosing strategies for antiplatelet therapy in percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clinical Protocols; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Hemorrhage; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Risk Assessment; Risk Factors; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome | 2010 |
What goes into a major acute coronary syndrome trial and what will future trials look like?
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clinical Trials as Topic; Clopidogrel; Cyclic N-Oxides; Eptifibatide; Heart Diseases; Humans; Peptides; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Research Design; Research Support as Topic; Risk Factors; Sample Size; Thiophenes; Ticagrelor; Ticlopidine; United Kingdom | 2010 |
Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Cost-Benefit Analysis; Humans; Models, Economic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quality of Life; Quality-Adjusted Life Years; Risk Assessment; Thiophenes; Ticlopidine; United Kingdom | 2010 |
New antithrombotic agents--insights from clinical trials.
Topics: Adenosine; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; Coumarins; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Thromboembolism; Ticagrelor; Ticlopidine | 2010 |
[Antiplatelet therapy in coronary heart disease. Some problems and achivements].
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Resistance; Gastrointestinal Hemorrhage; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Genetic; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Receptor, PAR-1; Thiophenes; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration | 2010 |
Prasugrel.
Topics: Acute Coronary Syndrome; Clinical Trials as Topic; Clopidogrel; Humans; Piperazines; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Stents; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome | 2010 |
[Platelet inhibition with prasugrel].
Topics: Acute Coronary Syndrome; Administration, Oral; Angina, Unstable; Biological Availability; Clopidogrel; Coronary Artery Disease; Humans; Metabolic Clearance Rate; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Secondary Prevention; Thiophenes; Ticlopidine | 2010 |
Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Disease Management; Drug Synergism; Drug Therapy, Combination; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Hirudins; Humans; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Recombinant Proteins; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
Controversies in oral antiplatelet therapy in patients undergoing aortocoronary bypass surgery.
Topics: Administration, Oral; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Thrombosis; Ticlopidine | 2010 |
A comparison of the metabolism of clopidogrel and prasugrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Carboxylic Ester Hydrolases; Clopidogrel; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Thiophenes; Thrombosis; Ticlopidine | 2010 |
Prasugrel as antiplatelet therapy in patients with acute coronary syndromes or undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Humans; Piperazines; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2010 |
Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability.
Topics: Animals; Biological Availability; Clopidogrel; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2010 |
Prevention of the renarrowing of coronary arteries using drug-eluting stents in the perioperative period: an update.
Topics: Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Thrombosis; Coronary Vessels; Drug-Eluting Stents; Humans; Myocardial Revascularization; Perioperative Care; Perioperative Period; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2010 |
The platelet P2Y₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects.
Topics: Adenosine; Adenosine Diphosphate; Animals; Blood Platelet Disorders; Blood Platelets; Clopidogrel; Female; Hemorrhage; Humans; Male; Mice; Mutation; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Signal Transduction; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Aspirin; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Histamine H2 Antagonists; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Thienopyridines; Thiophenes; Ticlopidine | 2010 |
Prasugrel: an efficacy and safety review of a new antiplatelet therapy option.
Topics: Acute Coronary Syndrome; American Heart Association; Angioplasty, Balloon, Coronary; Clinical Trials, Phase III as Topic; Clopidogrel; Hemorrhage; Humans; Patient Selection; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Assessment; Thiophenes; Ticlopidine; Treatment Outcome; United States | 2010 |
ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Aspirin; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Histamine H2 Antagonists; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Thienopyridines; Thiophenes; Ticlopidine | 2010 |
Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development.
Topics: Animals; Clopidogrel; Coronary Thrombosis; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2011 |
[New approaches and indications for the analysis of platelet function in cardiology].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Hemorrhage; Humans; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
[Novel agents in antiplatelet therapy].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Standard of Care; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2011 |
The onset of inhibition of platelet aggregation with prasugrel compared with clopidogrel loading doses using gatekeeping analysis of integrated clinical pharmacology data.
Topics: Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Female; Humans; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Time Factors | 2011 |
Antiplatelet therapy in the perioperative period.
Topics: Aspirin; Clopidogrel; Humans; Perioperative Period; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2010 |
[Coronary heart disease - what is of importance after coronary intervention?].
Topics: Adenosine; Aftercare; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Schedule; Drug Approval; Drug Therapy, Combination; Drug-Eluting Stents; Gastrointestinal Hemorrhage; Humans; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Proton Pump Inhibitors; Stents; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Pharmacokinetics, drug metabolism, and safety of prasugrel and clopidogrel.
Topics: Area Under Curve; Clopidogrel; Drug Interactions; Half-Life; Humans; Metabolic Clearance Rate; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2011 |
[Current options to manage clopidogrel poor responsiveness].
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Interactions; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Triple therapy in hospitalized patients: facts and controversies.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Hospitalization; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Warfarin | 2011 |
Is prasugrel more effective than clopidogrel at preventing future cardiac events?
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Restenosis; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2011 |
[Prasugrel for acute and long-term treatment of patients with acute coronary syndromes: what is state-of-the-art?].
Topics: Acute Coronary Syndrome; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Electrocardiography; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2011 |
Triple therapy: boon or bane for high-risk CV patients?
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Warfarin | 2011 |
Bleeding manifestations of congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate.
Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors.
Topics: Adenosine; Adenosine Monophosphate; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Humans; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Protein Binding; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2011 |
[Myocardial infarction: Role of new antiplatelet agents].
Topics: Adenosine; Adenosine Monophosphate; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Disease Management; Drug Resistance; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Reperfusion; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine; Time Factors | 2011 |
Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Hemorrhage; Humans; Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
[Recent advances on the studies of the platelet's inhibition and aggregation. State of the art of new P2Y12 antagonists].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Catheter Ablation; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Humans; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Antithrombotic management for transient ischemic attack and ischemic stroke (other than atrial fibrillation).
Topics: Adenosine; Aryl Hydrocarbon Hydroxylases; Brain Ischemia; Cilostazol; Clinical Trials as Topic; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Fibrinolytic Agents; Foramen Ovale, Patent; Genotype; Humans; Ischemic Attack, Transient; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Stroke; Tetrazoles; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Beyond aspirin and clopidogrel: is there a need for additional antiplatelet therapy in ACS?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Tetrazoles; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Ticagrelor for acute coronary syndrome?
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Contraindications; Drug Costs; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2011 |
Emerging antiplatelet therapies in percutaneous coronary intervention: a focus on prasugrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2011 |
Prasugrel resistance: fact or fiction.
Topics: Blood Platelets; Clopidogrel; Drug Resistance; Humans; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2012 |
Prasugrel vs. ticagrelor in acute coronary syndromes: which one to choose?
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Genotypic and phenotypic assessment of platelet function and response to P2Y12 antagonists.
Topics: Adenosine; Clopidogrel; Coronary Artery Disease; Female; Genetic Association Studies; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2011 |
Treating acute coronary syndromes with new antiplatelet drugs: the mortality issue with prasugrel and ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Angiography; Diabetes Mellitus; Female; Humans; Hypertension; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2011 |
Antiplatelet options for secondary prevention in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Risk Factors; Secondary Prevention; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Chronic Disease; Clinical Trials as Topic; Clopidogrel; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Hirudins; Humans; Kidney Diseases; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Recombinant Proteins; Thiophenes; Ticagrelor; Ticlopidine; Uremia | 2011 |
Antiplatelet therapy in patients with ST-elevation myocardial infarction undergoing myocardial revascularisation: beyond clopidogrel.
Topics: Adenosine; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
P2Y12 platelet inhibition in clinical practice.
Topics: Adenosine; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Platelet-mediated thrombosis and drug-eluting stents.
Topics: Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Equipment Design; Humans; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticlopidine | 2011 |
Unstable angina and non-ST elevation myocardial infarction.
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; Echocardiography; Electrocardiography; Humans; Myocardial Infarction; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
A comprehensive comparative review of adenosine diphosphate receptor antagonists.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Drug Interactions; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
InforMatrix: ADP antagonists in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Drug Information Services; Drugs, Generic; Evidence-Based Medicine; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Quantitative comparison of clopidogrel 600 mg, prasugrel and ticagrelor, against clopidogrel 300 mg on major adverse cardiovascular events and bleeding in coronary stenting: synthesis of CURRENT-OASIS-7, TRITON-TIMI-38 and PLATO.
Topics: Adenosine; Animals; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Piperazines; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients.
Topics: Acute Coronary Syndrome; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Secondary Prevention; Thiophenes; Ticlopidine | 2012 |
Advances in antiplatelet therapy for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Emergency Treatment; Female; Humans; Male; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Acute coronary syndromes: identifying the appropriate patient for prasugrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Assessment; Secondary Prevention; Thiophenes; Ticlopidine | 2012 |
Current antiplatelet options for NSTE-ACS patients.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Biological Availability; Clopidogrel; Comparative Effectiveness Research; Drug Monitoring; Drug Synergism; Drug Therapy, Combination; Electrocardiography; Humans; Pharmacovigilance; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y; Risk Assessment; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications.
Topics: Adenosine; Cardiovascular Diseases; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Drug Substitution; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
[New antithrombotic drugs].
Topics: Adenosine; Anticoagulants; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2012 |
Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options.
Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombolytic Therapy; Ticlopidine; Warfarin | 2012 |
Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Resistance; Evidence-Based Medicine; Genotype; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2012 |
Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Odds Ratio; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk; Stents; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
[Platelet function: new drugs, new assays : possible impacts on operative medicine?].
Topics: Adenosine; Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Systems; Postoperative Complications; Postoperative Hemorrhage; Practice Guidelines as Topic; Prasugrel Hydrochloride; Predictive Value of Tests; Stents; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2012 |
Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Kaplan-Meier Estimate; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Product Surveillance, Postmarketing; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Development and clinical use of prasugrel and ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Aspirin; Blood Platelets; Clopidogrel; Drug Design; Hemorrhage; Hemostasis; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome?
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clopidogrel; Coronary Thrombosis; Drug Interactions; Drug Resistance; Genotype; Hemorrhage; Humans; Patient Selection; Percutaneous Coronary Intervention; Pharmacogenetics; Phenotype; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Predictive Value of Tests; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Heparin; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticlopidine; Warfarin | 2012 |
A brief review of the past and future of platelet P2Y12 antagonist.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Stents; Sulfonamides; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2012 |
Antiplatelet therapy beyond 2012: role of personalized medicine.
Topics: Adenosine; Clopidogrel; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2012 |
Importance of potent P2Y(12) receptor blockade in acute myocardial infarction: focus on prasugrel.
Topics: Clopidogrel; Costs and Cost Analysis; Drug Interactions; Humans; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2012 |
[Comparative antiplatelet efficacy of prasugrel and high-dose clopidogrel in patients with coronary heart disease including acute coronary syndrome].
Topics: Clopidogrel; Coronary Disease; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
Clopidogrel in coronary artery disease: update 2012.
Topics: Adenosine; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Genetic considerations.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clopidogrel; Cytochrome P-450 CYP2C19; Genome-Wide Association Study; Genotype; Humans; Liver; Pharmacogenetics; Phenotype; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine | 2012 |
Advances in the monitoring of anti-P2Y12 therapy.
Topics: Adenosine; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 Enzyme System; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Prodrugs; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Thienopyridines and other ADP-receptor antagonists.
Topics: Adenosine; Adenosine Monophosphate; Animals; Clopidogrel; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thienopyridines; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
New anti-platelet agents: the end of resistance?
Topics: Adenosine; Animals; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Drug Design; Drug Resistance; Drug Therapy, Combination; Evidence-Based Medicine; Hemorrhage; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR).
Topics: Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purpura, Thrombotic Thrombocytopenic; Thienopyridines; Thiophenes; Ticlopidine | 2012 |
Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Stroke; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis.
Topics: Adenosine; Clopidogrel; Hemorrhage; Humans; Ischemia; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; PubMed; Randomized Controlled Trials as Topic; Stents; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2013 |
[Novel agents for antithrombotic therapy in cardiology].
Topics: Adenosine; Administration, Oral; Anticoagulants; Aspirin; Clopidogrel; Coumarins; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine | 2012 |
Metabolic differences of current thienopyridine antiplatelet agents.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Fibrinolytic Agents; Hemorrhage; Humans; Inactivation, Metabolic; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Thiophenes; Ticlopidine | 2013 |
Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology.
Topics: Adenosine; Cardiovascular Diseases; Clopidogrel; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Stents; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Antiplatelet drug use in patients with non-ST-segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy.
Topics: Adenosine; Aspirin; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Clopidogrel; Dabigatran; Drug Interactions; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2013 |
A transition of P2Y12 antagonists for acute coronary syndrome: benefits, risks and costs.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Antiplatelet therapy and cardiac surgery: review of recent evidence and clinical implications.
Topics: Adenosine; Blood Loss, Surgical; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
ADP-receptor inhibitors in the perioperative period: the good, the bad, and the ugly.
Topics: Adenosine; Cardiac Surgical Procedures; Clopidogrel; Hemorrhage; Humans; Perioperative Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Surgical Procedures, Operative; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
[Prominent features of management strategies in acute coronary syndromes with the new oral antiplatelet agents].
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
New anticoagulant and antiplatelet agents: a primer for the gastroenterologist.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Cholangiopancreatography, Endoscopic Retrograde; Clopidogrel; Dabigatran; Drug Interactions; Fondaparinux; Gastrointestinal Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Polysaccharides; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2014 |
Pharmacokinetic considerations for antithrombotic therapies in stroke.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Cilostazol; Clopidogrel; Factor Xa; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Stroke; Tetrazoles; Thiophenes; Thrombin; Ticlopidine; Vitamin K | 2013 |
Use of antiplatelet drugs in the treatment of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2013 |
Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Decision Support Techniques; Drug Therapy, Combination; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
New antiplatelet agents and the role of platelet function testing in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Contraindications; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Secondary Prevention; Stents; Stroke; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2013 |
Platelet reactivity tests for assessing antiplatelet drug response: what the clinician needs to know.
Topics: Adenosine; Cardiovascular Diseases; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
[Oral antiplatelet agents can still be used along with proton pump inhibitors in spite of drug interactions].
Topics: Adenosine; Administration, Oral; Aspirin; Clopidogrel; Cyclooxygenase Inhibitors; Drug Interactions; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Humans; Piperazines; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Thienopyridines; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
New antiplatelet agents for cardiovascular disease.
Topics: Adenosine; Cardiovascular Diseases; Clopidogrel; Coronary Artery Disease; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
[Thrombocyte aggregation inhibitors: what are the risks?].
Topics: Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Stents; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Anticoagulant and antiplatelet medications encountered in emergency surgery patients: a review of reversal strategies.
Topics: Anticoagulants; Aspirin; Benzimidazoles; Clopidogrel; Dabigatran; Emergencies; Enoxaparin; Fondaparinux; Heparin; Humans; Morpholines; Platelet Aggregation Inhibitors; Platelet Transfusion; Polysaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Ticlopidine; Warfarin | 2013 |
Use of antiplatelet agents in patients with atherosclerotic disease.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Atherosclerosis; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Dual antiplatelet therapy -- management in general practice.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis.
Topics: Adenosine; Aged; Aspirin; Cerebral Hemorrhage; Cerebrovascular Disorders; Clopidogrel; Cohort Studies; Data Interpretation, Statistical; Drug Therapy, Combination; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Population; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Secondary Prevention; Stroke; Thiophenes; Ticagrelor; Ticlopidine; Vascular Diseases | 2014 |
[Differentiated antiplatelet therapy for acute coronary syndromes].
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Transfusion; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Anticoagulation and antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Enoxaparin; Fondaparinux; Heparin; Hirudins; Humans; Morpholines; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2014 |
Unanswered questions in patients with concurrent atrial fibrillation and acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Morpholines; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thrombosis; Ticlopidine | 2014 |
Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Stents; Stroke; Sulfonamides; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine | 2014 |
Unravelling the smokers' paradox: cigarette smoking, high-risk coronary artery disease and enhanced clinical efficacy of oral P2Y₁₂ inhibitors.
Topics: Adenosine; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Reduction Behavior; Smoking; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Pharmacokinetic evaluation of prasugrel for the treatment of myocardial infarction.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2014 |
New antiplatelet agents in the treatment of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Coronary Thrombosis; Diabetes Complications; Hemorrhage; Humans; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Renal Insufficiency; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Efficacy and safety of prasugrel in acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2014 |
Dyspnea and reversibility profile of P2Y₁₂ antagonists: systematic review of new antiplatelet drugs.
Topics: Adenosine; Adenosine Monophosphate; Clopidogrel; Dyspnea; Humans; Incidence; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
[Use of antiplatelet agents in patients with chronic kidney disease: what is the evidence?].
Topics: Adenosine; Blood Platelet Disorders; Clopidogrel; Evidence-Based Practice; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Renal Insufficiency, Chronic; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2014 |
Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors.
Topics: Adenosine; Adenosine Monophosphate; Animals; Anti-Inflammatory Agents; Anticarcinogenic Agents; Clopidogrel; Drug Therapy, Combination; Humans; Off-Label Use; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Signal Transduction; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Role of phenotypic and genetic testing in managing clopidogrel therapy.
Topics: Acute Coronary Syndrome; Adenosine; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Substitution; Genetic Testing; Humans; Piperazines; Polymorphism, Genetic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
[Using ADP receptor antagonists in coronary heart disease and acute coronary syndrome].
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Early Medical Intervention; General Practice; Guideline Adherence; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Stents; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Management of acute coronary syndrome in the hospital: a focus on ACCF/AHA guideline updates to oral antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aspirin; Body Weight; Clopidogrel; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Quality of Health Care; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Prasugrel hydrochloride for the treatment of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Animals; Aspirin; Clinical Trials, Phase III as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine | 2015 |
Review of pharmacoeconomic evaluation of genotype-guided antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Genotype; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Risk Assessment; Thiophenes; Ticagrelor; Ticlopidine | 2015 |
[Anticoagulant therapy in secondary prevention of coronary events].
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Thiophenes; Ticlopidine; Warfarin | 2014 |
Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity.
Topics: Adenosine; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Research Design; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
Clinical evidence for oral antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Humans; Intraoperative Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Thiophenes; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Meta-Analysis of Randomized Controlled Trials Comparing Risk of Major Adverse Cardiac Events and Bleeding in Patients With Prasugrel Versus Clopidogrel.
Topics: Clopidogrel; Coronary Artery Disease; Global Health; Hemorrhage; Humans; Incidence; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticlopidine | 2015 |
Early P2Y12 inhibition in ST-segment elevation myocardial infarction: Bridging the gap.
Topics: Adenosine; Clopidogrel; Early Medical Intervention; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Meta-Analysis of Comparison of the Newer Oral P2Y12 Inhibitors (Prasugrel or Ticagrelor) to Clopidogrel in Patients With Non-ST-Elevation Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Dose-Response Relationship, Drug; Electrocardiography; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2015 |
Overcoming Clopidogrel Resistance: Three Promising Novel Antiplatelet Drugs Developed in China.
Topics: Acute Coronary Syndrome; China; Clopidogrel; Drug Discovery; Drug Resistance; Humans; Phenylacetates; Platelet Aggregation Inhibitors; Prodrugs; Thiophenes; Ticlopidine | 2017 |
162 trial(s) available for ticlopidine and thiophenes
Article | Year |
---|---|
[Platelet function inhibitors in peripheral arteriopathies].
Topics: Adrenal Cortex Hormones; Adrenergic alpha-Antagonists; Anti-Inflammatory Agents; Arachidonic Acid; Arachidonic Acids; Arteriosclerosis Obliterans; Aspirin; Blood Platelets; Calcium Channel Blockers; Clinical Trials as Topic; Cyclic AMP; Dipyridamole; Extremities; Heparin; Humans; Imidazoles; Prostaglandins; Prostanoic Acids; Pyrazoles; Pyrazolones; Quinacrine; Thiophenes; Thromboembolism; Thrombosis; Ticlopidine; Vascular Diseases | 1986 |
Therapy of atherosclerotic arteriopathy of lower limbs. Aspects and results.
Topics: Acute Disease; Arteriosclerosis; Chronic Disease; Clinical Trials as Topic; Glycosaminoglycans; Heparin; Humans; Injections, Subcutaneous; Leg; Pentoxifylline; Streptokinase; Thiophenes; Ticlopidine; Urokinase-Type Plasminogen Activator; Vasodilator Agents | 1985 |
Failure of a pure anti-platelet drug to decrease the number of attacks more than placebo in patients with Raynaud's phenomenon.
Topics: Adult; Aged; Anticoagulants; Clinical Trials as Topic; Double-Blind Method; Drug Eruptions; Female; Humans; Male; Middle Aged; Placebos; Random Allocation; Raynaud Disease; Thiophenes; Ticlopidine | 1986 |
Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis.
Topics: Anticoagulants; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Cardiovascular Diseases; Clinical Trials as Topic; Dipyridamole; Double-Blind Method; Female; Glomerulonephritis; Graft Occlusion, Vascular; Heart Valve Prosthesis; Humans; Ischemic Attack, Transient; Male; Myocardial Infarction; Postoperative Complications; Random Allocation; Sulfinpyrazone; Thiophenes; Ticlopidine | 1986 |
Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time.
Topics: Adolescent; Adult; Aged; Aspirin; Bleeding Time; Clinical Trials as Topic; Deamino Arginine Vasopressin; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Platelet Function Tests; Random Allocation; Thiophenes; Thrombocytopenia; Ticlopidine; von Willebrand Factor | 1986 |
Evaluation of antiplatelet agents in the prevention of aorto-coronary bypass occlusion.
Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Dipyridamole; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fibrinolytic Agents; Graft Occlusion, Vascular; Heparin; Humans; Platelet Aggregation; Saphenous Vein; Sulfinpyrazone; Thiophenes; Ticlopidine | 1986 |
Does placebo improve indexes of effort-induced myocardial ischemia? An objective study in 150 patients with chronic stable angina pectoris.
Topics: Adult; Aged; Angina Pectoris; Chronic Disease; Clinical Trials as Topic; Coronary Disease; Double-Blind Method; Electrocardiography; Exercise Test; Female; Heart Rate; Humans; Male; Middle Aged; Physical Exertion; Placebos; Thiophenes; Ticlopidine | 1986 |
Influence on lipoprotein metabolism of the platelet inhibitory drug ticlopidine.
Topics: Adult; Aged; Angina Pectoris; Arteriosclerosis; Clinical Trials as Topic; Double-Blind Method; Humans; Lipoproteins; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Thiophenes; Ticlopidine | 1986 |
Double-blind randomized trial of the effect of ticlopidine in arteriovenous fistulas for hemodialysis.
Topics: Anticoagulants; Arteriovenous Shunt, Surgical; Clinical Trials as Topic; Double-Blind Method; Graft Occlusion, Vascular; Humans; Renal Dialysis; Thiophenes; Thrombosis; Ticlopidine | 1985 |
Platelet inhibitors versus anticoagulants for prevention of aorto-coronary bypass graft occlusion.
Topics: Acenocoumarol; Anticoagulants; Clinical Trials as Topic; Coronary Angiography; Coronary Artery Bypass; Coronary Disease; Graft Occlusion, Vascular; Humans; Middle Aged; Postoperative Complications; Thiophenes; Ticlopidine | 1985 |
Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for haemodialysis.
Topics: Adult; Aged; Anticoagulants; Arteriovenous Shunt, Surgical; Clinical Trials as Topic; Double-Blind Method; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Postoperative Complications; Renal Dialysis; Thiophenes; Thrombosis; Ticlopidine | 1985 |
The effect of ticlopidine on platelet functions in acute myocardial infarction. A double blind controlled trial.
Topics: Adult; Aged; Anticoagulants; Blood Coagulation; Blood Platelets; Clinical Trials as Topic; Collagen; Double-Blind Method; Female; Fibrinolysis; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Placebos; Platelet Aggregation; Serotonin; Thiophenes; Ticlopidine | 1985 |
Effects of ticlopidine of platelet function in men with stable angina pectoris.
Topics: Adenosine Diphosphate; Adult; Aged; Angina Pectoris; Blood Platelets; Clinical Trials as Topic; Collagen; Double-Blind Method; Epinephrine; Epoprostenol; Humans; Male; Middle Aged; Platelet Aggregation; Thiophenes; Ticlopidine | 1985 |
Blood lipid profile in healthy subjects treated with ticlopidine.
Topics: Adult; Aged; Anticoagulants; Arteriosclerosis; Blood Platelets; Double-Blind Method; Drug Evaluation; Female; Humans; Lipids; Male; Middle Aged; Thiophenes; Ticlopidine | 1985 |
Effects of ticlopidine on blood fibrinogen and blood viscosity in peripheral atherosclerotic disease.
Topics: Aged; Arteriosclerosis; Blood Coagulation; Blood Platelets; Blood Viscosity; Female; Fibrinogen; Humans; Locomotion; Male; Middle Aged; Nicotinic Acids; Thiophenes; Ticlopidine | 1985 |
Rationale for the use of drugs inhibiting platelet function in claudicating patients with atherosclerotic leg arteries.
Topics: Anticoagulants; Arteriosclerosis; beta-Thromboglobulin; Blood Platelets; Clinical Trials as Topic; Humans; Intermittent Claudication; Leg; Platelet Aggregation; Platelet Factor 4; Suloctidil; Thiophenes; Thrombosis; Thromboxane A2; Ticlopidine | 1984 |
Effects of platelet inhibition on myocardial ischaemia.
Topics: Angina Pectoris; Animals; Clinical Trials as Topic; Coronary Circulation; Coronary Disease; Dogs; Double-Blind Method; Drug Evaluation, Preclinical; Female; Hemodynamics; Humans; Male; Middle Aged; Platelet Aggregation; Pyridines; Thiophenes; Ticlopidine | 1982 |
[Aftercare of heart infarct patients to reduce the risk of a subsequent infarction].
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Clinical Trials as Topic; Dipyridamole; Humans; Hypolipidemic Agents; Myocardial Infarction; Patient Care Planning; Platelet Aggregation; Recurrence; Risk; Sulfinpyrazone; Thiophenes; Ticlopidine | 1983 |
Effects of ticlopidine on platelet function and blood coagulation.
Topics: Adult; Aged; Arteriosclerosis; beta-Thromboglobulin; Blood Coagulation; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Humans; Male; Malondialdehyde; Middle Aged; Partial Thromboplastin Time; Platelet Aggregation; Platelet Function Tests; Prothrombin Time; Thiophenes; Ticlopidine | 1982 |
Ticlopidine activity on platelet function in patients with enhanced platelet aggregation. A short-term crossover study.
Topics: Adenosine Diphosphate; Adult; Aged; beta-Thromboglobulin; Bleeding Time; Blood Platelets; Collagen; Epoprostenol; Humans; Male; Middle Aged; Platelet Aggregation; Prostaglandin D2; Prostaglandins D; Thiophenes; Thromboxane B2; Ticlopidine | 1983 |
Failure of ticlopidine to inhibit deposition of indium-111-labeled platelets on Dacron prosthetic surfaces in humans.
Topics: Adult; Aged; Aorta; Bleeding Time; Blood Platelets; Blood Vessel Prosthesis; Clinical Trials as Topic; Humans; Indium; Male; Middle Aged; Placebos; Platelet Adhesiveness; Polyethylene Terephthalates; Radioisotopes; Radionuclide Imaging; Thiophenes; Ticlopidine | 1984 |
[The antiaggregation effect of ticlopidine on blood platelets preliminary results and prospectives for studies in various diseases].
Topics: Aged; Anticoagulants; Clinical Trials as Topic; Drug Evaluation; Humans; Middle Aged; Platelet Aggregation; Thiophenes; Ticlopidine | 1983 |
Clinical trials of an antiplatelet agent, ticlopidine, in diabetes mellitus.
Topics: Adult; Anticoagulants; Clinical Trials as Topic; Diabetic Angiopathies; Echocardiography; Female; Humans; Male; Middle Aged; Monitoring, Physiologic; Platelet Aggregation; Thiophenes; Ticlopidine | 1983 |
[Effect of ticlopidine on peripheral obliterating arteriopathy].
Topics: Angiography; Anticoagulants; Arterial Occlusive Diseases; Clinical Trials as Topic; Double-Blind Method; Humans; Leg; Placebos; Tablets; Thiophenes; Ticlopidine; Time Factors | 1984 |
Evaluation of the antithrombotic efficacy of ticlopidine in man.
Topics: Anticoagulants; Clinical Trials as Topic; Extracorporeal Circulation; Female; Fibrinolytic Agents; Humans; Leukocyte Count; Male; Premedication; Renal Dialysis; Thiophenes; Thrombocytopenia; Thrombosis; Ticlopidine | 1984 |
Therapeutic effect of ticlopidine for ischemic leg ulcers.
Topics: Anticoagulants; Arterial Occlusive Diseases; Clinical Trials as Topic; Female; Humans; Ischemia; Leg; Leg Ulcer; Male; Thiophenes; Ticlopidine | 1984 |
Ticlopidine and coronary surgery.
Topics: Anticoagulants; Clinical Trials as Topic; Coronary Angiography; Coronary Artery Bypass; Humans; Postoperative Complications; Thiophenes; Ticlopidine | 1984 |
Clinical and biological double-blind-study of ticlopidine in preventive treatment of sickle-cell disease crises.
Topics: Anemia, Sickle Cell; Anticoagulants; Clinical Trials as Topic; Double-Blind Method; Humans; Thiophenes; Ticlopidine | 1984 |
The influence of ticlopidine on the natural course of retinal vein occlusion.
Topics: Adenosine Diphosphate; Adult; Aged; Anticoagulants; Clinical Trials as Topic; Diabetes Mellitus; Female; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Platelet Aggregation; Retinal Diseases; Retinal Vein; Risk; Thiophenes; Ticlopidine; Visual Acuity | 1984 |
Ticlopidine in the secondary prevention of early diabetes-related microangiopathy: protocol of a multicenter therapeutic study (TIMAD study).
Topics: Adenosine Diphosphate; Adolescent; Adult; Aged; Anticoagulants; Brain Ischemia; Clinical Trials as Topic; Diabetic Angiopathies; Diabetic Neuropathies; Diabetic Retinopathy; Electrocardiography; Fluorescein Angiography; Follow-Up Studies; Humans; Middle Aged; Patient Compliance; Platelet Aggregation; Thiophenes; Ticlopidine | 1984 |
Ticlopidine: quo vadis? Subarachnoid hemorrhage.
Topics: Anticoagulants; Clinical Trials as Topic; Double-Blind Method; Humans; Intracranial Aneurysm; Ischemic Attack, Transient; Subarachnoid Hemorrhage; Thiophenes; Ticlopidine | 1984 |
The North American ticlopidine aspirin stroke study: structure, stratification variables, and patient characteristics.
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Random Allocation; Thiophenes; Ticlopidine | 1984 |
The effect of ticlopidine on TIA compared with aspirin: a double-blind, twelve-month follow-up study.
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Double-Blind Method; Follow-Up Studies; Humans; Ischemic Attack, Transient; Thiophenes; Ticlopidine | 1984 |
Canadian American ticlopidine study (cats) in thromboembolic stroke.
Topics: Anticoagulants; Clinical Trials as Topic; Follow-Up Studies; Humans; Intracranial Embolism and Thrombosis; Ischemic Attack, Transient; Patient Compliance; Thiophenes; Ticlopidine | 1984 |
Overview: clinical experiences with ticlopidine.
Topics: Anemia, Sickle Cell; Anticoagulants; Arterial Occlusive Diseases; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Artery Bypass; Extracorporeal Circulation; Humans; Renal Dialysis; Retinal Diseases; Subarachnoid Hemorrhage; Thiophenes; Ticlopidine | 1984 |
A double-blind trial of ticlopidine in sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Anticoagulants; Blood Coagulation Factors; Blood Platelets; Cell Survival; Clinical Trials as Topic; Double-Blind Method; Female; Heterozygote; Homozygote; Humans; Male; Placebos; Thalassemia; Thiophenes; Ticlopidine | 1984 |
Registry of prospective clinical trials--fifth report.
Topics: Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Dipyridamole; Double-Blind Method; Heart Valve Prosthesis; Heparin; Humans; Intermittent Claudication; Myocardial Infarction; Prospective Studies; Registries; Thiophenes; Thromboembolism; Thrombophlebitis; Thrombosis; Ticlopidine | 1982 |
Therapeutic effect of ticlopidine, a new inhibitor of platelet aggregation, on chronic arterial occlusive diseases, a double-blind study versus placebo.
Topics: Arterial Occlusive Diseases; Arteriosclerosis; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Elbow; Female; Foot; Humans; Ischemia; Knee; Male; Middle Aged; Pain; Placebos; Platelet Aggregation; Skin Ulcer; Thiophenes; Thromboangiitis Obliterans; Ticlopidine | 1982 |
Platelet inhibition with Ticlopidine in atherosclerotic intermittent claudication.
Topics: Adult; Aged; Arteriosclerosis; Clinical Trials as Topic; Double-Blind Method; Humans; Intermittent Claudication; Male; Middle Aged; Platelet Aggregation; Random Allocation; Thiophenes; Ticlopidine | 1982 |
The effect of Ticlopidine upon platelet function, haemorrhage and post-operative thrombosis in patients undergoing suprapubic prostatectomy.
Topics: Bleeding Time; Hemorrhage; Humans; Male; Platelet Function Tests; Postoperative Complications; Prostatectomy; Pyridines; Random Allocation; Thiophenes; Thrombophlebitis; Ticlopidine | 1981 |
Antiaggregatory, physiological and clinical effects of ticlopidine in subjects with peripheral atherosclerosis.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acids; Arteriosclerosis; Blood Coagulation; Epinephrine; Female; Humans; Male; Middle Aged; Platelet Aggregation; Pyridines; Thiophenes; Ticlopidine | 1980 |
[Ticlopidine in heart surgery with cardiopulmonary by-pass (author's transl)].
Topics: Adolescent; Adult; Aged; Blood Coagulation; Cardiac Surgical Procedures; Extracorporeal Circulation; Humans; Middle Aged; Platelet Aggregation; Postoperative Complications; Pyridines; Thiophenes; Thrombocytopenia; Thrombosis; Ticlopidine | 1980 |
Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial.
Topics: Adolescent; Adult; Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hemorrhage; Humans; Incidence; Male; Membrane Proteins; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2005 |
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2006 |
Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study.
Topics: Clopidogrel; Coronary Disease; Female; Flow Cytometry; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Stents; Thiophenes; Ticlopidine | 2006 |
Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infar
Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Follow-Up Studies; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Syndrome; Thiophenes; Thrombolytic Therapy; Thrombosis; Ticlopidine; Treatment Outcome | 2006 |
A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans.
Topics: Adolescent; Adult; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2007 |
A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.
Topics: Adult; Area Under Curve; Blood Platelets; Clopidogrel; Cross-Over Studies; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticlopidine | 2007 |
Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently.
Topics: Adult; Area Under Curve; Clopidogrel; Cross-Over Studies; Cytochrome P-450 CYP3A Inhibitors; Double-Blind Method; Drug Interactions; Enzyme Inhibitors; Female; Humans; Ketoconazole; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2007 |
Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects.
Topics: Adenosine Diphosphate; Adolescent; Adult; Aspirin; Bleeding Time; Clopidogrel; Collagen; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Male; Middle Aged; Peptide Fragments; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Stroke; Thiophenes; Thrombosis; Ticlopidine | 2007 |
Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel.
Topics: Adenosine Diphosphate; Adult; Area Under Curve; Blood Platelets; Clopidogrel; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2007 |
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Treatment Outcome | 2008 |
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Cross-Over Studies; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombolytic Therapy; Ticlopidine; Treatment Outcome | 2007 |
A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
Topics: Adenosine Diphosphate; Adult; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Flow Cytometry; Humans; Light; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Reproducibility of Results; Thiophenes; Ticlopidine; Time Factors | 2008 |
The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration.
Topics: Adult; Aspirin; Blood Coagulation Tests; Blood Platelets; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Point-of-Care Systems; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Reference Values; Reproducibility of Results; Thiophenes; Ticlopidine | 2008 |
Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Diphosphate; Adolescent; Adult; Aged; Area Under Curve; Biological Availability; Clopidogrel; Cross-Over Studies; Drug Interactions; Female; Humans; Lansoprazole; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Thiophenes; Ticlopidine | 2008 |
Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomi
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome | 2008 |
[The TRITON-TIMI 38 trial].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine | 2008 |
Approaching an age of reason with antiplatelet therapy.
Topics: Clopidogrel; Coronary Disease; Humans; Membrane Proteins; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Stents; Thiophenes; Thrombosis; Ticlopidine | 2008 |
Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolys
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Drug Therapy, Combination; Hemorrhage; Humans; Kaplan-Meier Estimate; Myocardial Infarction; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Purinergic P2 Receptor Antagonists; Stents; Thiophenes; Ticlopidine | 2008 |
Prasugrel in the poststroke cohort of the TRITON Trial: the clear and present danger.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Hemorrhage; Humans; Ischemic Attack, Transient; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Secondary Prevention; Stents; Stroke; Thiophenes; Ticlopidine; Treatment Outcome | 2008 |
Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects.
Topics: Adenosine Diphosphate; Adult; Aspirin; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Female; Hemorrhage; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2008 |
Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Secondary Prevention; Stroke; Thiophenes; Ticlopidine; Treatment Outcome | 2008 |
Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial I
Topics: Administration, Oral; Aged; Clopidogrel; Coronary Thrombosis; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombolytic Therapy; Ticlopidine; Treatment Outcome | 2008 |
Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.
Topics: Adult; Chromatography, Liquid; Clopidogrel; Cross-Over Studies; Drug Interactions; Histamine H2 Antagonists; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ranitidine; Tandem Mass Spectrometry; Thiophenes; Ticlopidine | 2008 |
Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease.
Topics: Adult; Aspirin; Biomarkers; Blood Platelets; Cell Communication; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Monocytes; P-Selectin; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2008 |
Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Models, Biological; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2008 |
Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects.
Topics: Adolescent; Adult; Anticholesteremic Agents; Area Under Curve; Atorvastatin; Chromatography, Liquid; Clopidogrel; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Interactions; Epistaxis; Heptanoic Acids; Humans; Liver; Male; Metabolic Clearance Rate; Middle Aged; Molecular Structure; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrroles; Tandem Mass Spectrometry; Thiophenes; Ticlopidine; United Kingdom; Young Adult | 2008 |
Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo.
Topics: Adult; Aged; Clopidogrel; Comorbidity; Coronary Artery Disease; Diabetes Complications; Double-Blind Method; Drug Resistance; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prevalence; Pyridines; Thiophenes; Ticlopidine; Treatment Failure; Treatment Outcome | 2008 |
Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin.
Topics: Anticoagulants; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Male; Optical Rotation; Phosphorylation; Piperazines; Point-of-Care Systems; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2009 |
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Endpoint Determination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2009 |
Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Coronary Angiography; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Severity of Illness Index; Survival Analysis; Thiophenes; Thromboembolism; Ticlopidine; Treatment Outcome | 2009 |
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.
Topics: Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Disease; Cytochrome P-450 CYP2C19; Drug Interactions; Female; Genetic Variation; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2009 |
Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Clopidogrel; Female; Humans; Male; Microfilament Proteins; Middle Aged; Myocardial Infarction; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2009 |
Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardi
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel; Combined Modality Therapy; Creatine Kinase, MB Form; Death, Sudden, Cardiac; Double-Blind Method; Humans; Incidence; Kaplan-Meier Estimate; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Thiophenes; Ticlopidine; Time Factors; Troponin T | 2009 |
The FDA prasugrel review: adjudication of myocardial infarction controversy.
Topics: Acute Coronary Syndrome; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Incidence; Male; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prognosis; Risk Assessment; Survival Analysis; Thiophenes; Ticlopidine; Treatment Outcome; United States; United States Food and Drug Administration | 2009 |
The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Pla
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Stents; Stroke; Thiophenes; Ticlopidine | 2009 |
Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitio
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2009 |
Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Paris; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
Reducing cardiac ischemic events in patients with ACS: prasugrel versus clopidogrel. Commentary.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Confidence Intervals; Double-Blind Method; Drug Therapy, Combination; Humans; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticlopidine | 2010 |
Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial.
Topics: Administration, Oral; Adult; Asian People; Blood Platelets; Cell Adhesion Molecules; China; Clopidogrel; Female; Flow Cytometry; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Singapore; Thiophenes; Ticlopidine; White People; Young Adult | 2010 |
Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data.
Topics: Aged; Angina, Unstable; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cohort Studies; Cytochrome P-450 CYP2C19; Genetic Variation; Genotype; Humans; Middle Aged; Myocardial Infarction; Pharmacogenetics; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk; Thiophenes; Ticlopidine; Treatment Outcome | 2010 |
Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage
Topics: Administration, Oral; Aged; Angina, Unstable; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Follow-Up Studies; Global Health; Humans; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Survival Rate; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
Prasugrel versus clopidogrel in Asian patients with acute coronary syndromes: design and rationale of a multi-dose, pharmacodynamic, phase 3 clinical trial.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Algorithms; Asian People; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Thiophenes; Ticlopidine; Young Adult | 2010 |
Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2010 |
Antagonism of P2Y₁₂ reduces physiological thromboxane levels.
Topics: Adenosine Diphosphate; Adolescent; Adult; Animals; Blood Platelets; Clopidogrel; Female; Humans; Male; Mice; Mice, Knockout; Middle Aged; Pilot Projects; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Thromboxanes; Ticlopidine; Young Adult | 2010 |
Safety and efficacy of prasugrel compared with clopidogrel in different regions of the world.
Topics: Acute Coronary Syndrome; Cause of Death; Clopidogrel; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Global Health; Humans; Incidence; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Thiophenes; Ticlopidine; Treatment Outcome | 2012 |
Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy.
Topics: Aspirin; Clopidogrel; Demography; Drug Resistance; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Receptors, Purinergic P2; Risk Factors; Thiophenes; Ticlopidine | 2011 |
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.
Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Thiophenes; Ticlopidine; Treatment Outcome; Young Adult | 2011 |
Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Chi-Square Distribution; Clopidogrel; Cross-Over Studies; Cytochrome P-450 CYP2C19; Drug Resistance; Drug Therapy, Combination; Female; Genotype; Greece; Humans; Least-Squares Analysis; Male; Middle Aged; Phenotype; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymerase Chain Reaction; Prasugrel Hydrochloride; Predictive Value of Tests; Prospective Studies; Risk Assessment; Risk Factors; Single-Blind Method; Stents; Thiophenes; Ticlopidine; Treatment Outcome | 2011 |
Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Thrombolytic Therapy; Ticlopidine | 2011 |
Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Clopidogrel; Cross-Over Studies; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Male; Pedigree; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Young Adult | 2012 |
Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44.
Topics: Adenosine Diphosphate; Aged; Clopidogrel; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Platelet Activating Factor; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2011 |
Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Cytochrome P-450 CYP1A2; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Smoking; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel.
Topics: Aged; Chronic Disease; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Female; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Single-Blind Method; Thiophenes; Ticlopidine; Treatment Outcome | 2011 |
Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity.
Topics: Aged; Blood Platelets; Clopidogrel; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Renal Dialysis; Single-Blind Method; Thiophenes; Ticlopidine | 2011 |
Pharmacodynamic assessment of a novel P2Y12 receptor antagonist in Japanese patients with coronary artery disease undergoing elective percutaneous coronary intervention.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Female; Humans; Japan; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Young Adult | 2012 |
A prospective randomized trial comparing the recovery of platelet function after loading dose administration of prasugrel or clopidogrel.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOppin
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Italy; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Predictive Value of Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2012 |
Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genetic Carrier Screening; Genetic Testing; Genotype; Humans; Loss of Heterozygosity; Male; Middle Aged; Pharmacogenetics; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Point-of-Care Systems; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2012 |
A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity
Topics: Aged; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2012 |
Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Cause of Death; Chest Tubes; Clopidogrel; Cohort Studies; Combined Modality Therapy; Coronary Artery Bypass; Drug Administration Schedule; Drug Therapy, Combination; Erythrocyte Transfusion; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Retrospective Studies; Risk Adjustment; Thiophenes; Ticlopidine | 2012 |
Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study.
Topics: Aged; Aged, 80 and over; Clopidogrel; Cohort Studies; Electrodes, Implanted; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Prospective Studies; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial.
Topics: Adult; Aged; Aspirin; Blood Loss, Surgical; Blood Platelets; Clopidogrel; Confounding Factors, Epidemiologic; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2012 |
Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Cross-Over Studies; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Angiographic and platelet reactivity outcomes with prasugrel 60 mg pretreatment and clopidogrel 600 mg pretreatment in primary percutaneous coronary intervention.
Topics: Adult; Aged; Asian People; Clopidogrel; Cohort Studies; Coronary Thrombosis; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Preoperative Care; Singapore; Thiophenes; Ticlopidine | 2012 |
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Stroke; Thiophenes; Ticlopidine | 2012 |
Prasugrel versus high dose clopidogrel to overcome early high on clopidogrel platelet reactivity in patients with ST elevation myocardial infarction.
Topics: Aged; Blood Platelets; Clopidogrel; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2012 |
Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.
Topics: Aged; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Cytochrome P-450 CYP2C19; Drug Substitution; Female; Genotype; Humans; Male; Middle Aged; Myocardial Ischemia; Percutaneous Coronary Intervention; Phenotype; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Rome; Thiophenes; Ticlopidine; Treatment Outcome | 2012 |
Randomized comparison of new dual-antiplatelet therapy (aspirin, prasugrel) and triple-antiplatelet therapy (aspirin, clopidogrel, cilostazol) using P2Y12 point-of-care assay in patients with STEMI undergoing primary PCI.
Topics: Adult; Aged; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Point-of-Care Systems; Prasugrel Hydrochloride; Prospective Studies; Receptors, Purinergic P2Y12; Tetrazoles; Thiophenes; Ticlopidine | 2013 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Myocardial Ischemia; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Stroke; Thiophenes; Ticlopidine; Treatment Outcome | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Point-of-Care Systems; Prasugrel Hydrochloride; Pyridines; Retreatment; Stents; Thiophenes; Ticlopidine | 2012 |
A randomized comparison of platelet reactivity in patients after treatment with various commercial clopidogrel preparations: the CLO-CLO trial.
Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Clopidogrel; Cross-Over Studies; Drugs, Generic; Female; Humans; Male; Middle Aged; Myocardial Ischemia; Patient Selection; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Single-Blind Method; Stents; Therapeutic Equivalency; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome | 2012 |
Selecting antiplatelet therapy at the time of percutaneous intervention for an acute coronary syndrome: weighing the benefits and risks of prasugrel versus clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Models, Statistical; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Stroke; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study.
Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Cytochrome P-450 CYP2C19; Double-Blind Method; Drug Substitution; Female; Genotype; Humans; Male; Microfilament Proteins; Middle Aged; Pharmacogenetics; Phenotype; Phosphoproteins; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Pharmacodynamic effect of prasugrel 5 mg vs clopidogrel 150 mg in elderly patients with high on-clopidogrel platelet reactivity.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Humans; Male; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Pharmacodynamic comparisons for single loading doses of prasugrel (30 mg) and clopidogrel (600 mg) in healthy Korean volunteers.
Topics: Adult; Analysis of Variance; Asian People; Clopidogrel; Cross-Over Studies; Humans; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Republic of Korea; Thiophenes; Ticlopidine; Time Factors; Young Adult | 2013 |
Comparison of prasugrel and clopidogrel reloading on high platelet reactivity in clopidogrel-loaded patients undergoing percutaneous coronary intervention (PRAISE-HPR): a study protocol for a prospective randomized controlled clinical trial.
Topics: Blood Platelets; Clinical Protocols; Clopidogrel; Drug Administration Schedule; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Republic of Korea; Research Design; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Single-Blind Method; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Smoking; Thiophenes; Ticlopidine | 2013 |
Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Reference Values; Severity of Illness Index; Single-Blind Method; Survival Rate; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
Topics: Abciximab; Acute Coronary Syndrome; Administration, Oral; Adult; Aged; Antibodies, Monoclonal; Blood Platelets; Clopidogrel; Drug Administration Routes; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2013 |
Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Disease Management; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hemorrhage; Humans; Longitudinal Studies; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
A randomized trial of platelet reactivity monitoring-adjusted clopidogrel therapy versus prasugrel therapy to reduce high on-treatment platelet reactivity.
Topics: Aged; Blood Platelets; Clopidogrel; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Single-Blind Method; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Clopidogrel; Coronary Angiography; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Stroke; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE).
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged; Clopidogrel; Combined Modality Therapy; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Practolol; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.
Topics: Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biotransformation; Blood Platelets; Cell Adhesion Molecules; Cells, Cultured; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Piperazines; Platelet Activation; Polymorphism, Genetic; Prasugrel Hydrochloride; Prospective Studies; Pyridines; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2013 |
Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial.
Topics: Acute Coronary Syndrome; Aged; Circadian Rhythm; Clopidogrel; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Thiophenes; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET):
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drug Dosage Calculations; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Practice Guidelines as Topic; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2013 |
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Embolism; Female; Humans; Kaplan-Meier Estimate; Male; Morpholines; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyridines; Rivaroxaban; Stroke; Thiophenes; Ticlopidine; Treatment Outcome; Warfarin | 2014 |
Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibit
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease.
Topics: Aspirin; Biomarkers; Blood Platelets; Body Mass Index; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Florida; Humans; Male; Microfilament Proteins; Middle Aged; Obesity; Phosphoproteins; Phosphorylation; Piperazines; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
Treatment patterns and outcomes in patients undergoing percutaneous coronary intervention treated with prasugrel or clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR]).
Topics: Acute Coronary Syndrome; Aged; Cause of Death; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Retrospective Studies; Survival Rate; Sweden; Thiophenes; Ticlopidine; Treatment Outcome | 2014 |
Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarctio
Topics: Acute Coronary Syndrome; Aged; Calcium Channel Blockers; Clopidogrel; Double-Blind Method; Drug Interactions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Propensity Score; Proportional Hazards Models; Proton Pump Inhibitors; Risk Factors; Stroke; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response--the TAILOR (Thrombocytes And IndividuaLization of ORal antiplatelet therapy in percutaneous coronary intervention) randomized trial.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prognosis; Thiophenes; Ticlopidine; Treatment Outcome | 2014 |
Detecting a thienopyridine effect by platelet reactivity assessment and its implications for risk stratification.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Point-of-Care Systems; Prasugrel Hydrochloride; Pyridines; Receptors, Purinergic P2Y12; Reproducibility of Results; ROC Curve; Sensitivity and Specificity; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Outcomes in patients with ST-segment elevation acute myocardial infarction treated with clopidogrel versus prasugrel (from the INFUSE-AMI trial).
Topics: Antithrombins; Clopidogrel; Coronary Angiography; Electrocardiography; Female; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Recombinant Proteins; Thiophenes; Ticlopidine; Treatment Outcome | 2014 |
Comparison of prasugrel and bivalirudin vs clopidogrel and heparin in patients with ST-segment elevation myocardial infarction: Design and rationale of the Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 trial.
Topics: Anticoagulants; Clopidogrel; Drug Therapy, Combination; Female; Heparin; Hirudins; Humans; Male; Myocardial Infarction; Peptide Fragments; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Recombinant Proteins; Thiophenes; Ticlopidine; Treatment Outcome | 2014 |
Switching from high-dose clopidogrel to prasugrel in ACS patients undergoing PCI: a single-center experience.
Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Substitution; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2014 |
Switching from clopidogrel to prasugrel in patients having coronary stent implantation.
Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Drug Substitution; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Renal Insufficiency, Chronic; Sex Factors; Stents; Thiophenes; Thrombosis; Ticlopidine | 2014 |
Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trial.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Double-Blind Method; Drug Administration Schedule; Drug Resistance; Drug Substitution; Female; Genotype; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Phenotype; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Asian People; Aspirin; Clopidogrel; Drug Therapy, Combination; Follow-Up Studies; Hemorrhage; Humans; Japan; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Time Factors | 2014 |
Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction.
Topics: Aged; Anticoagulants; Clopidogrel; Coronary Angiography; Coronary Stenosis; Drug Therapy, Combination; Early Termination of Clinical Trials; Heparin; Hirudins; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recombinant Proteins; Thiophenes; Ticlopidine; Treatment Outcome | 2014 |
Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial.
Topics: Angina, Unstable; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticlopidine; Treatment Outcome | 2014 |
Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Plate
Topics: Aged; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Thrombolytic Therapy; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: Insights from the TRILOGY ACS trial.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prognosis; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Smoking; Survival Rate; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome; United Kingdom; United States | 2014 |
The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.
Topics: Aged; Clinical Protocols; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Male; Middle Aged; Phenotype; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Treatment Outcome | 2014 |
Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study.
Topics: Adult; Aged; Anti-Ulcer Agents; Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Interactions; Female; Humans; Lansoprazole; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2014 |
An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Stents; Stroke; Thiophenes; Ticlopidine | 2014 |
The net clinical benefit of personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Prospective Studies; Purinergic P2Y Receptor Antagonists; Regression Analysis; Thiophenes; Ticlopidine | 2015 |
Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention.
Topics: Aged; Brain Ischemia; Clopidogrel; Combined Modality Therapy; Coronary Disease; Cytochrome P-450 CYP2C19; Double-Blind Method; Elective Surgical Procedures; Female; Follow-Up Studies; Gene Frequency; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Ticlopidine | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine; Time Factors | 2014 |
Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention: the ETAMI trial (early thieno
Topics: Aged; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Coronary Vessels; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Microfilament Proteins; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Phosphoproteins; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome; Vascular Patency | 2015 |
Comparison of patient intake of ticagrelor, prasugrel, or clopidogrel on restoring platelet function by donor platelets.
Topics: Adenosine; Adenosine Diphosphate; Aged; Blood Platelets; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; Flow Cytometry; Half-Life; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Transfusion; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2015 |
Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland.
Topics: Adolescent; Adult; Aged; Cerebrovascular Disorders; Clopidogrel; Drug-Eluting Stents; Female; Guideline Adherence; Hemorrhage; Humans; Length of Stay; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Recurrence; Risk Factors; Thiophenes; Ticlopidine; Treatment Outcome; Young Adult | 2015 |
An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention
Topics: Administration, Oral; Aged; Atrial Fibrillation; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electrocardiography; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Morpholines; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Rivaroxaban; Thiophenes; Ticlopidine; Treatment Outcome; Vitamin K | 2015 |
[Twelve or thirty months of dual antiplatelet Therapy after drug-eluting stents. Results of the DAPT trial].
Topics: Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Ischemia; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Postoperative Care; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Comparison of P2Y12 receptor inhibition by clopidogrel and prasugrel in patients undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Adult; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
ADP receptor antagonists in patients with acute myocardial infarction complicated by cardiogenic shock: a post hoc IABP-SHOCK II trial subgroup analysis.
Topics: Adult; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Shock, Cardiogenic; Thiophenes; Ticlopidine | 2016 |
Impacts of CYP2C19 genetic polymorphisms on bioavailability and effect on platelet adhesion of vicagrel, a novel thienopyridine P2Y
Topics: Biological Availability; Cross-Over Studies; Cytochrome P-450 CYP2C19; Female; Humans; Male; Phenylacetates; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Thiophenes; Ticlopidine | 2020 |
405 other study(ies) available for ticlopidine and thiophenes
Article | Year |
---|---|
[Use of a new platelet aggregation inhibitor, ticlopidine, in hemodialysis].
Topics: Adult; Aged; Blood Coagulation Disorders; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Platelet Aggregation; Pyridines; Renal Dialysis; Thiophenes; Thrombosis; Ticlopidine | 1979 |
Effects of ticlopidine on platelet prostaglandin metabolism. Possible consequences for prostacyclin production.
Topics: Adenosine Diphosphate; Anticoagulants; Arachidonic Acids; Blood Platelets; Epoprostenol; Humans; In Vitro Techniques; Platelet Aggregation; Prostaglandin Endoperoxides; Prostaglandins; Prostaglandins E; Pyridines; Thiophenes; Ticlopidine | 1979 |
[Changes of blood coagulability and effects of the platelet aggregation inhibitor (ticlopidine) in experimental subarachnoid hemorrhage in dogs].
Topics: Animals; Anticoagulants; Basilar Artery; Blood Coagulation; Dogs; Fibrinogen; Platelet Aggregation; Subarachnoid Hemorrhage; Thiophenes; Ticlopidine | 1985 |
Antithrombotic agents in necrobiosis lipoidica.
Topics: Adolescent; Adult; Diabetes Complications; Female; Fibrinolytic Agents; Humans; Necrobiosis Lipoidica; Thiophenes; Ticlopidine | 1986 |
Inhibition of platelet function by ticlopidine in arteriosclerosis obliterans of the lower limbs.
Topics: Aged; Arteriosclerosis Obliterans; beta-Thromboglobulin; Blood Platelets; Double-Blind Method; Drug Synergism; Epoprostenol; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Factor 4; Thiophenes; Thromboxane B2; Ticlopidine | 1985 |
[Should ticlopidine be forbidden for hemodialysis patients waiting for renal transplantation?].
Topics: Anticoagulants; Humans; Kidney Transplantation; Renal Dialysis; Thiophenes; Ticlopidine | 1985 |
[Does the use of ticlopidine in hemodialyzed patients contraindicate renal transplantation?].
Topics: Anticoagulants; Humans; Kidney Transplantation; Renal Dialysis; Risk; Thiophenes; Ticlopidine | 1986 |
Effect of the antiplatelet agents ticlopidine and dipyridamole on experimental immune complex glomerulonephritis in rats.
Topics: Animals; Antibodies; Antigen-Antibody Complex; Cattle; Creatinine; Dipyridamole; Fluorescent Antibody Technique; Glomerulonephritis; Immune Complex Diseases; Injections, Subcutaneous; Kidney Function Tests; Male; Platelet Aggregation; Proteinuria; Rats; Rats, Inbred SHR; Rats, Inbred Strains; Serum Albumin, Bovine; Thiophenes; Ticlopidine; Time Factors; Urea | 1986 |
Mechanism of interaction of ticlopidine and its analogues with the energy-conserving mechanism in mitochondria.
Topics: Adenosine Diphosphate; Adenosine Triphosphatases; Animals; Anticoagulants; Biological Transport; Energy Metabolism; Kinetics; Male; Mitochondria, Liver; Mitochondrial ADP, ATP Translocases; Oxygen Consumption; Platelet Aggregation; Rats; Rats, Inbred Strains; Structure-Activity Relationship; Thiophenes; Ticlopidine | 1986 |
[Abnormalities of blood coagulation and effect of anticoagulant therapy in postoperative patients with lung cancer].
Topics: Adult; Aged; Anticoagulants; beta-Thromboglobulin; Blood Coagulation Disorders; Female; Humans; Lung Neoplasms; Male; Middle Aged; Postoperative Complications; Thiophenes; Ticlopidine; Warfarin | 1986 |
Immunomodulatory activity of anti-atherogenic drugs: effects on blastogenesis, humoral response, delayed hypersensitivity and passive anaphylaxis by immune complexes.
Topics: Anaphylaxis; Animals; Antibody Formation; Antigen-Antibody Complex; Arteriosclerosis; Clofibrate; Clofibric Acid; Cyclic AMP; Cyclic GMP; Female; Hypersensitivity, Delayed; Lymphocyte Activation; Mice; Mice, Inbred BALB C; Niacin; Thiophenes; Ticlopidine | 1985 |
Platelet-dependent granulocyte activation in vitro: effect of ticlopidine.
Topics: Adenosine Diphosphate; Blood Platelets; Cytochalasin B; Glucuronidase; Humans; In Vitro Techniques; Neutrophils; Platelet Aggregation; Superoxides; Thiophenes; Ticlopidine | 1985 |
Spin label study of the effect of ticlopidine on platelets.
Topics: Animals; Anticoagulants; Blood Platelets; Blood Proteins; Chemical Phenomena; Chemistry, Physical; Cholesterol; Electron Spin Resonance Spectroscopy; In Vitro Techniques; Male; Membrane Fluidity; Phospholipids; Rats; Rats, Inbred Strains; Sodium Dodecyl Sulfate; Spin Labels; Thiophenes; Ticlopidine | 1985 |
Long-term low dose ticlopidine treatment in rheumatoid arthritis: effects on serum sulphydryl levels, technetium index, erythrocyte sedimentation rate, and clinical disease activity.
Topics: Adult; Aged; Arthritis, Rheumatoid; Blood Sedimentation; Female; Humans; Male; Middle Aged; Radionuclide Imaging; Sodium Pertechnetate Tc 99m; Sulfhydryl Compounds; Thiophenes; Ticlopidine | 1985 |
Functionally thrombasthenic state in normal platelets following the administration of ticlopidine.
Topics: Adenosine Triphosphate; Adult; Animals; Bleeding Time; Blood Platelet Disorders; Blood Platelets; Clot Retraction; Female; Fibrinogen; Glycoproteins; Humans; In Vitro Techniques; Male; Membrane Proteins; Platelet Aggregation; Platelet Membrane Glycoproteins; Rats; Thiophenes; Ticlopidine; von Willebrand Factor | 1985 |
[Use of ticlopidine in chronic hemodialyzed patients. Counter-indication in future renal transplant receivers].
Topics: Adult; Anticoagulants; Humans; Kidney Transplantation; Male; Renal Dialysis; Thiophenes; Ticlopidine | 1985 |
Effects of ticlopidine on platelet function and on coronary insufficiency in patients with angina pectoris.
Topics: Adult; Aged; Angina Pectoris; Blood Platelets; Coronary Disease; Humans; Male; Middle Aged; Nitroglycerin; Platelet Function Tests; Thiophenes; Ticlopidine; Time Factors | 1985 |
Metabolic side effects of the platelet-inhibitory drug ticlopidine.
Topics: Adult; Aged; Angina Pectoris; Blood Platelets; Cholesterol; Humans; Male; Middle Aged; Thiophenes; Ticlopidine; Time Factors; Triglycerides | 1985 |
Microcirculatory changes during skin allograft rejection and prolongation of survival time by antiplatelet agents.
Topics: Acrylates; Animals; Arterioles; Azathioprine; Blood Platelets; Capillaries; Graft Occlusion, Vascular; Graft Rejection; Graft Survival; Male; Methacrylates; Mice; Mice, Inbred BALB C; Microscopy, Electron; Skin; Skin Transplantation; Thiophenes; Thromboembolism; Thromboxane-A Synthase; Ticlopidine; Transplantation, Homologous; Transplantation, Isogeneic; Venules | 1986 |
Hemostatic effects of microfibrillar collagen hemostat (MCH) in experimental coagulopathy model and its mechanism of hemostasis.
Topics: Animals; Aspirin; Blood Coagulation Disorders; Cattle; Collagen; Dogs; Hemorrhage; Hemostatic Techniques; Hemostatics; Heparin; Spleen; Thiophenes; Thrombocytopenia; Ticlopidine; Warfarin | 1986 |
Antithrombotic effects of sodium salt of 17(R)-methyl-20-isopropylidenecarbacyclin in the arteriole of the hamster cheek pouch.
Topics: Adenosine Diphosphate; Animals; Arteries; Cheek; Cricetinae; Dipyridamole; Epoprostenol; Fibrinolytic Agents; Male; Mesocricetus; Regional Blood Flow; Thiophenes; Ticlopidine; Time Factors | 1986 |
Ticlopidine and platelet function.
Topics: Adenosine Diphosphate; Drug Synergism; Epoprostenol; Humans; Platelet Aggregation; Thiophenes; Ticlopidine | 1986 |
[Cholestatic fatty liver of probably iatrogenic origin].
Topics: Anticoagulants; Cholestasis, Intrahepatic; Fatty Liver; Female; Humans; Iatrogenic Disease; Middle Aged; Thiophenes; Ticlopidine | 1986 |
Swelling of mitochondria by the platelet antiaggregating agent ticlopidine.
Topics: Animals; Anticoagulants; Chloramphenicol; Kinetics; Male; Mitochondria, Liver; Mitochondrial Swelling; Oxidative Phosphorylation; Oxygen Consumption; Platelet Aggregation; Rats; Rats, Inbred Strains; Thiophenes; Ticlopidine; Uncoupling Agents | 1986 |
[Control of platelet antiaggregation therapy using an electronic aggregometer on whole blood].
Topics: Aged; Arterial Occlusive Diseases; Equipment and Supplies; Evaluation Studies as Topic; Female; Humans; Male; Middle Aged; Platelet Aggregation; Thiophenes; Ticlopidine | 1986 |
[Influencing the effectiveness of repeatedly used dialyzers by the administration of ticlopidine (Ticlid)].
Topics: Adult; Blood Platelets; Creatinine; Female; Heparin; Humans; Male; Renal Dialysis; Thiophenes; Ticlopidine; Urea | 1986 |
Ticlopidine versus aspirin and dipyridamole: influence on platelet deposition and three-month patency of polytetrafluoroethylene grafts.
Topics: Animals; Anticoagulants; Aspirin; Blood Vessel Prosthesis; Dipyridamole; Dogs; Female; Femoral Artery; Graft Occlusion, Vascular; Indium; Male; Platelet Aggregation; Polytetrafluoroethylene; Radioisotopes; Thiophenes; Ticlopidine | 1986 |
Platelet activation induced by a human neuroblastoma tumor cell line is reduced by prior administration of ticlopidine.
Topics: Adenosine Diphosphate; Adult; Blood Platelets; Cell Line; Female; Humans; In Vitro Techniques; Male; Middle Aged; Neuroblastoma; Perfusion; Platelet Aggregation; Thiophenes; Thrombosis; Ticlopidine | 1986 |
[Antagonism of collagen-induced ECG changes in rats by a thromboxane synthetase inhibitor, CV-4151].
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Collagen; Coronary Disease; Electrocardiography; Fatty Acids, Monounsaturated; Fatty Acids, Unsaturated; Humans; Pyridines; Rats; Rats, Inbred Strains; Thiophenes; Thromboxane B2; Ticlopidine | 1986 |
[Prevention and medical treatment of polyregional vascular lesions].
Topics: Adult; Anticoagulants; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Diet; Dipyridamole; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Risk; Sulfinpyrazone; Thiophenes; Thrombosis; Ticlopidine | 1985 |
[Ticlid].
Topics: Anticoagulants; Blood Platelet Disorders; Humans; Thiophenes; Ticlopidine | 1985 |
Anaemia and agranulocytosis associated with ticlopidine therapy.
Topics: Agranulocytosis; Anemia; Blood Protein Electrophoresis; Bone Marrow Examination; Cells, Cultured; Female; Humans; Lymphocytes; Middle Aged; Thiophenes; Ticlopidine | 1985 |
[Activity of ticlopidine and lysine acetylsalicylate in experimental atheromatosis. Effects on the production of PGI2].
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aorta; Arteriosclerosis; Aspirin; Diet, Atherogenic; Epoprostenol; Lysine; Male; Platelet Aggregation; Rabbits; Thiophenes; Ticlopidine | 1985 |
Membrane expansion as a mechanism explaining the antisickling action of ticlopidine observed in vitro.
Topics: Anemia, Sickle Cell; Antisickling Agents; Densitometry; Erythrocyte Membrane; Humans; Kinetics; Osmotic Fragility; Oxygen Consumption; Sickle Cell Trait; Thiophenes; Ticlopidine | 1985 |
Antiplatelet aggregators inhibit development of stress ulcers in Sprague-Dawley rats.
Topics: Animals; Anticoagulants; Aspirin; Capillaries; Dipyridamole; Gastric Mucosa; Male; Platelet Aggregation; Pyridines; Rats; Rats, Inbred Strains; Stomach Ulcer; Stress, Physiological; Sulfinpyrazone; Thiophenes; Thrombosis; Ticlopidine | 1985 |
Antithrombotic effect of ticlopidine in a platelet-independent model of venous thrombosis.
Topics: Animals; Aspirin; Blood Platelets; Fibrinolytic Agents; Male; Rats; Rats, Inbred Strains; Thiophenes; Thrombophlebitis; Ticlopidine | 1985 |
Effect of ticlopidine on platelet aggregation, adherence to damaged vessels, thrombus formation and platelet survival.
Topics: Animals; Anticoagulants; Blood Platelets; Cell Survival; In Vitro Techniques; Male; Neuraminidase; Platelet Adhesiveness; Platelet Aggregation; Rabbits; Rats; Rats, Inbred Strains; Thiophenes; Thrombosis; Ticlopidine | 1985 |
Intracoronary platelet activation in ischemic heart disease: effects of ticlopidine.
Topics: Adult; Aged; Anticoagulants; Aorta; Blood Platelets; Coronary Disease; Coronary Vessels; Female; Humans; Male; Middle Aged; Platelet Factor 4; Thiophenes; Ticlopidine | 1985 |
[Antithrombogenic therapy based on the study of the changes in platelet aggregability and blood coagulability in the early period after prosthetic valve replacement].
Topics: Adult; Anticoagulants; Blood Coagulation; Dipyridamole; Female; Heart Valve Diseases; Heart Valve Prosthesis; Humans; Male; Middle Aged; Platelet Aggregation; Postoperative Complications; Thiophenes; Thrombosis; Ticlopidine; Warfarin | 1985 |
A clinically relevant model of heart failure: effects of ticlopidine.
Topics: Animals; Blood Pressure; Coronary Circulation; Disease Models, Animal; Embolism; Female; Heart Failure; Heart Rate; Male; Platelet Aggregation; Swine; Thiophenes; Ticlopidine | 1985 |
Effect of ticlopidine on neutrophil chemotaxis in rats.
Topics: Adenosine Diphosphate; Administration, Oral; Animals; Cell Membrane; Chemotaxis, Leukocyte; Depression, Chemical; Male; Neutrophils; Platelet Aggregation; Rats; Thiophenes; Ticlopidine; Zymosan | 1985 |
[Agranulocytosis caused by ticlopidine].
Topics: Aged; Agranulocytosis; Anticoagulants; Bone Marrow; Female; Humans; Male; Middle Aged; Thiophenes; Ticlopidine | 1985 |
[Bone marrow culture in patients treated with Ticlopidine].
Topics: Adult; Aged; Agranulocytosis; Alprostadil; Anticoagulants; Bone Marrow; Cells, Cultured; Colony-Forming Units Assay; Female; Granulocytes; Humans; Male; Middle Aged; Prostaglandins E; Thiophenes; Ticlopidine | 1985 |
Ticlopidine as a hemorrhagic risk factor in coronary surgery.
Topics: Adult; Coronary Disease; Female; Hemorrhage; Humans; Male; Platelet Aggregation; Platelet Count; Postoperative Complications; Retrospective Studies; Risk; Thiophenes; Ticlopidine | 1985 |
[Prevention of thrombosis of a blood vessel prosthesis using the anti-aggregation drug ticlid].
Topics: Blood Vessel Prosthesis; Humans; Male; Middle Aged; Platelet Aggregation; Thiophenes; Thrombosis; Ticlopidine | 1985 |
Platelet sequestration during hypothermia in dogs treated with sulphinpyrazone and ticlopidine--reversibility accelerated after intra-abdominal rewarming.
Topics: Animals; Blood Platelets; Dogs; Hemodynamics; Hot Temperature; Hypothermia; Liver; Platelet Aggregation; Sulfinpyrazone; Thiophenes; Thrombocytopenia; Ticlopidine | 1985 |
[Status and trends in the field of inhibitors of thrombocyte function].
Topics: Animals; Blood Platelets; Cyclic AMP; Cyclooxygenase Inhibitors; Humans; Platelet Aggregation; Thiophenes; Thrombosis; Thromboxane-A Synthase; Ticlopidine | 1984 |
In vivo effect of ticlopidine on fibrinogen-platelet cofactor activity and binding of fibrinogen to platelets.
Topics: Adenosine Diphosphate; Anticoagulants; Blood Platelets; Fibrinogen; Humans; In Vitro Techniques; Platelet Aggregation; Platelet Membrane Glycoproteins; Receptors, Cell Surface; Thiophenes; Ticlopidine | 1984 |
Laser-induced thrombi in rat mesenteric vessels and antithrombotic drugs.
Topics: Animals; Aspirin; Blood Platelets; Dipyridamole; Disease Models, Animal; Fibrinolytic Agents; Heparin; Lasers; Male; Mesenteric Arteries; Mesenteric Vascular Occlusion; Molsidomine; Oxazoles; Platelet Aggregation; Propionates; Pyrazoles; Pyrazolones; Rats; Rats, Inbred Strains; Sydnones; Thiophenes; Thrombosis; Ticlopidine | 1983 |
Ticlopidine can cause chronic diarrhoea.
Topics: Aged; Anticoagulants; Chronic Disease; Diarrhea; Humans; Male; Thiophenes; Ticlopidine | 1984 |
[Effects of ticlopidine on the plasma levels of beta-thromboglobulin and thromboxane B2 in types 1 and 2 diabetics].
Topics: Beta-Globulins; beta-Thromboglobulin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Thiophenes; Thromboxane B2; Thromboxanes; Ticlopidine | 1984 |
[Results in peripheral arterial revascularization with the use of various antiaggregating substances].
Topics: Adult; Aged; Anticoagulants; Blood Vessel Prosthesis; Dicumarol; Graft Occlusion, Vascular; Humans; Middle Aged; Thiophenes; Ticlopidine | 1984 |
Beta-thromboglobulin and platelet factor 4 in polycythemia patients treated by ticlopidine.
Topics: Anticoagulants; Beta-Globulins; beta-Thromboglobulin; Erythrocyte Count; Humans; Platelet Count; Platelet Factor 4; Polycythemia; Thiophenes; Ticlopidine | 1984 |
[Side effects of ticlopidine; clinical observation and immunological study].
Topics: Aged; Agranulocytosis; Antibodies; Drug Eruptions; Female; Humans; Male; Middle Aged; Purpura, Thrombocytopenic; Thiophenes; Ticlopidine | 1982 |
The thrombogenicity of Dacron arterial grafts and its modification by platelet inhibitory drugs.
Topics: Arteries; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Dipyridamole; Drug Therapy, Combination; Humans; Microscopy, Electron; Platelet Adhesiveness; Platelet Aggregation; Polyethylene Terephthalates; Sulfinpyrazone; Thiophenes; Thrombosis; Ticlopidine | 1984 |
[Evaluation of platelet aggregation in patients treated with ticlopidine].
Topics: Adult; Aged; Anticoagulants; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; Platelet Aggregation; Thiophenes; Thromboembolism; Ticlopidine | 1984 |
[Quantification (by nomograms) of physiopathological parameters in an experimental model of passive anaphylaxis caused by immune complexes].
Topics: Anaphylaxis; Animals; Cyproheptadine; Immune Complex Diseases; Mathematics; Mice; Mice, Inbred Strains; Shock, Septic; Thiophenes; Ticlopidine | 1984 |
Interaction of ticlopidine with the erythrocyte membrane.
Topics: Blood Proteins; Electron Spin Resonance Spectroscopy; Electrophoresis, Polyacrylamide Gel; Erythrocyte Membrane; Erythrocytes; Humans; In Vitro Techniques; Osmosis; Spin Labels; Thiophenes; Ticlopidine | 1982 |
[Cholestatic hepatitis. Presumptive role of ticlopidine].
Topics: Aged; Chemical and Drug Induced Liver Injury; Cholestasis; Female; Humans; Thiophenes; Ticlopidine | 1983 |
Comparative effects of ticlopidine and analogues on in vitro myeloid colony (CFU-GM) growth.
Topics: Animals; Anticoagulants; Bone Marrow; Chloramphenicol; Chlorpromazine; Colony-Stimulating Factors; DNA; Granulocytes; Hematopoietic Stem Cells; Humans; In Vitro Techniques; Macrophages; Mice; Mice, Inbred C57BL; Thiophenes; Ticlopidine | 1984 |
New horizons in cardiology.
Topics: Adult; Angina, Unstable; Anticoagulants; Coronary Disease; Coronary Vessels; Electrocardiography; Female; Humans; Male; Methacrylates; Middle Aged; Myocardial Infarction; Perfusion; Stroke Volume; Thiophenes; Thromboxane A2; Thromboxane B2; Ticlopidine; Tomography, Emission-Computed; Urokinase-Type Plasminogen Activator | 1984 |
The effect of ticlopidine on human endothelial cells in culture.
Topics: Anticoagulants; Cell Adhesion; Cell Differentiation; Culture Techniques; Endothelium; Fibronectins; Fluorescent Antibody Technique; Humans; Thiophenes; Ticlopidine; Umbilical Veins | 1984 |
The effect of 5-(2-chlorobenzyl)-5,6,7,7a-tetrahydro 4H-thieno (3.2-C)-pyridine-2-one hydrochloride (PCR 3787), a metabolite of ticlopidine, on the aggregation of human platelets in vitro and on the aggregation inhibiting action of PGI2 and PGD2.
Topics: Collagen; Epoprostenol; Humans; Platelet Aggregation; Prostaglandin D2; Prostaglandins D; Thiophenes; Ticlopidine | 1984 |
Effects of ticlopidine and dexamethasone on fibronectin and factor VIII-related antigen synthesis by cultured endothelial cells.
Topics: Antigens; Cells, Cultured; Dexamethasone; Endothelium; Factor VIII; Fibrinolytic Agents; Fibronectins; Humans; In Vitro Techniques; Muscle, Smooth, Vascular; Thiophenes; Ticlopidine; von Willebrand Factor | 1983 |
[Changes in the unmodified vessels after aortocoronary bypass surgery].
Topics: Angina Pectoris; Anticoagulants; Arterial Occlusive Diseases; Coronary Artery Bypass; Coronary Disease; Humans; Male; Middle Aged; Prospective Studies; Thiophenes; Ticlopidine | 1983 |
[Changes in arterial blood gases after hemodialysis and the influence of platelet antiaggregation].
Topics: Adult; Blood Gas Analysis; Carbon Dioxide; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Oxygen; Partial Pressure; Renal Dialysis; Thiophenes; Ticlopidine | 1984 |
The effect of oral ticlopidine on arachidonic acid products in human platelets.
Topics: Administration, Oral; Anticoagulants; Arachidonic Acid; Arachidonic Acids; Blood Platelets; Collagen; Dose-Response Relationship, Drug; Humans; Malondialdehyde; Platelet Aggregation; Thiophenes; Thromboxane B2; Ticlopidine | 1984 |
[The effect of ticlopidine and lysine acetylsalicylate on fibrinolytic activity of the arterial wall in experimental atherosclerosis].
Topics: Animals; Arteriosclerosis; Aspirin; Fibrinolysis; Lysine; Male; Muscle, Smooth, Vascular; Rabbits; Thiophenes; Ticlopidine | 1984 |
Inhibition of thrombocytopenic episodes caused by the Arthus reaction, the sub-lethal Forssman reaction and ADP.
Topics: Adenosine Diphosphate; Animals; Antibodies; Arthus Reaction; Aspirin; Dipyridamole; Forssman Antigen; Guinea Pigs; Humans; Nervous System Diseases; Platelet Count; Pyridines; Sulfides; Sulfinpyrazone; Thiophenes; Thrombocytopenia; Ticlopidine | 1980 |
Effects of various antiplatelet drugs and defibrinating agent on experimental glomerulonephritis in rats.
Topics: Animals; Anticoagulants; Aspirin; Batroxobin; Blood Platelets; Dipyridamole; Glomerulonephritis; Immune Complex Diseases; Kidney; Nephritis; Proteinuria; Pyridines; Rats; Rats, Inbred Strains; Thiophenes; Ticlopidine | 1982 |
Effects of long-term ticlopidine treatment on platelet function and its tolerability in cerebrovascular disease.
Topics: Adult; Aged; Anticoagulants; Blood Coagulation Tests; Blood Platelets; Cerebrovascular Disorders; Female; Fibrinogen; Humans; Ischemic Attack, Transient; Male; Middle Aged; Platelet Adhesiveness; Platelet Aggregation; Thiophenes; Ticlopidine; Time Factors | 1984 |
[Thrombocytopenia due to antibodies induced by ticlopidine].
Topics: Aged; Antibody Formation; Anticoagulants; Arteriosclerosis; Blood Platelets; Humans; Platelet Count; Thiophenes; Thrombocytopenia; Ticlopidine | 1984 |
Effects of ticlopidine, a new platelet antiaggregating agent, and its analogues on mitochondrial metabolism. Oxidative phosphorylation, protein synthesis and DNA polymerase activity.
Topics: Animals; Anticoagulants; DNA-Directed DNA Polymerase; Kinetics; Male; Mitochondria, Liver; Oxidative Phosphorylation; Oxygen Consumption; Platelet Aggregation; Protein Biosynthesis; Rats; Rats, Inbred Strains; Structure-Activity Relationship; Thiophenes; Ticlopidine | 1984 |
[Ticlopidine in the prevention of recurrent cerebral ischemic accidents].
Topics: Anticoagulants; Brain Ischemia; Humans; Recurrence; Thiophenes; Ticlopidine | 1984 |
[Ticlopidine as something more than a platelet antiaggregant].
Topics: Animals; In Vitro Techniques; Lipids; Platelet Aggregation; Rats; Rats, Inbred Strains; Thiophenes; Ticlopidine | 1984 |
[Darier's erythema annulare centrifugum and primary Vaquez polycythemia].
Topics: Aged; Erythema; Follow-Up Studies; Humans; Male; Paraneoplastic Syndromes; Phosphorus Radioisotopes; Polycythemia Vera; Thiophenes; Ticlopidine | 1984 |
[Comparative action of different platelet anti-aggregants in the postoperative period].
Topics: Anticoagulants; Dipyridamole; Humans; Papaverine; Parasympatholytics; Platelet Aggregation; Postoperative Complications; Postoperative Period; Thiophenes; Thrombophlebitis; Ticlopidine | 1984 |
[Thrombus formation and its prevention during extracorporeal circulation--effect of preoperative administration with the antiplatelet drugs].
Topics: Adult; Dipyridamole; Extracorporeal Circulation; Humans; Microscopy, Electron, Scanning; Platelet Adhesiveness; Platelet Aggregation; Platelet Count; Preoperative Care; Thiophenes; Thrombosis; Ticlopidine | 1984 |
In vitro study of ticlopidine, as a model of antisickling action of platelet antiaggregant.
Topics: Anticoagulants; Antisickling Agents; Erythrocyte Membrane; Hemoglobin, Sickle; Humans; In Vitro Techniques; Thiophenes; Ticlopidine | 1984 |
In vivo study of platelet aggregation in rats.
Topics: Adenosine Diphosphate; Animals; Aspirin; Collagen; Diet; Dose-Response Relationship, Drug; Male; Methods; Platelet Aggregation; Platelet Count; Rats; Rats, Inbred Strains; Thiophenes; Thrombosis; Ticlopidine | 1984 |
[Case of thrombotic thrombocytopenic purpura. Successful treatment with ticlopidine].
Topics: Adult; Anticoagulants; Female; Humans; Purpura, Thrombotic Thrombocytopenic; Thiophenes; Ticlopidine | 1984 |
Ex vivo and in vivo evaluation of drugs that inhibit platelet function.
Topics: Adenosine Diphosphate; Animals; Aspirin; Bleeding Time; Blood Platelets; Collagen; Dipyridamole; Imidazoles; Male; Papio; Platelet Aggregation; Sulfinpyrazone; Thiazines; Thiophenes; Ticlopidine | 1983 |
Ticlopidine: quo vadis?
Topics: Animals; Anticoagulants; Humans; Thiophenes; Ticlopidine | 1984 |
Ex vivo effects of ticlopidine on human platelets: inhibition of fibrinogen binding by a mechanism independent of thromboxane formation.
Topics: Anticoagulants; Blood Platelets; Fibrinogen; Humans; Platelet Aggregation; Thiophenes; Thromboxanes; Ticlopidine | 1984 |
Ticlopidine: quo vadis? Adverse reactions in man.
Topics: Anticoagulants; Aspirin; Diarrhea; Humans; Neutropenia; Product Surveillance, Postmarketing; Thiophenes; Ticlopidine | 1984 |
Toxicological studies of ticlopidine in laboratory animals.
Topics: Animals; Anticoagulants; Blood; Carcinogens; Dose-Response Relationship, Drug; Female; Mice; Mutagens; Papio; Rabbits; Rats; Reproduction; Thiophenes; Ticlopidine | 1984 |
Beneficial effects of ticlopidine on cardiopulmonary function of sickle cell patients not in crisis.
Topics: Adult; Anemia, Sickle Cell; Anticoagulants; Heart; Heart Rate; Humans; Lung; Oxygen; Physical Exertion; Thiophenes; Ticlopidine | 1984 |
Ticlopidine as an experimental antithrombotic agent.
Topics: Animals; Anticoagulants; Blood Coagulation; Blood Vessels; Carotid Arteries; Fibrinolytic Agents; Platelet Aggregation; Rats; Thiophenes; Thrombophlebitis; Ticlopidine | 1984 |
Comparative study of platelet aggregation measured with 3 different methods (photometric and impedance) in ticlopidine treated patients.
Topics: Adenosine Diphosphate; Adult; Aged; Anticoagulants; Female; Humans; In Vitro Techniques; Male; Methods; Middle Aged; Platelet Aggregation; Spectrophotometry; Thiophenes; Ticlopidine | 1984 |
Ticlopidine and adenylate cyclase.
Topics: Adenylyl Cyclases; Alprostadil; Animals; Blood Platelets; Enzyme Activation; Male; Prostaglandins E; Rabbits; Rats; Rats, Inbred Strains; Thiophenes; Ticlopidine | 1984 |
[Effect of ticlopidine in the prevention of recurrences of cerebral ischemic accidents: comparative study with dipyridamol].
Topics: Brain Ischemia; Dipyridamole; Drug Evaluation; Female; Gastrointestinal Hemorrhage; Humans; Male; Rectum; Recurrence; Thiophenes; Ticlopidine | 1984 |
Effect of ticlopidine on saphenous vein bypass patency rates: a double-blind study.
Topics: Coronary Artery Bypass; Coronary Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Postoperative Complications; Radiography; Random Allocation; Saphenous Vein; Thiophenes; Ticlopidine | 1984 |
Thrombotic etiology of stress ulcers. 1. The effect of anticoagulant and antiplatelet aggregators in the development of stress ulcers in rats.
Topics: Animals; Anticoagulants; Aspirin; Dipyridamole; Gastric Acidity Determination; Gastric Mucosa; Heparin; Male; Peptic Ulcer Hemorrhage; Platelet Aggregation; Platelet Count; Rats; Rats, Inbred Strains; Stomach Ulcer; Stress, Physiological; Thiophenes; Thrombosis; Ticlopidine | 1983 |
On-line diode array UV-visible spectrometry in screening for drugs and drug metabolites by high-performance liquid chromatography.
Topics: Amiodarone; Animals; Bile; Biotransformation; Chromatography, High Pressure Liquid; Humans; Male; Middle Aged; Pharmaceutical Preparations; Rats; Rats, Inbred Strains; Spectrophotometry; Spectrophotometry, Ultraviolet; Thiophenes; Ticlopidine | 1983 |
Effect of intergranular versus intragranular cornstarch on tablet friability and in vitro dissolution.
Topics: Hardness; Microscopy, Electron, Scanning; Solubility; Starch; Tablets; Thiophenes; Ticlopidine; Time Factors | 1983 |
Ticlopidine: a promise for the prevention and treatment of thrombosis and its complications.
Topics: Animals; Anticoagulants; Blood Platelets; Hemodynamics; Humans; Kinetics; Thiophenes; Thrombosis; Ticlopidine | 1983 |
Anti-platelet drugs during chronic hemodialysis: an experience with ticlopidine, the 5-(o-chlorobenzyl)-4,5,6,7-tetrahydrothieno-[3,2-c] pyridine.
Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Platelet Aggregation; Renal Dialysis; Thiophenes; Ticlopidine | 1983 |
Effects of ticlopidine and aspirin on endotoxin-induced disseminated intravascular coagulation in rats.
Topics: Animals; Aspirin; Disseminated Intravascular Coagulation; Rats; Thiophenes; Ticlopidine | 1983 |
[Platelet antiaggregants and bleeding time lengthening: management in the preoperative period].
Topics: Adrenal Cortex Hormones; Aspirin; Blood Coagulation; Humans; Platelet Aggregation; Preoperative Care; Thiophenes; Ticlopidine | 1983 |
Antiplatelet drugs and thrombosis prevention: ticlopidine in perspective.
Topics: Anticoagulants; Bleeding Time; Humans; Platelet Aggregation; Thiophenes; Thrombosis; Ticlopidine | 1983 |
Antiplatelet drugs and thrombosis prevention: ticlopidine in perspective.
Topics: Adenosine Diphosphate; Aspirin; Bleeding Time; Blood Platelets; Fibrinolytic Agents; Humans; Thiophenes; Thrombosis; Ticlopidine | 1984 |
A platelet aggregation inhibitor--ticlopidine--in diabetic nephropathy: a randomized double blind study.
Topics: Adult; Creatinine; Diabetic Nephropathies; Double-Blind Method; Drug Evaluation; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Platelet Aggregation; Random Allocation; Thiophenes; Ticlopidine | 1984 |
Platelet survival, atherosclerotic intermittent claudication and ticlopidine.
Topics: Aged; Arteriosclerosis; Blood Platelets; Cell Survival; Humans; Indium; Intermittent Claudication; Male; Middle Aged; Radioisotopes; Thiophenes; Ticlopidine | 1984 |
Effects of antiplatelet agents on pulmonary metastases.
Topics: Adenosine Diphosphate; Animals; Depression, Chemical; Diltiazem; Dipyridamole; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Lung Neoplasms; Male; Melanoma; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Platelet Aggregation; Thiophenes; Ticlopidine; Trapidil | 1984 |
[Structural aspects of the kidney in experimental atheromatosis].
Topics: Animals; Arteriosclerosis; Blood Platelets; Fibrinolysis; Kidney; Male; Platelet Aggregation; Rabbits; Salicylates; Thiophenes; Ticlopidine; Tranexamic Acid | 1984 |
Inhibition by ticlopidine of Paf-acether-induced in vitro aggregation of rabbit and human platelets.
Topics: Adenosine Diphosphate; Animals; Arachidonic Acids; Humans; Platelet Activating Factor; Platelet Aggregation; Rabbits; Thiophenes; Ticlopidine | 1984 |
The in vitro effect of ticlopidine on fibrinogen and factor VIII binding to human platelets.
Topics: Anticoagulants; Blood Platelets; Cells, Cultured; Depression, Chemical; Factor VIII; Fibrinogen; Humans; In Vitro Techniques; Platelet Aggregation; Pyridines; Thiophenes; Ticlopidine | 1981 |
The effect of ticlopidine on the aggregation of rat blood platelets and on the formation of metabolites from arachidonic acid and 8,11,14-eicosatrienoic acid in rat platelets during aggregation, and in the rat kidney.
Topics: 8,11,14-Eicosatrienoic Acid; Animals; Arachidonic Acid; Arachidonic Acids; Biotransformation; Blood Platelets; Collagen; Fatty Acids, Unsaturated; Kidney; Male; Platelet Aggregation; Rats; Rats, Inbred Strains; Thiophenes; Ticlopidine | 1982 |
Platelet aggregation measured in rabbit whole blood: in vitro study of 3 aggregating agents and ex vivo inhibition by aspirin and ticlopidine.
Topics: Adenosine Diphosphate; Animals; Arachidonic Acid; Arachidonic Acids; Aspirin; Collagen; In Vitro Techniques; Platelet Aggregation; Platelet Count; Rabbits; Thiophenes; Ticlopidine | 1982 |
Study of platelet aggregation induced by platelet activating factor (PAF) after administration of ticlopidine or aspirin.
Topics: Adult; Aged; Anticoagulants; Aspirin; Epinephrine; Humans; In Vitro Techniques; Middle Aged; Platelet Activating Factor; Platelet Aggregation; Thiophenes; Ticlopidine | 1983 |
[The effects of ticlopidine on platelet aggregation: study on 13 atherosclerotic patients].
Topics: Aged; Anticoagulants; Arteriosclerosis; Female; Humans; Male; Platelet Aggregation; Thiophenes; Ticlopidine | 1983 |
Spinal subarachnoid hematoma after lumbar puncture in a patient receiving antiplatelet therapy.
Topics: Aged; Anesthesia, Spinal; Anticoagulants; Female; Hematoma; Humans; Postoperative Complications; Spinal Cord Diseases; Spinal Puncture; Subarachnoid Hemorrhage; Thiophenes; Ticlopidine | 1983 |
Effects of ticlopidine and aspirin on endotoxin-induced disseminated intravascular coagulation in rats.
Topics: Animals; Aspirin; Disease Models, Animal; Disseminated Intravascular Coagulation; Endotoxins; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Kidney Glomerulus; Partial Thromboplastin Time; Platelet Count; Prothrombin Time; Rats; Rats, Inbred Strains; Thiophenes; Ticlopidine | 1983 |
[Platelet aggregation inhibitors].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Dipyridamole; Humans; Platelet Aggregation; Pyridines; Thiophenes; Thrombosis; Ticlopidine | 1981 |
Comparison between the antiaggregating effect of ticlopidine in whole blood, platelet-rich plasma and washed platelets of the rat.
Topics: Adenosine Diphosphate; Animals; Dinoprostone; Epoprostenol; In Vitro Techniques; Male; Plasma; Platelet Aggregation; Prostaglandins E; Rats; Rats, Inbred Strains; Thiophenes; Ticlopidine | 1982 |
[Hematological toxicity of ticlopidine? (author's transl)].
Topics: Aged; Agranulocytosis; Female; Humans; Male; Middle Aged; Pancytopenia; Platelet Aggregation; Thiophenes; Ticlopidine | 1982 |
Multiple human serum binding of two thienopyridinic derivatives, ticlopidine and PCR 2362, and their distribution between HSA, alpha1-acid glycoprotein and lipoproteins.
Topics: Humans; Lipoproteins; Orosomucoid; Platelet Aggregation; Protein Binding; Serum Albumin; Thiophenes; Ticlopidine | 1982 |
[Physicochemical study of ticlopidine absorption kinetics on human platelet membrane (author's transl)].
Topics: Adsorption; Blood Platelets; Cell Membrane; Chemical Phenomena; Chemistry, Physical; Humans; Kinetics; Membrane Fluidity; Thiophenes; Ticlopidine | 1982 |
[Platelet release proteins in plasma in peripheral arterial obliterative disease during ticlopidine administration].
Topics: Adult; Arterial Occlusive Diseases; Blood Coagulation Factors; Double-Blind Method; Female; Humans; Male; Platelet Factor 4; Thiophenes; Ticlopidine | 1982 |
A possible method to control prolongations of bleeding time under antiplatelet therapy with ticlopidine.
Topics: Adenosine Diphosphate; Administration, Oral; Adult; Bleeding Time; Female; Humans; Hydrocortisone; Injections, Intravenous; Male; Platelet Aggregation; Prednisolone; Thiophenes; Ticlopidine; Vasoconstrictor Agents | 1982 |
Platelet survival in patients treated with ticlopidine following reconstructive arterial surgery.
Topics: Aged; Aorta; Blood Platelets; Blood Vessel Prosthesis; Cell Survival; Dose-Response Relationship, Drug; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Postoperative Complications; Thiophenes; Ticlopidine | 1982 |
Antiaggregant effect of ticlopidine in atherosclerotic patients.
Topics: Aged; Arteriosclerosis; Female; Humans; Male; Middle Aged; Platelet Aggregation; Thiophenes; Ticlopidine | 1982 |
A comparison of ticlopidine and heparin on hemodialysis in dogs.
Topics: Animals; Anorexia; Diarrhea; Dogs; Heparin; Renal Dialysis; Thiophenes; Ticlopidine; Uremia | 1982 |
A new in vivo model of arterial thrombosis: the effect of administration of ticlopidine and verapamil in dogs.
Topics: Administration, Oral; Animals; Disease Models, Animal; Dogs; Drug Evaluation, Preclinical; Femoral Artery; Fibrinolytic Agents; Injections, Intravenous; Platelet Aggregation; Thiophenes; Thrombosis; Ticlopidine; Verapamil | 1982 |
Modulation of the inhibitory action of prostaglandin E1 on platelet aggregation in rats: a study with ticlopidine, aspirin, dipyridamole and sulfinpyrazone.
Topics: Adenosine Diphosphate; Alprostadil; Animals; Aspirin; Dipyridamole; Male; Phosphorylation; Platelet Aggregation; Prostaglandins E; Rats; Rats, Inbred Strains; Sulfinpyrazone; Thiophenes; Ticlopidine | 1982 |
Effects of long term administration of ticlopidine on platelet function and hemostatic variables.
Topics: Adult; Afibrinogenemia; Aged; Antithrombin III; Bleeding Time; Blood Platelets; Blood Sedimentation; Female; Fibrinogen; Hemostasis; Humans; Male; Middle Aged; Platelet Aggregation; Pyridines; Thiophenes; Ticlopidine; Time Factors | 1980 |
Antithrombotic therapy with ticlopidine in chronic renal failure patients on maintenance hemodialysis--a multicenter collaborative double blind study.
Topics: Adult; Aged; Blood Urea Nitrogen; Chlorides; Creatinine; Double-Blind Method; Female; Fibrinolytic Agents; Humans; Kidney Failure, Chronic; Male; Middle Aged; Phosphoric Acids; Platelet Count; Pyridines; Renal Dialysis; Thiophenes; Thrombosis; Ticlopidine | 1980 |
[Effects of ticlopidine on blood circulation and thrombin-induced platelet aggregation in experimental diabetic rats- and it's efficacy for remedy of diabetic retinopathy (author's transl)].
Topics: Animals; Blood Circulation; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Male; Platelet Aggregation; Pyridines; Rats; Thiophenes; Thrombin; Ticlopidine | 1981 |
Effect of ticlopidine on arachidonic acid metabolism in platelet phospholipids in vitro.
Topics: Arachidonic Acids; Blood Platelets; Humans; In Vitro Techniques; Phosphatidylcholines; Phosphatidylinositols; Phospholipids; Pyridines; Thiophenes; Ticlopidine | 1981 |
Metabolism of ticlopidine in rats: identification and quantitative determination of some its metabolites in plasma, urine and bile.
Topics: Animals; Bile; Biotransformation; Chemical Phenomena; Chemistry; Chromatography, Gas; Chromatography, Thin Layer; Male; Pyridines; Rats; Thiophenes; Ticlopidine | 1981 |
Compression properties of granulations made with binders containing different moisture contents.
Topics: Drug Compounding; Excipients; Hardness; Humidity; Powders; Pressure; Pyridines; Tablets; Thiophenes; Ticlopidine | 1981 |
Effects of 5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride (Ticlopidine), a platelet aggregation inhibitor, on blood-borne metastasis.
Topics: Animals; Cell Line; Female; Liver Neoplasms, Experimental; Lung Neoplasms; Male; Melanoma; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Neoplastic Cells, Circulating; Platelet Aggregation; Pyridines; Rats; Thiophenes; Ticlopidine | 1981 |
Effects of ticlopidine on thrombotic obstruction of A-V shunts and on dialysance of artificial kidneys.
Topics: Adult; Arteriovenous Shunt, Surgical; Blood Coagulation; Female; Fibrinolytic Agents; Humans; Kidneys, Artificial; Middle Aged; Platelet Aggregation; Pyridines; Renal Dialysis; Thiophenes; Thrombosis; Ticlopidine | 1980 |
Antithrombotic effects of ticlopidine, acetylsalicyclic acid and dipyridamole in vascular shunt model in rats.
Topics: Animals; Arteriovenous Shunt, Surgical; Aspirin; Blood Coagulation; Blood Coagulation Tests; Dipyridamole; Fibrinogen; Fibrinolytic Agents; Hematocrit; Male; Platelet Aggregation; Platelet Count; Pyridines; Rats; Serum Globulins; Thiophenes; Ticlopidine | 1980 |
Pharmacological studies on ticlopidine, a new platelet aggregation inhibitor. Part I: Cardiovascular effects.
Topics: Animals; Cerebrovascular Circulation; Coronary Circulation; Dogs; Ear; Female; Heart Rate; Hemodynamics; In Vitro Techniques; Male; Muscle Tonus; Myocardium; Oxygen Consumption; Papaverine; Platelet Aggregation; Pyridines; Rabbits; Rats; Regional Blood Flow; Respiration; Thiophenes; Ticlopidine | 1980 |
[Migraine or transient ischemic attacks in a patient with essential thrombocythaemia. Treatment with ticlopidine (author's transl)].
Topics: Blood Platelets; Humans; Ischemic Attack, Transient; Male; Middle Aged; Migraine Disorders; Platelet Aggregation; Pyridines; Thiophenes; Thrombocytosis; Ticlopidine | 1980 |
Effect of ticlopidine on human platelet responsiveness ex vivo: comparison with aspirin.
Topics: Adenosine Diphosphate; Adult; Aspirin; Collagen; Dose-Response Relationship, Drug; Epinephrine; Female; Humans; Male; Middle Aged; Platelet Aggregation; Pyridines; Serotonin; Thiophenes; Ticlopidine | 1980 |
Effect of ticlopidine treatment on liver metabolizing enzymes in man.
Topics: Adult; Antipyrine; Enzyme Induction; Half-Life; Humans; Liver; Male; Microsomes, Liver; Pyridines; Thiophenes; Ticlopidine | 1980 |
The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties.
Topics: Adenosine Diphosphate; Administration, Oral; Animals; Arteriovenous Shunt, Surgical; Binding, Competitive; Bleeding Time; Blood Platelets; Clopidogrel; Collagen; Cyclic AMP; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrinolytic Agents; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P2; Thionucleotides; Thiophenes; Thrombin; Thrombosis; Ticlopidine; Time Factors; Tritium | 2000 |
Characterization of novel dihydrothienopyridinium and thienopyridinium metabolites of ticlopidine in vitro: role of peroxidases, cytochromes p450, and monoamine oxidases.
Topics: Animals; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; DNA, Complementary; Horseradish Peroxidase; Humans; In Vitro Techniques; Insecta; Magnetic Resonance Spectroscopy; Mass Spectrometry; Microsomes, Liver; Monoamine Oxidase; Oxidation-Reduction; Peroxidases; Platelet Aggregation Inhibitors; Pyridinium Compounds; Thiophenes; Ticlopidine | 2004 |
Prasugrel, clopidogrel, and combining Swedish apples with American oranges.
Topics: Clinical Trials, Phase II as Topic; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2006 |
Highly selective copper-catalyzed ring expansion of vinyl thiiranes: application to synthesis of biotin and the heterocyclic core of plavix.
Topics: Biotin; Catalysis; Clopidogrel; Copper; Heterocyclic Compounds; Sulfides; Thiophenes; Ticlopidine; Vinyl Compounds | 2007 |
The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite.
Topics: Adenosine Diphosphate; Alprostadil; Animals; Blood Platelets; Clopidogrel; Cyclic AMP; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Rats; Rats, Sprague-Dawley; Thiophenes; Ticlopidine | 2007 |
Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status.
Topics: Clopidogrel; Humans; Nephelometry and Turbidimetry; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Time Factors | 2007 |
Antiplatelet agents make a comeback in ST-elevation myocardial infarction.
Topics: Adenosine; Antifibrinolytic Agents; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2007 |
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.
Topics: Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Female; Genotype; Humans; Male; Middle Aged; Mixed Function Oxygenases; Phenotype; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Reference Values; Research Design; Retrospective Studies; Thiophenes; Ticlopidine | 2007 |
Intensifying platelet inhibition--navigating between Scylla and Charybdis.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemia; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2007 |
Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
Topics: Administration, Oral; Adult; Animals; Clopidogrel; Dogs; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; In Vitro Techniques; Macaca fascicularis; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Rabbits; Rats; Rats, Sprague-Dawley; Species Specificity; Thiophenes; Thrombosis; Ticlopidine | 2008 |
[Prasugrel, a new thienopyridine].
Topics: Clinical Trials, Phase II as Topic; Clopidogrel; Coronary Thrombosis; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticlopidine | 2007 |
The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses.
Topics: Adenosine Monophosphate; Adult; Annexin A5; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Cytoplasmic Granules; Humans; In Vitro Techniques; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2008 |
[Prasugrel versus clopidogrel. From the American Heart Association meeting, 2007].
Topics: Clopidogrel; Congresses as Topic; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2008 |
Prasugrel versus clopidogrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Stroke; Thiophenes; Ticlopidine | 2008 |
Prasugrel versus clopidogrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk; Thiophenes; Ticlopidine | 2008 |
Prasugrel versus clopidogrel.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Monitoring, Physiologic; Myocardial Infarction; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2008 |
Bleeding risks with prasugrel in the TRITON trial: good news ... bad news.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Therapy, Combination; Hematemesis; Hematuria; Hemorrhage; Humans; Intracranial Hemorrhages; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine | 2008 |
Excess rates of nonfatal myocardial infarction in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel (preventing clinical events or chasing enzymatic ghosts?).
Topics: Clinical Trials, Phase III as Topic; Clopidogrel; Dose-Response Relationship, Drug; Female; Humans; Male; Multicenter Studies as Topic; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine; Treatment Outcome | 2008 |
A perspective on the efficacy and safety of intensive antiplatelet therapy in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38.
Topics: Clinical Trials, Phase III as Topic; Clopidogrel; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Humans; Multicenter Studies as Topic; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Research Design; Thiophenes; Ticlopidine; Treatment Outcome | 2008 |
The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Blood Platelets; Cells, Cultured; Clopidogrel; Drug Interactions; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2008 |
For better or for worse: the future of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Disease; Forecasting; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stroke; Thiophenes; Thrombolytic Therapy; Thrombosis; Ticlopidine | 2008 |
Multiple electrode aggregometry and P2Y(12) antagonists.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Anticoagulants; Clopidogrel; Dose-Response Relationship, Drug; Electrodes; Equipment Design; Hirudins; Humans; Peptide Fragments; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2008 |
Antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2008 |
[Commentary to the article: Wiviott S D, Braunwald E, McCabe C H et al. Prasugrel versus clopidogrel in patients with acute coronary syndrome. N Engl J Med 2007; 357: 2001-15].
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Treatment Outcome | 2008 |
Intensive antiplatelet therapy for reduction of ischaemic events.
Topics: Clopidogrel; Humans; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine; Time Factors | 2008 |
[Prasugrel versus Clopidogrel in patients with acute coronary syndromes. Results of the TRITON-TIMI 38 trial].
Topics: Acute Coronary Syndrome; Clopidogrel; Double-Blind Method; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2008 |
Modulation of clopidogrel pharmacodynamic response.
Topics: Anticholesteremic Agents; Area Under Curve; Atorvastatin; Clopidogrel; Drug Interactions; Heptanoic Acids; Humans; Metabolic Clearance Rate; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrroles; Thiophenes; Ticlopidine | 2008 |
Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel.
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2B6; Dose-Response Relationship, Drug; Humans; Lactones; Microsomes, Liver; Oxidoreductases, N-Demethylating; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2009 |
The pursuit of clinically relevant measures of platelet function after antiplatelet drug therapy.
Topics: Blood Platelets; Clopidogrel; Coronary Artery Disease; Diabetes Complications; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Risk Factors; Thiophenes; Ticlopidine; Treatment Failure | 2008 |
Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Clinical Trials, Phase III as Topic; Clopidogrel; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine | 2009 |
Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine.
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6 Inhibitors; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Oxidoreductases, N-Demethylating; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticlopidine | 2008 |
Another view on prasugrel.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Aspirin; Blood Platelets; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Drug Administration Schedule; Drug Resistance; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Research Design; Risk Assessment; Stents; Thiophenes; Ticlopidine; Treatment Outcome | 2009 |
Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability.
Topics: Adenosine Diphosphate; Administration, Oral; Animals; Binding, Competitive; Bleeding Time; Clopidogrel; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrinolytic Agents; Hemorrhage; Hemostasis; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Rabbits; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thionucleotides; Thiophenes; Thrombosis; Ticlopidine | 2009 |
Facts and controversies of aspirin and clopidogrel therapy.
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Blood Platelets; Brain Ischemia; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticlopidine | 2009 |
Ischaemia versus bleeding: the art of clinical decision-making.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Decision Making; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine | 2009 |
Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs.
Topics: Animals; Area Under Curve; Clopidogrel; Cytochrome P-450 Enzyme System; Dogs; Hydrolysis; Male; Molecular Structure; Oxidation-Reduction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Rats; Rats, Sprague-Dawley; Thiophenes; Ticlopidine | 2009 |
Novel antiplatelet strategies in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clinical Trials, Phase III as Topic; Clopidogrel; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine | 2009 |
Prasugrel STEMI subgroup analysis.
Topics: Clopidogrel; Data Interpretation, Statistical; Electrocardiography; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Research Design; Thiophenes; Ticlopidine; Treatment Outcome | 2009 |
Prasugrel STEMI subgroup analysis.
Topics: Clopidogrel; Data Interpretation, Statistical; Drug Administration Schedule; Electrocardiography; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Research Design; Thiophenes; Ticlopidine; Treatment Outcome | 2009 |
Prasugrel STEMI subgroup analysis.
Topics: Aspirin; Clopidogrel; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Thiophenes; Ticlopidine | 2009 |
Can we override clopidogrel resistance?
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Coronary Restenosis; Drug Resistance; Genotype; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prasugrel Hydrochloride; Prodrugs; Radiography; Stents; Thiophenes; Ticlopidine | 2009 |
Future of oral antiplatelet therapy: four challenged hypotheses.
Topics: Adenosine; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Cost-Benefit Analysis; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Prognosis; Purinergic P2 Receptor Antagonists; Pyridines; Risk Assessment; Survival Rate; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2009 |
Pharmacy benefit spending poised to increase for antithrombotic drug therapy -- prasugrel versus clopidogrel.
Topics: Clopidogrel; Commerce; Drug Costs; Humans; Insurance, Pharmaceutical Services; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine | 2009 |
Relevance of metabolic activation pathways: the example of clopidogrel and prasugrel.
Topics: Animals; Biotransformation; Clopidogrel; Cytochrome P-450 Enzyme System; Genetic Variation; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2009 |
[Pharmazie in unserer Zeit 4/2009].
Topics: Aspirin; Atherosclerosis; Clopidogrel; Drug Resistance; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticlopidine | 2009 |
Test before you stop.
Topics: Adenosine; Algorithms; Aspirin; Clinical Trials as Topic; Clopidogrel; Humans; Perioperative Care; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Pyridines; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis.
Topics: Adenosine; Animals; CHO Cells; Clopidogrel; Cricetinae; Cricetulus; Disease Models, Animal; Dogs; Hemostasis; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Rats; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine; Transfection | 2009 |
Cardiovascular disease gets personal.
Topics: Anticoagulants; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Female; Genetic Predisposition to Disease; Genetic Testing; Genetic Variation; Genome-Wide Association Study; Genomics; Humans; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Warfarin | 2009 |
A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel.
Topics: Clopidogrel; Cytochrome P-450 Enzyme System; Genetic Variation; Humans; Microsomes, Liver; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticlopidine | 2009 |
Ticagrelor--is there need for a new player in the antiplatelet-therapy field?
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Risk of combining PPIs with thienopyridines: fact or fiction?
Topics: Biotransformation; Clopidogrel; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Pyridines; Thiophenes; Ticlopidine | 2009 |
[New thrombocyte inhibitor. Fewer ischemic complications in acute coronary syndrome].
Topics: Acute Coronary Syndrome; Clopidogrel; Double-Blind Method; Humans; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine | 2009 |
[Prasugrel or clopidogrel in patients with coronary intervention].
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Double-Blind Method; Endpoint Determination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Ticlopidine | 2009 |
Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel.
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Kinetics; Microsomes, Liver; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2009 |
Stent thrombosis: who's guilty?
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Blood Vessel Prosthesis; Cardiology; Clinical Competence; Clopidogrel; Cytochrome P-450 CYP2C19; Drug-Eluting Stents; Graft Occlusion, Vascular; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticlopidine | 2009 |
Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Drug-Eluting Stents; Europe; Hemorrhage; Humans; Ischemic Attack, Transient; Myocardial Infarction; Neoplasms; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Recurrence; Stents; Stroke; Thiophenes; Ticlopidine; Treatment Outcome | 2009 |
[Changing times for clopidogrel].
Topics: Clopidogrel; Drug Interactions; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2 Receptor Antagonists; Thiophenes; Ticlopidine | 2009 |
Clopidogrel versus prasugrel: times are changing, but not for everyone.
Topics: Acute Coronary Syndrome; Clinical Trials as Topic; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2009 |
Prasugrel for acute coronary syndromes: faster, more potent, but higher bleeding risk.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Hemorrhage; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2009 |
Clinical trial update II: TRITON-TIMI 38 provides reassurance on concomitant use of proton pump inhibitors and thienopyridines.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Interactions; Gastrointestinal Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine | 2009 |
The TRITON versus PLATO trials: differences beyond platelet inhibition.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Drug Evaluation; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasug
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Cost-Benefit Analysis; Databases, Factual; Drug Costs; Follow-Up Studies; Hemorrhage; Hospitalization; Humans; Life Expectancy; Multicenter Studies as Topic; Myocardial Infarction; Outcome and Process Assessment, Health Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Stroke; Thiophenes; Thrombolytic Therapy; Ticlopidine; United States | 2010 |
Ticagrelor in ACS: redefining a new standard of care?
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
Lack of outcome benefit and clopidogrel "resistance." The TRITON trial challenge.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Approval; Drug Resistance; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Stroke; Survival Analysis; Thiophenes; Ticlopidine; Treatment Outcome | 2010 |
Role of ticagrelor in clopidogrel nonresponders: resistance is futile?
Topics: Adenosine; Clopidogrel; Coronary Artery Disease; Drug Resistance; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
Trial watch. DAPT study.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2010 |
Delays of event adjudication in the TRITON trial.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cerebral Infarction; Clopidogrel; Coronary Restenosis; Data Collection; Disease-Free Survival; Hemorrhage; Myocardial Infarction; Observer Variation; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Reproducibility of Results; Research Design; Stents; Thiophenes; Ticlopidine; Treatment Outcome; United States; United States Food and Drug Administration | 2010 |
Prasugrel, Māori, and personalised medicine in New Zealand.
Topics: Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Genetic Markers; Genetic Testing; Humans; Native Hawaiian or Other Pacific Islander; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Precision Medicine; Stents; Thiophenes; Thrombosis; Ticlopidine; Vascular Diseases | 2010 |
A comparison of the VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: an integrated analysis.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aged; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Databases, Factual; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Systems; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2010 |
[Interview with Prof. Franz-Joseph Krozingen: Interventional cardiology on the success course].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cardiology; Clinical Trials as Topic; Clopidogrel; Emergencies; Fibrinolysis; Forecasting; Humans; Length of Stay; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Stents; Thiophenes; Ticlopidine; Time Factors | 2010 |
[Comparison of effects of prasugrel and clopidogrel in patients with acute coronary syndrome, subjected to percutaneous coronary intervention: TRITON-TIMI 38 trial].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug-Eluting Stents; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Stroke; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome | 2010 |
Letter by Serebruany regarding article, "Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by O
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Cost-Benefit Analysis; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombolytic Therapy; Ticlopidine; Treatment Outcome | 2010 |
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genetic Variation; Genotype; Humans; Male; Middle Aged; Pharmacogenetics; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine | 2010 |
Response to antiplatelet treatment: from genes to outcome.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prasugrel Hydrochloride; Stents; Thiophenes; Ticlopidine | 2010 |
Effects of thienopyridines and thienopyrimidinones on L-type calcium current in isolated cardiomyocytes.
Topics: Action Potentials; Animals; Atrial Appendage; Calcium Channels, L-Type; Cells, Cultured; Clopidogrel; Guinea Pigs; Heart Ventricles; Humans; In Vitro Techniques; Myocytes, Cardiac; Patch-Clamp Techniques; Platelet Aggregation Inhibitors; Pyrimidines; Thienopyridines; Thiophenes; Ticlopidine | 2010 |
Prasugrel as alternative treatment strategy in a case with a hypersensitivity reaction to clopidogrel.
Topics: Aged; Angioedema; Clopidogrel; Drug Hypersensitivity; Exanthema; Fever; Humans; Male; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Tachycardia; Thiophenes; Thrombosis; Ticlopidine | 2011 |
Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Topics: Adenosine; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Antineoplastic Agents; Clopidogrel; Docetaxel; Drug Resistance; Drug-Eluting Stents; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Taxoids; Thiophenes; Thrombosis; Ticlopidine | 2011 |
Prasugrel and cancer.
Topics: Clinical Trials as Topic; Clopidogrel; Humans; Neoplasms; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2010 |
[Evidence-based management of ST-segment elevation myocardial infarction (STEMI). Latest guidelines of the European Society of Cardiology (ESC) 2010].
Topics: Aftercare; Anticoagulants; Cardiovascular Agents; Clopidogrel; Combined Modality Therapy; Contraindications; Electrocardiography; Emergency Medical Services; Emergency Service, Hospital; Europe; Evidence-Based Medicine; Humans; Life Style; Myocardial Infarction; Myocardial Reperfusion; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Thrombolytic Therapy; Ticlopidine; Time Factors | 2010 |
An algorithm for use of prasugrel (effient) in patients undergoing cardiac catheterization and percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Cardiac Catheterization; Clinical Protocols; Clinical Trials as Topic; Clopidogrel; Comparative Effectiveness Research; Guidelines as Topic; Hemorrhage; Humans; Myocardial Infarction; Patient Care Planning; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Assessment; Standard of Care; Thiophenes; Thrombolytic Therapy; Ticlopidine; Treatment Outcome | 2010 |
Antiplatelet and antithrombotic treatment after primary percutaneous coronary intervention: balancing safety and efficacy.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration Schedule; Fibrinolytic Agents; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Safety; Secondary Prevention; Thiophenes; Ticlopidine; Treatment Outcome; Warfarin | 2010 |
Resistance to anti-platelet agents.
Topics: Adenosine; Aspirin; Clopidogrel; Drug Resistance; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
[Do genetic factors reduce the effects of clopidogrel?].
Topics: Adenosine; Clopidogrel; Cytochrome P-450 Enzyme System; Genetic Variation; Genotype; Hemorrhage; Humans; Isoenzymes; Pharmacogenetics; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2011 |
[Multiple arterial thrombosis and resistance to conventional antiaggregation].
Topics: Aged; Angiography; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Resistance; Electrocardiography; Female; Femoral Artery; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine | 2011 |
Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Cerebrovascular Disorders; Cilostazol; Clopidogrel; Drug Monitoring; Drug Resistance; Drug Substitution; Electrodes; Female; Germany; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Prospective Studies; Risk Assessment; Risk Factors; Stents; Tetrazoles; Thiophenes; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
Prasugrel as a safe alternative for clopidogrel-associated arthritis.
Topics: Arthritis; Clopidogrel; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2011 |
Oral antiplatelet agents clopidogrel and prasugrel for the prevention of cardiovascular events.
Topics: Administration, Oral; Cardiovascular Diseases; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2011 |
[Specificities of diabetes in acute coronary syndromes].
Topics: Acute Coronary Syndrome; Algorithms; Angioplasty; Anti-Inflammatory Agents, Non-Steroidal; Clopidogrel; Diabetes Complications; Diabetes Mellitus; Drug Therapy, Combination; Enoxaparin; Evidence-Based Medicine; Fibrinolytic Agents; Heparin; Humans; Hypoglycemic Agents; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Secondary Prevention; Stents; Thiophenes; Ticlopidine; Treatment Outcome | 2011 |
Subacute stent thrombosis owing to complete clopidogrel resistance successfully managed with prasugrel.
Topics: Angioplasty, Balloon, Coronary; Anterior Wall Myocardial Infarction; Clopidogrel; Contraindications; Coronary Artery Disease; Drug Resistance; Drug-Eluting Stents; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Thiophenes; Thrombosis; Ticlopidine; Treatment Failure; Treatment Outcome | 2011 |
Massive thrombus burden with recurrence of intracoronary thrombosis early after stenting and delayed onset of prasugrel action in a patient with ST-elevation myocardial infarction and cardiac shock.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiopulmonary Resuscitation; Catecholamines; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Interactions; Electrocardiography; Female; Heart Arrest; Humans; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Recurrence; Stents; Thiophenes; Ticlopidine; Time Factors | 2011 |
Direct vasoactive properties of thienopyridine-derived nitrosothiols.
Topics: Animals; Aorta, Thoracic; Clopidogrel; Glutathione; Guanylate Cyclase; Hydrogen-Ion Concentration; In Vitro Techniques; Luminescent Measurements; Male; Mass Spectrometry; Molecular Structure; Nitro Compounds; Oxadiazoles; Ozone; Piperazines; Prasugrel Hydrochloride; Quinoxalines; Rabbits; S-Nitrosothiols; Sodium Nitrite; Spectrophotometry, Ultraviolet; Thienopyridines; Thiophenes; Ticlopidine; Vasodilation; Vasodilator Agents | 2011 |
Dissecting the activation of thienopyridines by cytochromes P450 using a pharmacodynamic assay in vitro.
Topics: Aryl Hydrocarbon Hydroxylases; Baculoviridae; Biosensing Techniques; Biotransformation; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Assays; Humans; Microsomes; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet-Rich Plasma; Prasugrel Hydrochloride; Thienopyridines; Thiophenes; Ticlopidine | 2011 |
Impact of dyspnea on medical utilization and affiliated costs in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Costs and Cost Analysis; Diagnostic Techniques and Procedures; Drug Therapy, Combination; Dyspnea; Emergency Service, Hospital; Female; Humans; Insurance Claim Review; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2011 |
Use of prasugrel in a patient with clopidogrel hypersensitivity.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Drug Hypersensitivity; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome | 2011 |
Ticagrelor (Brilinta)--better than clopidogrel (Plavix)?
Topics: Adenosine; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Approval; Drug Interactions; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine; United States | 2011 |
A case of acute stent thrombosis during treatment with the thrombopoietin receptor agonist peptide--romiplostim.
Topics: Acute Disease; Aspirin; Chest Pain; Clopidogrel; Eptifibatide; Female; Humans; Middle Aged; Peptides; Piperazines; Platelet Aggregation Inhibitors; Platelet Count; Prasugrel Hydrochloride; Purpura, Thrombocytopenic, Idiopathic; Receptors, Thrombopoietin; Risk Factors; Stents; Thiophenes; Thrombosis; Ticlopidine; Ultrasonography, Interventional | 2012 |
Allergic reaction to prasugrel and cross-reactivity with clopidogrel.
Topics: Aged; Clopidogrel; Cross Reactions; Female; Humans; Hypersensitivity; Piperazines; Prasugrel Hydrochloride; Pruritus; Thiophenes; Ticlopidine | 2012 |
Platelet function profiles in the elderly: results of a pharmacodynamic study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity.
Topics: Aged; Aged, 80 and over; Blood Platelets; Clinical Protocols; Clopidogrel; Drug Substitution; Female; Humans; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2011 |
Cost-effectiveness of prasugrel in a US managed care population.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cost Control; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Humans; Interviews as Topic; Male; Managed Care Programs; Middle Aged; Models, Economic; Outcome Assessment, Health Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; United States | 2012 |
High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study.
Topics: Acute Coronary Syndrome; Adult; Age Factors; Aged; Aged, 80 and over; Clopidogrel; Cross-Sectional Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Thiophenes; Ticlopidine | 2012 |
Variability and treatment of high on-prasugrel platelet reactivity in patients with initial high on-clopidogrel platelet reactivity.
Topics: Blood Platelet Disorders; Clopidogrel; Female; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2012 |
Post percutaneous coronary intervention antiplatelet therapy: current perceptions, prospects and perplexity.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Drug Resistance; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Metals; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prosthesis Design; Risk Assessment; Risk Factors; Stents; Tetrazoles; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome | 2011 |
Successful use of prasugrel, an alternative antiplatelet agent, in a patient with clopidogrel allergy.
Topics: Clopidogrel; Drug Hypersensitivity; Humans; Hypersensitivity, Immediate; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2011 |
Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: a placebo-controlled study in rats.
Topics: Adenosine; Adenosine Diphosphate; Animals; Arteries; Clopidogrel; Muscle Contraction; Myocytes, Smooth Muscle; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Rats; Rats, Wistar; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Toward a therapeutic window for antiplatelet therapy in the elderly.
Topics: Acute Coronary Syndrome; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2012 |
"Conversations in cardiology": How do you pick the best antiplatelet drug--clopidogrel, prasugrel, ticagrelor for your PCI patient?
Topics: Adenosine; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Decision Making; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
New look at antiplatelet agent-related peptic ulcer: an update of prevention and treatment.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Interactions; Gastrointestinal Hemorrhage; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Thiophenes; Ticlopidine | 2012 |
Desensitization to prasugrel: cardiology's increased need for allergy consultation.
Topics: Atherectomy, Coronary; Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Artery Disease; Desensitization, Immunologic; Drug Dosage Calculations; Drug Hypersensitivity; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Referral and Consultation; Stents; Thiophenes; Ticlopidine | 2012 |
Management of a hypersensitivity reaction to thienopyridines: prasugrel-induced fever and hepatitis resolved after switching to clopidogrel.
Topics: Adult; Clopidogrel; Coronary Artery Disease; Drug Hypersensitivity; Female; Fever; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2012 |
Prasugrel as a safe alternative for clopidogrel-induced polyarthralgias.
Topics: Arthralgia; Clopidogrel; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2012 |
[Optimal antiplatelet and antithrombotic therapy in patients with ST elevation myocardial infarction].
Topics: Abciximab; Adenosine; Antibodies, Monoclonal; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
[Letter to Kardiologia Polska concerning optimal treatment of myocardial infarction].
Topics: Adenosine; Clopidogrel; Cost-Benefit Analysis; Humans; Models, Theoretical; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Overcoming clopidogrel resistance: discovery of vicagrel as a highly potent and orally bioavailable antiplatelet agent.
Topics: Administration, Oral; Animals; Biological Availability; Clopidogrel; Drug Resistance; Female; In Vitro Techniques; Male; Mice; Microsomes, Liver; Phenylacetates; Platelet Aggregation Inhibitors; Prodrugs; Rats; Stereoisomerism; Structure-Activity Relationship; Thiophenes; Ticlopidine | 2012 |
A risk-benefit assessment of prasugrel, clopidogrel, and genotype-guided therapy in patients undergoing percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Probability; Risk Assessment; Thiophenes; Ticlopidine | 2012 |
Cost is not a barrier to implementing clopidogrel pharmacogenetics.
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombolytic Therapy; Ticlopidine | 2012 |
Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clopidogrel; Computer Simulation; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Trees; Drugs, Generic; Genotype; Hemorrhage; Humans; Models, Economic; Models, Statistical; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombolytic Therapy; Ticlopidine | 2012 |
Suboptimal response to clopidogrel and the effect of prasugrel in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; New Zealand; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Using models to predict the future: what to do when the data run out?
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2012 |
Prasugrel: a guide to its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention in the US.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Economics, Pharmaceutical; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Thrombosis; Ticlopidine; United States | 2012 |
Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrel.
Topics: Clopidogrel; Drug Interactions; Humans; In Vitro Techniques; Microsomes, Liver; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Prasugrel Hydrochloride; Proton Pump Inhibitors; Thiophenes; Ticlopidine | 2012 |
Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor.
Topics: Adenosine; Aged; Cardiopulmonary Resuscitation; Clopidogrel; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Shock, Cardiogenic; Stents; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2012 |
Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel: a commentary.
Topics: Aryl Hydrocarbon Hydroxylases; Humans; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombolytic Therapy; Ticlopidine | 2012 |
CYP2C19 genotype-guided antiplatelet therapy in a patient with clopidogrel resistance.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Resistance; Genotype; Humans; Male; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Ticlopidine; Treatment Outcome | 2012 |
P2Y12 inhibitors in acute coronary syndromes: how do we choose the best drug for our patients?
Topics: Adenosine; Cardiovascular Diseases; Clopidogrel; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Switching patients from clopidogrel to prasugrel in acute coronary syndrome: effects of prasugrel loading dose on residual platelet reactivity.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2012 |
Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Risk Assessment; Stroke; Thiophenes; Ticlopidine; Treatment Outcome; Warfarin | 2012 |
A potent alternative to clopidogrel emerges. Prasugrel appears to lower heart attack risk for patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Dosage Calculations; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2010 |
[Removal of epidural catheter under dual antiplatelet therapy following acute coronary syndrome : scenario without special consideration to the current guidelines on epidural regional anesthesia].
Topics: Acute Coronary Syndrome; Analgesia, Epidural; Aspirin; Catheterization; Clopidogrel; Digestive System Surgical Procedures; Drug Interactions; Hemorrhage; Humans; Male; Middle Aged; Pain, Postoperative; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Risk; Thiophenes; Ticlopidine | 2012 |
High frequency of CYP2C19*2 carriers in PCI-treated patients switched over from clopidogrel to prasugrel based on platelet function monitoring.
Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Substitution; Heterozygote; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine | 2013 |
Failure of high-dose clopidogrel in recurrent stent thrombosis.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Drug-Eluting Stents; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine; Treatment Failure | 2012 |
The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Alleles; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Trees; Diagnosis-Related Groups; Drugs, Generic; Female; Genetic Testing; Hospital Costs; Hospitalization; Humans; Male; Middle Aged; Monte Carlo Method; Native Hawaiian or Other Pacific Islander; New Zealand; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Quality-Adjusted Life Years; Thiophenes; Ticlopidine | 2012 |
Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Bypass; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Transfusion; Prasugrel Hydrochloride; Retrospective Studies; Risk Factors; Thiophenes; Ticlopidine | 2013 |
Residual platelet activation through protease-activated receptors (PAR)-1 and -4 in patients on P2Y12 inhibitors.
Topics: Adult; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Oligopeptides; Peptide Fragments; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptor, PAR-1; Receptors, Purinergic P2Y12; Receptors, Thrombin; Thiophenes; Ticlopidine | 2013 |
Effects of rivaroxaban, acetylsalicylic acid and clopidogrel as monotherapy and in combination in a porcine model of stent thrombosis.
Topics: Animals; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Morpholines; Platelet Aggregation; Rivaroxaban; Stents; Swine; Swine, Miniature; Thiophenes; Thrombosis; Ticlopidine | 2012 |
Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial.
Topics: Adolescent; Adult; Aged; Blood Platelets; Body Weight; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Single-Blind Method; Thiophenes; Ticlopidine; Young Adult | 2012 |
Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Diabetes Mellitus; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Prevention of stent thrombosis with reduced dose of prasugrel in two patients undergoing treatment of cerebral aneurysms with pipeline embolisation devices.
Topics: Blood Platelets; Clopidogrel; Embolization, Therapeutic; Female; Hemorrhage; Humans; Intracranial Aneurysm; Intracranial Thrombosis; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Thiophenes; Ticlopidine; Treatment Outcome | 2012 |
Measured drug effect and cardiovascular outcomes in patients receiving platelet P2Y12 receptor antagonists: clarifying the time and place for intensive inhibition.
Topics: Acute Coronary Syndrome; Clopidogrel; Female; Humans; Male; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2012 |
Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Cerebrovascular Disorders; Clopidogrel; Computer Simulation; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Support Techniques; Disease-Free Survival; Drug Costs; Gene Frequency; Genetic Predisposition to Disease; Genetic Testing; Health Care Costs; Hemorrhage; Humans; Insurance, Health, Reimbursement; Kaplan-Meier Estimate; Markov Chains; Medicare; Models, Economic; Myocardial Infarction; Percutaneous Coronary Intervention; Pharmacogenetics; Phenotype; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Quality-Adjusted Life Years; Risk Assessment; Risk Factors; Thiophenes; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome; United States | 2013 |
Trilogy: in search of the lost ring.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clinical Trials as Topic; Clopidogrel; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2013 |
Pharmacokinetics of vicagrel, a promising analog of clopidogrel, in rats and beagle dogs.
Topics: Animals; Clopidogrel; Dogs; Female; Male; Phenylacetates; Rats; Rats, Sprague-Dawley; Thiophenes; Ticlopidine | 2013 |
Clopidogrel pretreatment of patients with ST-elevation myocardial infarction does not affect platelet reactivity after subsequent prasugrel-loading: platelet reactivity in an observational study.
Topics: Aged; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2013 |
Prevention of stent thrombosis with reduced dose of prasugrel in two patients undergoing treatment of cerebral aneurysms with pipeline embolisation devices.
Topics: Carotid Artery, Internal, Dissection; Cerebral Angiography; Clopidogrel; Embolization, Therapeutic; Female; Follow-Up Studies; Humans; Intracranial Aneurysm; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Stents; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome | 2013 |
Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aspirin; Chi-Square Distribution; Clopidogrel; Endpoint Determination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Statistics, Nonparametric; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
A pilot study of prasugrel followed by post-procedural maintenance with clopidogrel in patients receiving percutaneous coronary intervention.
Topics: Aged; Clopidogrel; Female; Humans; Male; Percutaneous Coronary Intervention; Pilot Projects; Piperazines; Platelet Aggregation Inhibitors; Postoperative Care; Prasugrel Hydrochloride; Preoperative Care; Retrospective Studies; Thiophenes; Ticlopidine | 2013 |
Prasugrel versus clopidogrel for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angina, Unstable; Female; Humans; Male; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Ticlopidine | 2013 |
Prasugrel versus clopidogrel for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angina, Unstable; Female; Humans; Male; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Ticlopidine | 2013 |
Hirudin anticoagulation allows more rapid determination of P2Y₁₂ inhibition by the VerifyNow P2Y12 assay.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Antithrombins; Area Under Curve; Cations; Citrates; Clopidogrel; Coronary Angiography; Female; Hematologic Tests; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Function Tests; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Sodium Citrate; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
High on-treatment platelet reactivity (HPR): what does it mean, and does it matter?
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Substitution; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2013 |
Prasugrel reduces agonists' inducible platelet activation and leukocyte-platelet interaction more efficiently than clopidogrel.
Topics: Aged; Blood Platelets; Cell Communication; Clopidogrel; Female; Humans; Male; Middle Aged; Monocytes; P-Selectin; Peptide Fragments; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2013 |
Promise and peril of clinical decision support: translating medical evidence to the individual patient.
Topics: Acute Coronary Syndrome; Clopidogrel; Female; Humans; Male; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2013 |
Antiplatelet efficacy of prasugrel in patients with high on-clopidogrel treatment platelet reactivity and a history of coronary stenting.
Topics: Aged; Blood Platelets; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Registries; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey.
Topics: Acute Coronary Syndrome; Age Factors; Clopidogrel; Comorbidity; Cost-Benefit Analysis; Europe; Humans; Markov Chains; Models, Economic; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Thiophenes; Ticlopidine; Turkey | 2013 |
Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications.
Topics: Acute Coronary Syndrome; Alleles; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genetic Variation; Genotype; Hemorrhage; Humans; Male; Microfilament Proteins; Middle Aged; Myocardial Infarction; Phosphoproteins; Piperazines; Polymerase Chain Reaction; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Unclassified pleomorphic and spindle cell pulmonary neoplasm with brain metastases after prasugrel.
Topics: Aged; Aspirin; Brain Neoplasms; Carcinoma; Clinical Trials, Phase III as Topic; Clopidogrel; Colonic Neoplasms; Coronary Stenosis; Diabetes Mellitus, Type 1; Diabetic Cardiomyopathies; Drug Therapy, Combination; Drug-Eluting Stents; Fatal Outcome; Female; Humans; Lung Neoplasms; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticlopidine; Time Factors | 2013 |
Letter by Alexopoulos et al regarding article, "pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel dose versus prasugrel: the RESET GENE Trial".
Topics: Aryl Hydrocarbon Hydroxylases; Blood Platelets; Coronary Artery Disease; Drug Substitution; Female; Humans; Male; Myocardial Ischemia; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2013 |
Switching acute coronary syndrome patients from prasugrel to clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Chi-Square Distribution; Clopidogrel; Drug Resistance; Drug Substitution; Female; Hemorrhage; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Risk Assessment; Risk Factors; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Switching from prasugrel to clopidogrel: navigating in unknown waters.
Topics: Acute Coronary Syndrome; Blood Platelets; Clopidogrel; Drug Substitution; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2013 |
Prasugrel use in a patient allergic to clopidogrel: effect of a drug shortage on selection of dual antiplatelet therapy.
Topics: Aged; Clopidogrel; Drug Hypersensitivity; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2013 |
Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Myocardial Ischemia; Patient Selection; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Vitamin K | 2013 |
Tailoring antiplatelet therapy--insanity or good sense?
Topics: Asian People; Clopidogrel; Humans; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2013 |
Thiolactone sulfoxides as new reactive metabolites acting as bis-electrophiles: implication in clopidogrel and prasugrel bioactivation.
Topics: Clopidogrel; Cytochrome P-450 Enzyme System; Humans; Lactones; Microsomes, Liver; Molecular Structure; Oxidation-Reduction; Piperazines; Prasugrel Hydrochloride; Prodrugs; Sulfoxides; Thiophenes; Ticlopidine | 2013 |
Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease.
Topics: Adenosine; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Aspirin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Humans; Pharmacogenetics; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
[Your patient needs antithrombotics, 2. What do the new substances offer? (interview by Dr. med. Peter Stiefelhagen)].
Topics: Adenosine; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Clopidogrel; Dabigatran; Fibrinolytic Agents; Guideline Adherence; Humans; Morpholines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Pressure; Case-Control Studies; Clopidogrel; Endothelium, Vascular; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Peripheral Arterial Disease; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Preserved thrombin-inducible platelet activation in thienopyridine-treated patients.
Topics: Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Female; Humans; Integrin beta3; Male; Middle Aged; P-Selectin; Peptide Fragments; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Membrane Glycoprotein IIb; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Thrombin; Ticlopidine | 2013 |
Cytochrome P450 2B6 and 2C9 genotype polymorphism--a possible cause of prasugrel low responsiveness.
Topics: Aryl Hydrocarbon Hydroxylases; Aspirin; Biomarkers, Pharmacological; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C9; Drug Resistance; Drug Therapy, Combination; Female; Gene Frequency; Genetic Association Studies; Genotype; Humans; Male; Middle Aged; Piperazines; Polymorphism, Genetic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2013 |
Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cohort Studies; Cost-Benefit Analysis; Decision Trees; Dose-Response Relationship, Drug; Drug Costs; Drug Therapy, Combination; Drugs, Generic; Female; Humans; Male; Markov Chains; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Quality-Adjusted Life Years; Receptors, Purinergic P2Y12; Survival Rate; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
[Interview with the Daiichi-Sankyo managing director Ralf Göddertz (interview by Dirk Einecke and Cornelius Heyer)].
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost Savings; Cost-Benefit Analysis; Drug Costs; Drug Industry; Drugs, Generic; Forecasting; Germany; Humans; National Health Programs; Patents as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
ED administration of thienopyridines in non-ST-segment elevation myocardial infarction: results from the NCDR.
Topics: Aged; Clopidogrel; Drug Administration Schedule; Emergency Service, Hospital; Female; Hemorrhage; Hospital Mortality; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Registries; Retrospective Studies; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Viewpoint: mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Europe; Evidence-Based Medicine; Guideline Adherence; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; United States | 2013 |
Differences between ACC/AHA and ESC Guidelines on antiplatelet therapy in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Europe; Evidence-Based Medicine; Guideline Adherence; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; United States | 2013 |
The impact of the environment on diseases and drugs.
Topics: Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Smoking; Thiophenes; Ticlopidine | 2013 |
Predictors of bleeding in acute coronary syndromes with clopidogrel and prasugrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Follow-Up Studies; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticlopidine | 2013 |
Predictors of myocardial infarction after an acute coronary syndrome with clopidogrel and prasugrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Follow-Up Studies; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticlopidine | 2013 |
Upstream antiactivation antiplatelet therapy: first, do no harm. Then consider doing some good.
Topics: Emergency Service, Hospital; Female; Humans; Male; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Ticlopidine | 2013 |
Gastrointestinal adverse events after dual antiplatelet therapy: clopidogrel is safer than ticagrelor, but prasugrel data are lacking or inconclusive.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Chemical and Drug Induced Liver Injury; Clinical Trials, Phase III as Topic; Clopidogrel; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Humans; Kaplan-Meier Estimate; Male; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Erosive arthritis and hepatic granuloma formation induced by peptidoglycan polysaccharide in rats is aggravated by prasugrel treatment.
Topics: Animals; Arthritis, Experimental; Clopidogrel; Cytokines; Female; Granuloma; Inflammation; Joints; Liver; Peptidoglycan; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Rats; Rats, Inbred Lew; Thiophenes; Ticlopidine | 2013 |
Effectiveness of switching 'hyper responders' from Prasugrel to Clopidogrel after acute coronary syndrome: the POBA (Predictor of Bleeding with Antiplatelet drugs) SWITCH study.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Substitution; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Sequential value-of-information assessment for prospective drug safety monitoring using claims databases: the comparative safety of prasugrel v. clopidogrel.
Topics: Clopidogrel; Drug Monitoring; Humans; Insurance Claim Review; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Thiophenes; Ticlopidine | 2013 |
Identification of poor response to P2Y12 inhibitors in ACS patients with a new ELISA-based vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation assay.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Cell Adhesion Molecules; Cell Separation; Clopidogrel; Enzyme-Linked Immunosorbent Assay; Feasibility Studies; Female; Flow Cytometry; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Piperazines; Platelet Function Tests; Prasugrel Hydrochloride; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Thiophenes; Ticlopidine | 2013 |
A comparative study of bivalirudin plus clopidogrel versus bivalirudin plus prasugrel in primary angioplasty using propensity score matching.
Topics: Angioplasty; Antithrombins; Clopidogrel; Cohort Studies; Drug Combinations; Female; Hirudins; Humans; Male; Middle Aged; Myocardial Infarction; Peptide Fragments; Piperazines; Postoperative Complications; Prasugrel Hydrochloride; Recombinant Proteins; Retrospective Studies; Thiophenes; Thrombosis; Ticlopidine | 2013 |
TRILOGY ACS: prasugrel of benefit only after angiography?
Topics: Angina, Unstable; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2013 |
Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs).
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Area Under Curve; Biomarkers; Cell Adhesion Molecules; Clopidogrel; Coronary Thrombosis; Drug Resistance; Female; Hemorrhage; Humans; Logistic Models; Male; Microfilament Proteins; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Phosphoproteins; Phosphorylation; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Risk Assessment; Risk Factors; ROC Curve; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Bleeding and thrombosis risk matters: how long can we stick to the one-size-fits-all strategy of platelet inhibition?
Topics: Acute Coronary Syndrome; Clopidogrel; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2013 |
Antiplatelet effect of thienopyridine (clopidogrel or prasugrel) pretreatment in patients undergoing primary percutaneous intervention for ST elevation myocardial infarction.
Topics: Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Pyridines; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
Contributions of intestine and plasma to the presystemic bioconversion of vicagrel, an acetate of clopidogrel.
Topics: Acetates; Animals; Clopidogrel; Esterases; Humans; Hydrolysis; Intestinal Mucosa; Microsomes; Phenylacetates; Prodrugs; Rats; Rats, Sprague-Dawley; Thiophenes; Ticlopidine | 2014 |
Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; China; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; Models, Economic; Morpholines; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Ticlopidine; Warfarin | 2014 |
Comparison of the degree of platelet aggregation inhibition with prasugrel versus clopidogrel and clinical outcomes in patients with unprotected left main disease treated with everolimus-eluting stents.
Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Everolimus; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Sirolimus; Thiophenes; Ticlopidine; Treatment Outcome | 2013 |
[What kind of antiplatelet treatment in acute coronary syndrome?--Intensive antiplatelet treatment only for patients with invasive strategy].
Topics: Angina, Unstable; Female; Humans; Male; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Ticlopidine | 2013 |
Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Topics: Adenosine; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Drug Design; Female; Germany; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Impact of obesity and the metabolic syndrome on response to clopidogrel or prasugrel and bleeding risk in patients treated after coronary stenting.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Incidence; Male; Metabolic Syndrome; Middle Aged; Obesity; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Stents; Thiophenes; Ticlopidine; United States | 2014 |
Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Biotransformation; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Substitution; Female; Genetic Testing; Genotype; Health Personnel; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Postoperative Complications; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Sequence Deletion; Thiophenes; Ticlopidine | 2013 |
Drug interactions with good old clopidogrel: case closed.
Topics: Acute Coronary Syndrome; Calcium Channel Blockers; Clopidogrel; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Thiophenes; Ticlopidine | 2013 |
'VASPFix' for measurement of VASP phosphorylation in platelets and for monitoring effects of P2Y12 antagonists.
Topics: Adenosine; Adenosine Diphosphate; Alprostadil; Biomarkers, Pharmacological; Blood Platelets; Bucladesine; Cell Adhesion Molecules; Cells, Cultured; Clopidogrel; Cyclic AMP; Humans; Iloprost; Microfilament Proteins; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Reproducibility of Results; Sensitivity and Specificity; Thiophenes; Thrombophilia; Ticlopidine | 2014 |
In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prevalence, predictors and short-term outcome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Piperazines; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Antiplatelet therapy in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: a retrospective observational study of prasugrel and clopidogrel.
Topics: Adult; Aged; Clopidogrel; Electrocardiography; Female; Hospital Mortality; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Retrospective Studies; Thiophenes; Ticlopidine | 2014 |
Association of thrombin generation potential with platelet PAR-1 regulation and P-selectin expression in patients on dual antiplatelet therapy.
Topics: Adult; Aged; Aspirin; Biomarkers; Blood Platelets; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; P-Selectin; Peptide Fragments; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prothrombin; Receptor, PAR-1; Thiophenes; Thrombin; Ticlopidine | 2014 |
P2Y12-based platelet function assays should be complemented with cyclooxygenase-dependent testing in framing the therapeutic windows for dual antiplatelet therapy.
Topics: Acute Coronary Syndrome; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Thiophenes; Ticlopidine | 2014 |
Reply: P2Y12-Based platelet function assays should be complemented with cyclooxygenase-dependent testing in framing the therapeutic windows for dual antiplatelet therapy.
Topics: Acute Coronary Syndrome; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Thiophenes; Ticlopidine | 2014 |
Smoking status and the effects of antiplatelet drugs.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Smoking; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Combined Modality Therapy; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; Risk Assessment; Severity of Illness Index; Stents; Stroke; Survival Rate; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome | 2014 |
Near-real-time monitoring of new drugs: an application comparing prasugrel versus clopidogrel.
Topics: Aged; Clopidogrel; Cohort Studies; Databases, Factual; Electronic Health Records; Female; Hemorrhage; Humans; Ischemia; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Product Surveillance, Postmarketing; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2014 |
High rates of prasugrel and ticagrelor non-responder in patients treated with therapeutic hypothermia after cardiac arrest.
Topics: Adenosine; Clopidogrel; Female; Flow Cytometry; Heart Arrest; Humans; Hypothermia, Induced; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis.
Topics: Aged, 80 and over; Aspirin; Clopidogrel; Coronary Angiography; Diabetes Mellitus, Type 2; Drug Resistance; Electrocardiography; Heparin; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Thrombosis; Ticlopidine | 2014 |
DTB Select: 3 | March 2014.
Topics: Alzheimer Disease; Antibodies, Monoclonal, Murine-Derived; Automobile Driving; Child; Chronic Pain; Clopidogrel; Hepatitis B; Histamine H2 Antagonists; Humans; Hypertension; Practice Guidelines as Topic; Practice Patterns, Physicians'; Proton Pump Inhibitors; Respiratory Tract Infections; Rituximab; Thiophenes; Ticlopidine | 2014 |
Safer heart-attack prevention for seniors with revised drug regimen. Half the normal dose of prasugrel, a lifesaving medication, is just as effective as the larger dose, and reduces risk of serious side effects.
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Secondary Prevention; Thiophenes; Ticlopidine | 2013 |
Transient receptor potential ankyrin 1 (TRPA1) channel activation by the thienopyridine-type drugs ticlopidine, clopidogrel, and prasugrel.
Topics: Calcium; Calcium Channels; Cell Line; Clopidogrel; Enterochromaffin-like Cells; Gene Expression Regulation; HEK293 Cells; Humans; Mutation; Nerve Tissue Proteins; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Serotonin; Thiophenes; Ticlopidine; Time-Lapse Imaging; Transient Receptor Potential Channels; TRPA1 Cation Channel | 2014 |
A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry.
Topics: Aged; Aged, 80 and over; Blood Platelets; Case-Control Studies; Clopidogrel; Coronary Thrombosis; Drug Resistance; Drug Substitution; Female; Germany; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Risk Factors; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Alleles; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Thrombosis; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Support Techniques; Direct Service Costs; Drug Therapy, Combination; Drugs, Generic; Genotype; Hemorrhage; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Quality-Adjusted Life Years; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Controversies in acute cardiovascular care.
Topics: Adenosine; Clinical Trials as Topic; Clopidogrel; Emergency Medical Services; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry.
Topics: Aged; Clopidogrel; Drug Administration Schedule; Drug Utilization Review; Female; Guideline Adherence; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Retrospective Studies; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome; United States | 2014 |
Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery.
Topics: Adenosine; Aspirin; Blood Platelets; Clopidogrel; Consensus; Coronary Artery Bypass; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Postoperative Care; Prasugrel Hydrochloride; Preoperative Care; Purinergic P2Y Receptor Antagonists; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Triple antithrombotic therapy: risky but sometimes necessary.
Topics: Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clopidogrel; Dabigatran; Drug Therapy, Combination; Humans; Morpholines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticlopidine; Vitamin K | 2014 |
Is it appropriate to compare the results from two clinical trials with one drug in common?
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Evaluation of comparative treatment effects using indirect comparisons.
Topics: Acute Coronary Syndrome; Adenosine; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine | 2013 |
Evaluation of comparative treatment effects using indirect comparisons. Response.
Topics: Acute Coronary Syndrome; Adenosine; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine | 2013 |
Viewpoint: "underutilisation of novel antiplatelet agents--myths, generics, and economics".
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combination; Drug Utilization; Evidence-Based Medicine; Humans; Japan; Marketing; Piperazines; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
There's life in the old dog yet: clopidogrel competing with prasugrel and ticagrelor for treatment of ACS patients.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Drug Substitution; Drug Therapy, Combination; Economic Competition; Humans; Piperazines; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Utilisation of novel anti-platelet agents: evidence, guidelines and proven patients' value.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Costs and Cost Analysis; Drug Utilization; Evidence-Based Medicine; Humans; International Cooperation; Marketing; Patient Satisfaction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Switching patients from clopidogrel to novel P2Y12 receptor inhibitors in acute coronary syndrome: comparative effects of prasugrel and ticagrelor on platelet reactivity.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Drug Substitution; Female; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Prasugrel increases the need for platelet transfusions and surgical reexploration rates compared with clopidogrel in coronary artery bypass surgery.
Topics: Anticoagulants; Clopidogrel; Coronary Artery Bypass; Forecasting; Humans; Logistic Models; Piperazines; Platelet Transfusion; Postoperative Hemorrhage; Prasugrel Hydrochloride; Preoperative Period; Purinergic P2Y Receptor Antagonists; Reoperation; Thiophenes; Ticlopidine | 2015 |
Improving outcomes with bivalirudin in primary percutaneous coronary intervention.
Topics: Anticoagulants; Clopidogrel; Heparin; Hirudins; Humans; Male; Myocardial Infarction; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recombinant Proteins; Thiophenes; Ticlopidine | 2014 |
Concerning antiplatelet therapy.
Topics: Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2014 |
Concerning antiplatelet therapy. Reply.
Topics: Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2014 |
Impact of the adjusted dosing regimen of prasugrel for Japanese patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Aspirin; Humans; Piperazines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2014 |
Resolution of clopidogrel-associated polyarthritis after conversion to prasugrel.
Topics: Aged; Arthritis; Clopidogrel; Humans; Male; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2014 |
Uncovering the shroud on antiplatelet therapy for patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Topics: Clopidogrel; Electrocardiography; Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Thiophenes; Thrombolytic Therapy; Ticlopidine | 2014 |
The importance of genotype variation beyond different antiplatelet therapy in nonresponder patients.
Topics: Acute Coronary Syndrome; Cause of Death; Female; Humans; Male; Piperazines; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Ticlopidine | 2014 |
Reply: The importance of genotype variation beyond different antiplatelet therapy in nonresponder patients.
Topics: Acute Coronary Syndrome; Cause of Death; Female; Humans; Male; Piperazines; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Ticlopidine | 2014 |
Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Stroke; Thiophenes; Ticlopidine; Treatment Outcome; United States | 2014 |
In-hospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the national cardiovascular data registry.
Topics: Acute Disease; Age Factors; Aged; Clopidogrel; Drug Substitution; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Postoperative Complications; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Recurrence; Registries; Risk Factors; Thiophenes; Thrombosis; Ticlopidine; United States | 2014 |
Optimizing human apyrase to treat arterial thrombosis and limit reperfusion injury without increasing bleeding risk.
Topics: Adenosine Diphosphate; Animals; Apyrase; Clopidogrel; Coronary Circulation; Dogs; Fibrinolysis; Hemorrhage; Humans; Mice, Inbred C57BL; Myocardial Infarction; Myocardial Reperfusion Injury; Piperazines; Platelet Aggregation; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Thrombosis; Ticlopidine; Time Factors; Tissue Plasminogen Activator; Treatment Outcome; Vascular Patency | 2014 |
Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction. Results of the ISAR-SHOCK registry.
Topics: Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Coronary Thrombosis; Female; Germany; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Recurrence; Registries; Risk Factors; Shock, Cardiogenic; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
PRASFIT-ACS: important evidence against a "one-guideline-fits-all-races" approach to antiplatelet therapy.
Topics: Aspirin; Humans; Piperazines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2014 |
PRASFIT-ACS: important evidence against a "one-guideline-fits-all-races" approach to antiplatelet therapy.
Topics: Aspirin; Humans; Piperazines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2014 |
Prasugrel vs. clopidogrel in acute coronary syndrome patients treated with prasugrel.
Topics: Acute Coronary Syndrome; Aged; Bayes Theorem; Clopidogrel; Cohort Studies; Female; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Retrospective Studies; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2014 |
Preoperative prasugrel discontinuation management in coronary artery surgery.
Topics: Coronary Artery Bypass; Humans; Piperazines; Platelet Transfusion; Purinergic P2Y Receptor Antagonists; Reoperation; Thiophenes; Ticlopidine | 2015 |
Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Coronary Artery Disease; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Prospective Studies; Registries; Stents; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Dual antiplatelet therapy after drug-eluting stents--how long to treat?
Topics: Aspirin; Clopidogrel; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine | 2014 |
Antiplatelet therapy: risks and benefits of extended DAPT after stenting.
Topics: Aspirin; Cardiovascular Diseases; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Thrombosis; Ticlopidine | 2015 |
Point-of-care platelet reactivity determination with VerifyNow-P2Y12 following administration of clopidogrel or prasugrel: data from a real-world, clinical care inpatient setting.
Topics: Aged; Clopidogrel; Electronic Health Records; Female; Hospitalization; Hospitals, Urban; Humans; Logistic Models; Male; Medical Audit; Middle Aged; Piperazines; Platelet Aggregation; Point-of-Care Systems; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine | 2014 |
A pharmacodynamic comparison of 5 anti-platelet protocols in patients with ST-elevation myocardial infarction undergoing primary PCI.
Topics: Adenosine; Aged; Blood Platelets; Clinical Protocols; Clopidogrel; Drug Administration Schedule; Electrocardiography; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
World heart federation expert consensus statement on antiplatelet therapy in east asian patients with ACS or undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine; Asia, Eastern; Cardiology; Clopidogrel; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Societies, Medical; Thiophenes; Ticagrelor; Ticlopidine; World Health Organization | 2014 |
Reply by the authors of the original article.
Topics: Coronary Artery Bypass; Humans; Piperazines; Platelet Transfusion; Purinergic P2Y Receptor Antagonists; Reoperation; Thiophenes; Ticlopidine | 2015 |
Prolonged dual antiplatelet therapy after drug-eluting stent reduces the risk of stent thrombosis and major cardiovascular events but increases the rate of bleeding.
Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombosis; Ticlopidine | 2015 |
Investigation of possible prophylactic, renoprotective, and cardioprotective effects of thromboprophylactic drugs against ischemia-reperfusion injury.
Topics: Animals; Anticoagulants; Aryldialkylphosphatase; Aspirin; Cardiotonic Agents; Clopidogrel; Dipeptidases; Drug Evaluation, Preclinical; Enoxaparin; Femoral Artery; Heparin, Low-Molecular-Weight; Hindlimb; Kidney; Male; Malondialdehyde; Morpholines; Myocardium; Nitric Oxide; Oxidative Stress; Rats, Sprague-Dawley; Reperfusion Injury; Rivaroxaban; Thiophenes; Ticlopidine | 2015 |
Predictors of high on-aspirin platelet reactivity in high-risk vascular patients treated with single or dual antiplatelet therapy.
Topics: Adenosine; Aged; Aspirin; Cerebrovascular Disorders; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Fibrinogen; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Secondary Prevention; Thiophenes; Ticagrelor; Ticlopidine | 2015 |
Balancing the risks and benefits of dual platelet inhibition.
Topics: Adenosine; Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2015 |
ACP journal club. Dual antiplatelets for 30 mo after drug-eluting stents reduced stent thrombosis and CV and cerebrovascular events.
Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombosis; Ticlopidine | 2015 |
Synthesis of the alkylated active metabolite of tipidogrel.
Topics: Alkylation; Animals; Chromatography, High Pressure Liquid; Clopidogrel; Half-Life; Piperidines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Pyridines; Rats; Receptors, Purinergic P2Y12; Tandem Mass Spectrometry; Thiophenes; Ticlopidine | 2015 |
Duration of dual antiplatelet therapy after drug-eluting stents.
Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombosis; Ticlopidine | 2015 |
Duration of dual antiplatelet therapy after drug-eluting stents.
Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombosis; Ticlopidine | 2015 |
Duration of dual antiplatelet therapy after drug-eluting stents.
Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombosis; Ticlopidine | 2015 |
Duration of dual antiplatelet therapy after drug-eluting stents.
Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombosis; Ticlopidine | 2015 |
Duration of dual antiplatelet therapy after drug-eluting stents.
Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombosis; Ticlopidine | 2015 |
Duration of dual antiplatelet therapy after drug-eluting stents.
Topics: Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombosis; Ticlopidine | 2015 |
Dual antiplatelet therapy after acute coronary syndrome: a cardiologist-based optimal decision.
Topics: Female; Humans; Male; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2015 |
Lights and Shadows of Antiplatelet Therapy in Primary Percutaneous Coronary Intervention.
Topics: Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Ticlopidine | 2015 |
Reply: Lights and Shadows of Antiplatelet Therapy in Primary Percutaneous Coronary Intervention.
Topics: Female; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Ticlopidine | 2015 |
An optimum prophylactic dose of prasugrel monotherapy may safely and effectively prevent the development of experimental thrombotic strokes.
Topics: Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stroke; Thiophenes; Ticlopidine | 2015 |
Defining a Role for Prasugrel in Patients With Stable Coronary Artery Disease Undergoing Ad Hoc Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Treatment Outcome | 2016 |
Significant Improvement of Metabolic Characteristics and Bioactivities of Clopidogrel and Analogs by Selective Deuteration.
Topics: Adenosine Diphosphate; Animals; Clopidogrel; Hydrolysis; Male; Metabolic Networks and Pathways; Models, Molecular; Molecular Conformation; Phenylacetates; Platelet Aggregation; Platelet Aggregation Inhibitors; Rats; Thiophenes; Ticlopidine | 2016 |
Choices for Potent Platelet Inhibition in Patients With Diabetes Mellitus.
Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; Diabetes Mellitus; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Treatment Outcome | 2016 |
The FDA-approved drugs ticlopidine, sertaconazole, and dexlansoprazole can cause morphological changes in C. elegans.
Topics: Animals; Bioaccumulation; Caenorhabditis elegans; Dexlansoprazole; Drug Approval; Epigenesis, Genetic; Humans; Imidazoles; Larva; Molting; Mutation; Thiophenes; Ticlopidine; United States; United States Food and Drug Administration | 2020 |
Semi-mechanistic population pharmacokinetics analysis reveals distinct CYP2C19 dependency in the bioactivation of vicagrel and clopidogrel to active metabolite M15-2.
Topics: Clopidogrel; Cytochrome P-450 CYP2C19; Galanin; Humans; Phenylacetates; Platelet Aggregation Inhibitors; Substance P; Thiophenes; Ticlopidine | 2022 |